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ABSTRACT
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by
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Under the Supervision of Professor Teresa Johnson Ph.D., RN

Preeclampsia affects 3-8% of all pregnancies and is a global issue that significantly effects
the short and long-term health of women and neonates. The pathophysiology of preeclampsia
remains unclear and there seems to be two distinct subtypes, early and late onset. Each subtype
may have a unique pathophysiology and set of risk factors. Preeclampsia is linked to long-term
risk of cardiovascular disease in previously affected women. Subsequently, risk factors shared
between preeclampsia and cardiovascular disease should be explored. The main aim of this study
was to determine the strength of association between maternal ABO blood type and preeclampsia
subtype. This hospital-based case control study was completed at one community hospital in the
Mid Atlantic, United States. The study included 126 female subjects with early onset
preeclampsia (≤ 33 6/7 weeks gestation), 126 female subjects with late onset preeclampsia (≥ 34
weeks gestation) and 259 control subjects with no history of preeclampsia. Strict diagnostic
criteria were used and preeclamptic subjects were classified by subtype based on gestational age at
diagnosis. Data on ABO blood type, as well other physical and socio-demographic variables were
extracted from the electronic health record. No significant association was noted between
ii

preeclampsia subtype and non-O blood type (p=.456) and ABO blood phenotype trended towards
significance (p=.062). After exclusion of subjects with comorbidities (CHTN, GDM and DM)
from the sample (n=403), there was a significant association noted between ABO blood type and
preeclampsia subtype (p=.001). A significant association was also noted between preeclamptic
subjects with growth restriction and ABO blood type (p= <.001). Preeclamptic subjects with the B
blood type had OR=3.44, 95% CI 1.58, 7.50 of having a growth-restricted fetus than did those with
other blood types. Finally, when adjusting for race only, subjects with AB blood type had the
following odds (OR=3.03, 95% CI 1.04, 8.80; OR=3.35, 95% CI 1.02, 11.03.) of developing preeclampsia and late onset preeclampsia respectively. When other clinical risk factors of
preeclampsia are included in the model, AB blood type significantly predicts membership in the
early onset preeclampsia subtype (OR=5.41, 95% CI, 1.19, 24.55) and was trend-level in the late
onset group (p=.053). Preeclamptic women with B blood type had three times the odds of having
a growth-restricted fetus, subsequently; they may require close ultrasound surveillance. AB blood
type was significantly associated with three times increased odds of late onset preeclampsia.
When included in a model with other common risk factors of preeclampsia, ABO blood type only
accounted for a small amount of variability in the model. ABO blood type may not be a valuable
addition to a preeclampsia-screening algorithm that already includes common clinical risk factors
of preeclampsia. However, when controlling for other common clinical risk factors of
preeclampsia, women with AB blood type had over 5 times the odds of developing early onset
preeclampsia. Further research is necessary to examine if blood type regulates biomarkers that
mediate the development of each preeclampsia subtype or in some way is associated with severe
features of the disease.
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CHAPTER 1
This chapter begins by introducing the problem of preeclampsia. Preeclampsia is linked
to a variety of poor short and long-term outcomes for both mother and neonate. The disease is
heterogeneous in nature and there are two distinct subtypes, early and late onset. Preeclampsia
has been associated with increased risk of cardiovascular disease in previously effected women
and shared risk factors should be investigated. Next, this chapter provides a pathophysiologic
framework that describes the role of blood type in both disease processes. The purpose of this
proposed dissertation study is given and research questions posed. Finally, contributions to the
future of nursing science and practice are discussed.
Introduction
Incidence
Preeclampsia affects 3-8% of all pregnancies and is a global issue that significantly
affects the short and long-term health of both women and neonates (Hutcheon, Liskonova &
Joseph, 2011). Roughly, 1 in 12 pregnancies are affected by preeclampsia (Ilekis, Reddy &
Roberts, 2007). Rates of preeclampsia have risen by 25% in the past two decades in the United
States and the disease is linked to significant maternal morbidity and mortality as well as listed
as a major contributor to prematurity (Ferrazzani et al., 2011; Wallis, Saftlas, Hsia, & Arish,
2008). Preeclampsia is a global issue, related to significant maternal and neonatal morbidity and
mortality. Worldwide, hypertensive disorders of pregnancy are responsible for 76,000 maternal
and 500,000 infant deaths each year (The Preeclampsia Foundation, 2016). Hypertensive
disorders of pregnancy account for 16% of maternal deaths in developed countries and even
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higher rates of maternal mortality related to these disorders are seen in Latin American and
Caribbean countries (Khan, Wojdyla, Say, Gülmezoglu, & Van Look, 2006).
Maternal Complications
Hypertensive disorders of pregnancy account for 9.4% of maternal deaths in the United
States (Creanga et al., 2015). In addition to the significant associated maternal mortality,
preeclampsia is also linked to severe maternal morbidity, such as, eclampsia, acute renal failure,
pulmonary edema, placental abruption, end organ damage and neurologic sequelae such as stroke
(Sibai, Dekker & Kupferminc, 2005; Lisonkova & Joseph, 2013). These women, particularly
those with early onset disease, are at higher risk for induction of labor and cesarean section
(Alanis et al., 2008). The risk of serious complication increases with the severity of the disease
(Hutcheon et al., 2011).
Infant Complications
Although preeclampsia is a maternal hypertensive disorder, with significant associated
short and long-term maternal morbidity and mortality, there is also significant fetal and neonatal
risk associated with the disease. Fifteen percent of pregnancies affected by preeclampsia result
in spontaneous or medically indicated preterm birth (Alanis et al., 2008). There is a twofold risk
of neonatal death in infants born to women diagnosed with preeclampsia, and significant
associated neonatal morbidity, such as lower Apgar scores, seizures, and neonatal
encephalopathy (Lisonkova, & Joseph, 2013). Fetal growth restriction (FGR) is commonly seen
in infants of preeclamptic mothers, particularly those with early onset disease. Although rates of
stillbirth are decreasing, women with preeclampsia continue to have far higher rates of stillbirth
than unaffected pregnancies in both developed and developing countries (Hutcheon et al., 2011).
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Definition and Diagnostic Criteria
Preeclampsia is defined by ACOG (2013) as the new onset of hypertension, with blood
pressure greater than or equal to 140 mmHg systolic or greater than or equal to 90 mm Hg
diastolic on two occasions at least 4 hours apart after 20 0/7 weeks gestation in a previously
normotensive women, and proteinuria (≥ 300mg in a 24-hour urine collection). In the absence of
proteinuria the patient may have any one or more of the following in order to meet diagnostic
criteria:
● platelets < 100,000 microliter
● serum creatinine > 1.1 or doubling of serum creatinine in the absence of renal
disease
● elevated concentrations of blood liver transaminases to twice normal levels
● pulmonary edema
● new onset of cerebral or visual disturbances (ACOG, 2013, p. 4).
Non-proteinuric pre-eclampsia occurs in about 25% of all cases (Tranquilli, Brown, Zeeman,
Deeker & Sibai, 2013). Removal of proteinuria from the definitive diagnosis of preeclampsia
proved important, as previously, many women with other signs and symptoms preeclampsia
went undiagnosed solely due to lack of proteinuria. Unfortunately, while providers waited for
women to become proteinuric in order to meet diagnostic criteria, the severity of the illness
increased.
Severity. Due to the documented aggressive and dynamic nature of preeclampsia, there
has been a change in nomenclature when documenting severity (ACOG, 2013). Preeclampsia is
no longer documented as mild or severe, but rather “with severe features” and “without severe
features” (ACOG, 2013, p. 8). Preeclampsia “with severe features” is documented when patients
meet the basic criteria for diagnosis of preeclampsia and have any one or more of the below
findings:
● systolic blood pressure ≥160 mmHg and/or diastolic blood pressure >/=
3

●
●
●
●
●

110mmHg
platelet count <100,000 per microliter
impaired liver function as evidenced by severe persistent right upper quadrant or
epigastric pain or elevated liver enzymes twice normal blood concentration
progressive renal insufficiency as evidenced by worsening serum creatinine
pulmonary edema
cerebral or visual disturbances (ACOG, 2013).

Quantity of urinary protein, uric acid levels, FGR and edema are no longer diagnostic of
increasing severity, however, may warrant closer surveillance of the pregnancy (ACOG, 2013).
Additionally, even in the absence of preeclampsia diagnosis, maternal report of individual
symptoms such as new onset of cerebral or visual disturbance, severe epigastric or right upper
quadrant pain, or an objective clinical finding of an elevation in blood pressure compared with an
early pregnancy baseline blood pressure should result in close obstetrical evaluation (ACOG,
2013).
Classic Risk Factors
Clinical risk factors for preeclampsia include nulliparity, extremes in maternal age (<18
or >35 years), multiple gestation, obesity, African American race, utilization of assisted
reproductive techniques, family history of preeclampsia, and history of previous preeclamptic
pregnancy. Other preexisting diseases such as chronic hypertension, anti-phospholipid
syndrome, lupus and diabetes have also been shown to increase risk of preeclampsia (Bartsch,
Medcalf, Park, & Ray, 2016; Boyd, Tahir, Wohlfahrt & Melbye , 2013; Lisonkova & Joseph,
2013; O'Brien, Ray, & Chan, 2003; Paré et al., 2014). Women not affected by preeclampsia
during their first pregnancy, have only a 1% chance of developing preeclampsia in a subsequent
pregnancy if the pregnancy is with the same partner. However, if preeclampsia occurs in the first
pregnancy, and the women is pregnant again by the same partner, the chance of preeclampsia
recurring is 7-15% (Hutcheon et al., 2011). Chance of recurrence increases even further in the
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third pregnancy if both of the previous pregnancies were affected. Early gestational age at onset
of preeclampsia also seems to increase risk of reoccurrence (Hutcheon et al., 2011).
Risk screening models. Due to the heterogeneous nature of disease, developing riskscreening models has proven difficult, as there are modifiable, non-modifiable, graded and
interactional risk factors for preeclampsia (Osol & Bernstein, 2014). Additionally, over 200
biomarkers have also been explored alone and in combination, however, none have been
revealed to be sensitive enough to result in prediction (Osol & Bernstein, 2014). Further
research is necessary on the use of biochemical and biophysical markers already commonly
collected during prenatal care for use in preeclampsia prediction.
Subtypes of Preeclampsia
Preeclampsia is heterogeneous in nature (Founds et al., 2011; Myatt et al., 2014). There
are two distinct subtypes, early and late onset. It is important to note that these two subtypes are
defined in relation to the timing of onset of the disease during pregnancy, not necessarily
severity, and either subtype can have severe features (Kucukgoz Gulec et al., 2013). The
American College of Obstetricians and Gynecologist guidelines for management of preeclampsia
are based on the presence or absence of severe features. However, the subtypes seem to have
differing clinical and laboratory findings of each subtype seem to differ ( Kucukgoz Gulec et al.,
2013). Subsequently, ACOG (2013) has called for more research into each preeclampsia
subtype in order to determine if each subtype has a unique pathophysiology or risk factors and
thus could require different management and/or treatment.
It has been difficult to synthesize research literature on preeclampsia subtypes as studies
have used differing definitions of the early and late onset subtypes. In the literature, the
definition of early onset preeclampsia varies, typically stated as onset of preeclampsia
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symptomology occurring anywhere from prior to 28 0/7 weeks gestation to 37 0/7 weeks
gestation (Tranquilli et al., 2013). Recently, the International Society for the Study of
Hypertension in Pregnancy (ISSHP) set out to construct clear definitions of each preeclampsia
subtype, in order to allow for improved synthesis of the research literature moving forward.
Early onset preeclampsia is now defined by the ISSHP as occurrence of preeclampsia ≤ 33 6/7
weeks gestation, while late onset preeclampsia occurs ≥ 34 0/7 weeks (Lisonkova, & Joseph,
2013). Late onset preeclampsia is further subdivided to include preterm preeclampsia, which can
occur anywhere between 34 1/7 weeks until 37 0/7 weeks gestation, and term preeclampsia,
which occurs ≥ 37 1/7 weeks gestation (Tranquilli et al., 2013).
Myatt et al. (2014) further support the importance of standardizing preeclampsia research
design and provide guidelines for preeclampsia research. Myatt and colleagues (2014) also
recognized variation in the definition of each preeclampsia subtype, noting that most research
which explored preeclampsia subtypes do so in relation to timing of delivery, and utilized <37
0/7 weeks gestation and >37 0/7 weeks gestation as criteria for the early and late onset subtypes.
Noting the significant increased risk of perinatal morbidity associated with preeclampsia cases
that occur prior to 34 0/7 weeks gestation, Myatt and colleagues (2014) support the criteria
outlined by the ISSHP and also recommend using <34 0/7 weeks gestation as criteria for early
onset preeclampsia.
Early onset preeclampsia. Early onset preeclampsia is often more severe in nature than
its late onset counterpart (Kucukgoz Gulec et al., 2013). It is suggested that early onset
preeclampsia may have a significant genetic component and poor early placentation is seen more
frequently in this subtype (Boyd et al., 2013; Steegers, Von Dadelszen, Duvekot, & Pijnenborg,
2010 ). Kucukgoz Gulec et al. (2013) observed increased rates of Hemolysis, Elevated Liver
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Enzymes and Low Platelets (HELLP) syndrome, eclampsia, and admission to critical care units
in women with early onset preeclampsia. These authors also reported that gestational age at
admission seems to indicate worse neonatal outcomes. Early onset preeclampsia is also more
often associated with abnormal uterine artery doppler velocimetry (Phillips, Janowiak, Badger &
Bernstein, 2010) as well as FGR (Kucukgoz Gulec et al., 2013). Early onset preeclampsia may
be unique in that there seems to be a significant uteroplacental component, as well as certain
maternal pre-pregnancy characteristics that may predispose women to both the early onset
subtype as well increased long-term cardiovascular risk (Phillips et al., 2010). “Early
preeclampsia appears to be characterized by a state of high total vascular resistance and low
cardiac output, whereas low total vascular resistance and high cardiac output mark term and
near-term preeclampsia” (Phillips et al., 2010, p. 624). Although the ACOG Task Force (2013)
did not construct preeclampsia treatment/management guidelines based on preeclampsia
gestational age at onset, however, ACOG (2013) did make recommendations for initiation of late
first trimester aspirin therapy based on prior pregnancy with early onset preeclampsia.
Late onset preeclampsia. Although early onset preeclampsia is often more severe in its
presentation, late onset preeclampsia can also include “severe features” as described by ACOG
(2013). The late onset subtype has been shown to have a higher incidence than early onset
preeclampsia (Lisonkova, & Joseph, 2013). Boyd and colleagues (2013) suggest that
environmental factors may contribute most to late onset preeclampsia.
Cardiovascular Disease and Preeclampsia
Previously it was thought that preeclampsia was completely cured by delivery of the
pregnancy. However, more recently, research has begun to support that preeclampsia increases
long-term risk of cardiovascular disease in women and infants who survive the pregnancy
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disorder (Firoz & Melnik, 2011; Fraser et al., 2012; Geelhoed et al., 2010; Hermes et al., 2013;
Herrera-Garcia, & Contag, 2014; Mongraw-Chaffin, Cirillo, & Cohn, 2010; van Rijn, et al.,
2013). Women who were previously affected by early onset preeclampsia have been shown to
have seven to nine times the increased risk of cardiovascular disease. Late onset preeclampsia
has been shown to impart twice the risk of cardiovascular disease later in life in those who have
been previously affected (Mongraw-Chaffin, Cirillo, & Cohn, 2010; van Rijn, et al., 2013).
Currently, no postpartum evidenced based cardiovascular risk reduction programs have
been designed for women who have been diagnosed with either subset of preeclampsia, nor have
screening strategies been created (Bushnell et al., 2014; Cusimano, Pudwell, Roddy, Cho, &
Smith, 2014; Firoz & Melnik, 2011). Although traditional cardiovascular interventions may be
used, there is no evidence to support their efficacy among women with preeclampsia and these
interventions may differ by preeclampsia subtype (Celi et al., 2013; Firoz & Melnik, 2011;
Veerbeek et al., 2015). Recent American Heart Association guidelines (2014) for the prevention
of stroke in women reported that 18.2% of women with a history of preeclampsia had a
cardiovascular event in the 10 years following the delivery of the effected pregnancy compared
to 1.7% of women with uncomplicated pregnancies (Bushnell et al., 2014). With an
understanding of the connection between cardiovascular disease (CVD) and preeclampsia, health
care providers and women should view pregnancy as a unique opportunity, one that allows
women and their health care providers an early glimpse into future health risk. Additionally, this
provides women with an opportunity to begin to utilize preventative strategies proactively with
an aim towards health promotion (Bushnell et al., 2014).
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Blood Type as a Risk Factor
Due to the link between later life cardiovascular disease and preeclampsia, researchers
should explore shared risk factors. Both cardiovascular disease and preeclampsia may be
associated with blood type. Further examination of risk factors shared between the two disease
processes is necessary, in the hope of establishing a clearer pathophysiologic basis for
preeclampsia (Biswas et al., 2013; Bushnell et al., 2014). Several studies have revealed a
correlation between ABO blood type and preeclampsia (Alpoim et al., 2011; Alpoim et al., 2012;
Clark, Walker, Govan, Wu, & Greer., 2007; Hiltunen et al., 2009; Phaloprakarn & Tangjitgamol,
2013; Seyfizadeh et al., 2014; Than et al., 2011). No recent research has been done in the United
States looking at the correlation between blood type and preeclampsia subtype.
Early onset preeclampsia has been linked to higher risk of cardiovascular disease than its
late onset counterpart (van Rijn et al., 2013). It is proposed that the two subtypes have differing
pathophysiology. Since ABO blood type has also been linked to cardiovascular disease, it is
necessary to explore its role in the pathophysiology of both preeclampsia subtypes. With an
understanding of the link between preeclampsia and cardiovascular disease, the pathophysiologic
basis for preeclampsia may in fact be revealed through further investigation of biomarkers shared
between preeclampsia and CVD (Biswas et al., 2013; Bushnell et al., 2014). Understanding nonmanipulable risk factors of preeclampsia may help to find manipulable agents that can used in
treatment and management of preeclampsia (Shadish, Cook & Campbell, 2002).
Pathophysiologic Framework of the Study
Pathophysiology
There are four major human blood groups A, B, O and AB (Seyfizadeh et al., 2014).
Current research supports that ABO blood phenotypes are now far more useful than in
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hematology and transfusion medicine alone (Franchini & Lippi, 2015). Research indicates that
blood phenotype may be linked to cancer particularly gastric and pancreatic cancers,
cardiovascular disease as well as a variety of infectious disease (Biswas et al., 2013; Edgren et
al., 2010; Franchini & Lippi, 2015). ABO antigens are expressed differently on the red cell
surface as well as in a “variety of human cells and tissues, including epithelium, sensory neurons,
platelets, and vascular endothelium” (Franchini & Lippi, 2015, p. 1). ABO blood phenotype
effects hemostasis, due to varying levels of Von Willebrand factor (VWF) and Factor VIII by
blood type (Franchini, Mengoli, Lippi, 2016). Non-O groups have approximately 25% higher
levels of VWF than other types (Franchini & Lippi, 2015). Thusly, those with Non-O blood
phenotypes are at increased risk for venous thrombosis, arterial thrombosis, myocardial
infarction (MI) and ischemic stroke (Franchini & Lippi, 2015). The link between alteration in
hemostasis seen in certain blood types as well as preeclampsia supports the biologic plausibility
of this study.
Feminism
Traditional science holds significant power to improve outcomes, however, long held
beliefs surrounding the biologic similarities of male and female bodies have hampered progress
particularly related to cardiovascular research focused on women’s health. Although the basis of
this study is highly pathophysiologic, feminism provides an excellent framework by which to
examine the role preeclampsia plays in risk of future CVD. It is important for researchers in this
area to have an understanding of how women’s oppression plays into their social reality (Yuill,
2012). A feminist framework allows for in-depth analysis of phenomena surrounding women
bodies as well as their overall health, and provides a platform by which researchers can advocate
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for the health of women and challenge a patriarchal dominated medical community (Routledge,
2007).
Purpose of the Proposed Study
This study will focus on identifying the strength of association between maternal blood
type and preeclampsia subtype with an aim at improving identification and screening of those at
increased risk for future cardiovascular disease. Additionally, the study will aim to identify risk
factors and birth outcomes associated with both early and late onset preeclampsia.
Hypotheses and Research Questions
The research questions that will be addressed in this study include:
Research Question 1:
What are the maternal characteristics of women with preeclampsia and with each preeclampsia
subtype?
Hypothesis 1: Individuals with early onset preeclampsia will have more traditional
cardiovascular risk factors such as higher body mass index (BMI) and chronic hypertension and
diabetes; additionally, more subjects in the early onset subtype will be of African American race
and of lower socioeconomic class.
Research Question 2:
Is there an association between preeclampsia subtype and ABO blood phenotype?
Hypothesis 2: Early onset preeclampsia will be more highly correlated with non-O blood
types than its late onset counterpart will. This directional hypothesis is based on several previous
studies, which showed women with non-O blood types were at increased risk of preeclampsia
due to elevated coagulation factors noted in these blood types as well as differences in
inflammatory biomarkers (Alpoim et al., 2011; Hiltunen et al., 2009; Lee, Zhang et al., 2012;
Phaloprakarn & Tangjitgamol, 2013). The main aim of these studies was not to assess this
association by preeclampsia subtype, but rather preeclampsia as a homogenous group. Since
11

there is evidence to support two distinct subtypes of the disease, it is important to look at if blood
type more significantly correlates with one subtype. Since cardiovascular risk is higher in the
early onset subtype and non-O blood types correlate with increased cardiovascular risk (Chen et
al., 2014; Etemadi et al., 2015; Gong et al., 2014a; Gong et al. 2014b; He et al., 2012; Karabuva,
Carević, Radić, & Fabijanić , 2013; Lee, Zhang et al., 2012; Zakai et al., 2014), this author
hypothesizes that non-O, blood types will also be more common in the early onset preeclampsia
subtype.
Research Question 3:
What is the association between preeclampsia subtype and Rh type?
Hypothesis 3: Rh factor will not be associated with preeclampsia or preeclampsia
subtype. In most previous studies which assessed the association between Rh factor and both
preeclampsia and CVD no relationship was reported (Etemadi et al., 2015; He et al., 2012;
López-Pulles et al., 2010; Shamsi et al., 2010). Although most studies did not find an association
between Rh factor and preeclampsia, Sezik, Toyran and Yapar (2002) reported an association
between O negative women and increased risk of HELLP syndrome. Subsequently, Rh data will
be included in the study in order to determine if Rh factor is associated with either subtype of
preeclampsia.
Research Question 4
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation and
preeclampsia development?
Hypothesis 4: ABO blood type will be associated with platelet count at ≥ 28 6/7 weeks
gestation in each preeclampsia subtype. Preeclampsia diagnostic criteria can include platelet
count < 100,000 microliter in the absence of proteinuria, and platelet count < 100, 000 microliter
can also indicate increasing severity of the disease. ABO antigens are expressed on both the red

12

cell as well as on platelets (Franchini & Lippi, 2015). Since risk of preeclampsia is said to differ
by ABO blood type, platelet count may also differ (Freitas, Alpoim, Komatsuzaki, Carvalho, &
Dusse, 2013; Hiltunen et al., 2009; Lee, Zhang et al., 2012; Phaloprakarn & Tangjitgamol,
2013).
Research Question 5:
What is the association between ABO blood type and fetal growth restriction in preeclamptic
women?
Hypothesis 5: ABO blood type will be associated with FGR in preeclamptic women.
Preeclampsia, particular early onset has been associated with increased risk of FGR (Kucukgoz
Gulec et al., 2013). Hiltunen et al. (2009) discovered an association between AB blood type and
growth restriction in preeclamptic women.
Research Question 6
What factors are significantly associated with preeclampsia and preeclampsia subtype?
Hypothesis 6: Non-O blood types will have increased odds of preeclampsia and
preeclampsia early onset subtype. Traditional clinical and sociodemographic risk covariates
such as increased BMI, nulliparity, lower socioeconomic status, Black race, extremes in maternal
age will increase odds of the early onset preeclampsia subtype (Bartsch et al., 2016; Boyd et al.,
2013; Lisonkova & Joseph, 2013; O'Brien, Ray, & Chan, 2003; Paré et al., 2014).
Study Setting
Due to accessibility, the electronic health record (EHR) from a large suburban
community hospital in the Mid Atlantic United States that has roughly 3000 births per year was
utilized to obtain the desired data. There are only two other small community hospitals with in
the area; however, the majority of high-risk pregnancies are delivered at this hospital due to its
NICU and high risk obstetrical facilities. Additionally, maternal fetal medicine specialists also
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care for women not geographically close to this institution. Subsequently, women go on to
deliver at this institution while following up with their high-risk care. This may result in a higher
proportion of women with preeclampsia being seen at this institution.
Contributions to Nursing
Over the past 20 years, scientists have learned much about preeclampsia and the focus
has moved away from blood pressure as the central etiology of the disease. Recent research has
begun to focus on biomarkers that may provide insight into origins of the disease this however,
has not resulted in earlier recognition or improved management (Myatt et al., 2014). In
November of 2013, preeclampsia diagnostic criteria was updated and no longer requires
proteinuria for diagnosis (ACOG, 2013). In turn, this may result in women that would
previously not have been diagnosed with preeclampsia now being included in studies. Inclusion
of this new population of women may in turn reveal new characteristics about women with
preeclampsia. Many previous studies did not explore specific subtypes of preeclampsia; research
aimed at exploring specific subtypes of preeclampsia may lead to an enhanced understanding of
the pathophysiology of the disease (Myatt et al., 2014). A more clear understanding of the
pathophysiology may improve prediction. Additionally, with the known association between
cardiovascular disease and preeclampsia, a better understanding of risk factors that mediate the
two diseases may lead to the creation of targeted therapies as well as cardiovascular preventive
interventions specific to each subtype of preeclampsia.
Chapter Summary
Preeclampsia in heterogeneous in nature, each subtype is associated to a varying degree
with poor long-term cardiovascular sequelae. Thusly, it is important to explore shared risk
factors. If the primary hypothesis of this study is supported, non-O blood types will be
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associated with an increased risk of early onset preeclampsia, which in turn may shed light on
the pathophysiologic process that mediates its relationship to cardiovascular disease. This study
may then provide new information on how to tailor cardio preventive therapies geared towards
women who have had preeclampsia or aid in the design of tools aimed at preeclampsia
prediction.
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CHAPTER 2
Philosophical Framework and Literature Review
Introduction to the Chapter
The aim of this study is to 1) examine the association between ABO blood type, Rh factor
and preeclampsia subtype and to 2) determine which other factors most significantly influence
the development of each preeclampsia subtype. Additionally, epidemiological data will be
collected in order to better describe each preeclampsia subtype. It is well established that
women with preeclampsia have an increased risk of CVD (Mongraw-Chaffin, Cirillo, & Cohn,
2010; van Rijn, et al., 2013). Of the two subtypes, women with the early onset subtype have a
significantly higher risk of cardiovascular disease than the late onset subtype (van Rijn, et al.,
2013. It is hypothesized that due to the increased cardiac risk associated with non-O blood types,
non –O blood types may also be associated with the development of early onset preeclampsia.
Chapter 2 begins by outlining the philosophical framework from which this study is
grounded. Since preeclampsia is a uniquely female cardiac risk factor, feminism provides an
excellent framework by which to address research gaps and pose questions. Feminist empiricism
as well as the role feminism plays in cardiovascular research is described. Next, the proposed
pathophysiology of preeclampsia will be described and non-classic biomarkers discussed.
Finally, a review of the literature that assesses the current evidence on both the relationship
between both ABO blood type and preeclampsia as well as cardiovascular disease and
preeclampsia was completed in order to describe common themes.
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Philosophical Framework
Cardiovascular disease (CVD) remains the leading cause of death in women in the United
States, with heart attack the leading cause and stroke the third leading cause of mortality (Tindall
& Vanderman-Winter, 2011). Although millions of dollars have been allocated towards research
on cardiovascular disease, women have not seen the same improvement in outcomes, as have
men. Rates of cardiovascular mortality have been declining in men since the early 1980s
however, rates in women have been declining at a much slower rate, with CVD effecting 1 in 3
women (American Heart Association, 2015). Even within this gendered component of the
disease, there continues to be racial disparities. CVD disproportionately affects African
American and Hispanic women (Mosca, Hammond, Mochari-Greenberger, Towfighi, & Albert,
2013). In order to appropriately study this vexing problem, taking a gendered approach is
necessary. A gendered approach requires studying both biologic as well as socially constructed
differences between the lives of men and women (Davidson, 2012). Preeclampsia has significant
implications for the long-term cardiovascular health of women, and is a cardiovascular risk
factor unique to women. Thusly, more in depth study of preeclampsia and its relationship to
cardiovascular disease needs to occur. Although blood type is not a uniquely female
characteristic, it is important to assess how ABO blood type mediates preeclampsia risk as well
as long-term cardiovascular disease risk in women, as this may improve prediction of both
diseases.
Feminist empiricism. Feminist empiricism supports the basic principles of scientific
inquiry, accepts that the world can be seen objectively and believes that knowledge is gained
through experiences. The feminist empiricist also supports that research should be done by
women on female participants in order to further maintain the feminist paradigm (Yuill, 2012).
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There has been much debate as to what constitutes nursing knowledge, particularly how it relates
to questions of basic science (Perry, 1994). Biologic research is indeed nursing research. For as
nurses, we provide holistic care, and with this said, biologic phenomena cannot be separated
from the holistic context (Perry, 1994). Perry et al. (1994) stated that “In order to prevent illness
and promote health, it is necessary to generate knowledge about cellular processes that is less
distorted and biased then that produced by a method entrenched in androcentrism” (p. 491). This
quote speaks to the fact that the utilization of a feminist framework in biologic studies is
paramount to the creation of new knowledge in this area.
Both women and men perpetuate androcentrism in the basic sciences (Perry, 1994).
Historically, women and issues of women’s health have been excluded from basic science
research as well as research agendas. A scientific community largely made up of men has
designed these agendas. Subsequently, the health issues of women as well how women are
effected by disease has not been studied as extensively due to allocation of funds towards
androcentric research agendas (Perry, 1994). It is necessary to begin to focus basic science
research on the health and wellness of women and continue to acknowledge the effect gender
bias has had in cardiovascular research (McCormik & Bunting, 2002).
Feminist empiricism may be helpful in addressing research gaps specific to the biologic
functioning of women by accounting for androcentric bias found in theories and methodologies
often used in basic science (Perry, 1994). The researcher and the phenomena being studied are
inextricably linked, thus objectivity in research is value laden (Perry, 1994; Potochnik, 2012).
Social values shape ways of knowing in the scientific community, and thus scientific practice
(Potochnik, 2012). This not only influences what studies are undertaken but also, hypotheses
postulated, variables chosen, judgments made and answers found (Potochnik, 2012). Perry
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(1994) suggests that increasing the number of women working within the scientific realm to
determine and study biologic problems specific to women, has the potential to alter the research
agenda and greatly improve outcomes in women.
Feminist Framework
A feminist framework can be used to gather both quantitative and qualitative data, as “it
is the point of view of the researcher that makes research feminist in nature” (McCormick &
Bunting, 2002, p.824). McCormick and Bunting (2002) listed eight criteria gathered from
multiple authors, which define feminist research:









“principle investigator was a woman,
feminist methodology was used,
the study had the potential to help the subjects as well as the researcher,
the research focused on the experience of the woman,
the investigator’s purpose was to study women within their role as women,
the word “feminist” or “feminism” was used in the report,
bibliographic references to feminist literature were made, and
nonsexist language was used” (p. 824).
Several of the above criteria will be addressed as this author sets out to study the

phenomena of preeclampsia and risk factors related to long-term cardiovascular disease.
Foundational to this study is the aspect that cardiovascular research, prevention strategies, and
risk factor identification strategies do not adequately represent the needs and risk factors unique
to women. When a feminist viewpoint is used to study cardiovascular disease in women, the
potential for understanding the phenomena is enhanced. In addition, this author’s study aims to
improve the health of women, valuing the experience of pregnancy as unique as well as sex
specific.
Women’s Awareness of CVD
Clarke (1992) called for the use of a feminist methodology in health promotion research
and asked researchers to consider gender and sex when designing and conceptualizing research
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studies. For many years, CVD was socially constructed as a male illness, however, in the past
decade, there has been a significant effort to increase women’s awareness of their risk for this
disease (Long, Taubenheim, Wayman, Temple, & Ruoff, 2008; Mosca, Hammond, MochariGreenberger, Towfighi, & Albert, 2013). Although awareness is improving, it continues to lag
particularly in racial and ethnic minorities (Mosca, Mochari-Greenberger, Dolor, Newby, &
Robb, 2010). Even with improvement in women’s awareness of CVD risk, due to androcentric
worldviews and gender bias in health research, how women are affected by, their risk factors for,
and symptomology of CVD has been under studied (McCormick & Bunting, 2002).
Lack of research on how sex and gender specific factors affect cardiovascular disease
and outcomes provide inadequate science for nurses to adequately educate and care for their
female clients. Since health care providers are relatively unaware of the link between certain
pregnancy complications and long-term cardiovascular risk, women remain under educated
about their increased CVD risk if they had a pregnancy complicated by preeclampsia (Young,
Hacker, & Rana, 2012). Subsequently, women are unable to make decisions to initiate lifestyle
modifications aimed at prevention of CVD. Adams et al. (2014) called for improved
communication and collaboration between obstetrical and primary care providers as well as
increased patient education about the importance of pregnancy history to cardiovascular
outcomes.
Feminist Research
In order to improve women’s health research initiatives, in 1993, the NIH Revitalization
Act required that women be included in clinical trials, the same year the FDA reversed its ruling
that barred childbearing women from participating in clinical research (Mosca, Barrett-Connor,
& Kass Wenger, 2011). Although these were great strides towards improvement and
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identification of women’s health issues, in 2003, the Food and Drug Administration Office of
Women’s Health (FDA OWH) reported that although women and men are equally participating
in research, these results are not presented as gender specific (Mosca, Barrett-Connor, & Kass
Wenger, 2011). It is integral to differentiate between the concepts of sex and gender
(Hammarstrom et al., 2014). Examining biologic mechanisms unique to women allows
researchers to begin to better understand their role in long-term health outcomes. A more clear
understanding of uniquely female biologic concepts, such as preeclampsia and other pregnancy
specific complications may be integral to improving health in women. There are biologic, social
and environmental factors that must be considered when assessing risk and protective
mechanisms that occur in the lives of men and women (Lorber & Moore, 2002). With this said,
pregnancy is uniquely female, and the effect this process has on the long-term health of women
must be considered.
Sex and Gender Specific Factors of Cardiovascular Disease
Yentl syndrome. In 1991, Dr. Bernadette Healy published an article in the New England
Journal of Medicine describing Yentl Syndrome. Yentl syndrome is named after a woman in a
short story who had to disguise herself as a man to receive equal treatment. Dr. Healy felt that
women did not receive equal treatment for CVD until their symptomology presented like that of
a man. She cited research showing that women were less likely to undergo coronary
angiography, angioplasty and surgery when admitted to the hospital with similar diagnosis as
their male counterparts; additionally women exhibited more debilitating angina then men and
continued not to receive cardiac catheterization (Healy, 1991). It was not until after women had
procedures such as cardiac catheterization and angioplasty or were determined definitively to
have had a myocardial infarction that they received treatments at the same rate as men. At this
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point, due to delayed treatment, major damage was often done. Dr. Healy described this
inequitable treatment of women with cardiovascular symptomology as Yentl syndrome (Healy,
1991). Sex specific cardiovascular risk factors such as preeclampsia may further complicate
identification of women at risk for CVD. Obstetrical risk factors for CVD such as preeclampsia,
fetal growth restriction (FGR), and prematurity are not factored into cardiovascular risk models
or acknowledged by health care providers as CVD risk factors further perpetuating Yentl
syndrome as described by Dr. Healy over thirty years ago (Smith, Pudwell, Walker & Wen,
2012).
Biologic differences. Although there has been improvement in cardiovascular care in
the past two decades, there continues to be more women than men living with, and dying from
CVD and stroke, and women continue to have higher rates of hypertension then men (Mosca et
al., 2011; McCormick & Bunting, 2002). Much of the early biomedical health research was
conducted utilizing male participants, often generalizing these findings to women. Social issues
notwithstanding, there are significant biologic as well as anatomical differences between the
cardiovascular systems of men and women. Sex specific factors such as pregnancy, menopause,
and hormones may have an effect on CVD (Craici, Wagner, & Garovic, 2008). These sex
specific factors may influence onset and diagnosis of CVD, as well as its clinical course, efficacy
of therapy, and outcomes (Craici et al., 2008). Biologic differences between men and women
include; women have smaller coronary arteries, increased rates of mitral value prolapse and left
ventricular hypertrophy, lower hematocrit levels, and lower premenopausal blood pressures
(McSweeney, Pettey, Souder, & Rhoads, 2011). These biologic dissimilarities can result in
differences in CVD risk factors between the sexes (McSweeney et al., 2011).
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Differences in symptoms. Women with coronary heart disease (CHD) present with
different symptomology than do men and often present with silent myocardial ischemia.
However, in contrast to men who often report crushing chest pain during episodes of cardiac
ischemia, women frequently present with what health care providers often term ‘atypical’ chest
pain. Women often report abdominal pain, persistent flu-like symptoms, shortness of breath as
well as nausea and fatigue during periods of cardiac ischemia (McCormick & Bunting,

2002;

Nicholson, 2007, p. 44). This atypical presentation often results in misdiagnosis and delay in
treatment which may in turn effect long-term outcomes (McSweeney et al., 2011). However,
researchers and clinicians should be cautious describing women’s symptoms as ‘atypical’ and
work to redefine symptoms of heart disease to be inclusive.
Women as caregivers. In addition to sex specific factors, gender specific factors also
play a role as to how women experience cardiovascular disease. Research has shown that
women wait longer with symptoms before seeking cardiovascular care (Nicholson, 2007). A
women’s delay in seeking care for CVD symptoms is often related to their role as wife, mother,
and caregiver (Davidson et al., 2012). When considering timing of cardiovascular interventions
after preeclampsia it is important to contemplate a women’s role as new mother. Women are
often distracted caring for others, and put their own needs last; however, during the postpartum
period they may be motivated to embrace lifestyle changes in order to promote the health and
wellness of their family (Cusimano et al., 2014; Mosca et al., 2006; Seely et al., 2013). Women
are often faced with role strain as they struggle to care for family, often balancing work outside
the home. Having health care providers that honor mutuality in decision-making may improve a
women’s willingness to access health care (Davidson et al., 2012). The socially constructed
roles of women are important to consider when attempting to understand preeclampsia’s
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relationship to long-term cardiovascular risk as well as when creating interventions to protect
against or treat cardiovascular disease in women who have had preeclampsia.
Biomedical discourse. Historically, uniquely female biologic experiences have been
characterized by medical establishments as being a flawed state or a deficiency, resulting in
medicalization (Hyde, Nee, Howlett, Drennan, & Butler, 2010). This has occurred with
menopause, which is more often considered a deficiency disorder by the medical community
subsequently shaping the way women and health care providers view the biologic changes that
accompany menopause (Hyde et al., 2010). Many times women feel guilty after a preeclamptic
pregnancy due to poor infant outcomes that are often associated with this disease and may feel
overwhelmed when learning of their risk of CVD at such a young age (Seely et al., 2013).
Although preeclampsia may in fact be an independent risk factor of cardiovascular disease, it
will be important to acknowledge that pregnancy is not a “flawed” state and not allow medical
discourse to shape a women’s childbirth experience (McCormick & Bunting, 2002). Although it
is important to recognize preeclampsia as a sex specific risk factor of CVD, nurses should use
this an opportunity to empower women and advocate for improvements in their health and
wellness as well as that of their family (McCormick & Bunting, 2002).
Health Care Provider Awareness of Preeclampsia and Cardiovascular Disease
As with CVD, in preeclampsia, when women are uneducated, they are often unaware of
the signs and symptoms. Additionally, the physical complaints associated with preeclampsia are
often non-descript. Because of this, health care providers often delay diagnosis and treatment
(You, Wolf, Bailey, & Grobman, 2012). In obstetrical patients, health care providers need to be
encouraged to listen carefully to women when they call into the office with reports of vague
complaints such as they are “just not feeling right.” Health care providers in all settings tend to
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minimize these reports, which are often missed opportunities for early evaluation and improved
outcomes (Tsigas, 2006; Walsh, 2013). A common theme of women’s experiences with both
preeclampsia as well as cardiovascular disease is lack of recognition of symptomology by the
medical community. Only 60% of primary care providers are aware of up to date American
Heart Association guidelines for prevention of CVD in women (Ehrenthal et al., 2013), similarly,
physician’s awareness of preeclampsia as a risk factor for future cardiovascular disease is also
low (Young, Hacker, & Rana, 2012). These gaps in recognition, response, as well as education
may occur due to gender bias that has been perpetuated through medical and health care texts
which are often outgrowths of “male-centered medical research” (McCormick & Bunting, 2002,
p. 823). Nursing as a female dominated profession is ideally situated to bring voice to the gender
specific disparities in the cardiovascular care of women (McCormick & Bunting, 2002).
Pathophysiology of Preeclampsia
In order to better understand possible shared risk factors between cardiovascular disease
and preeclampsia an understanding of the hypothesized pathophysiology of preeclampsia is
necessary. Preeclampsia has been studied in biologic, immunologic, genetic and
pathophysiologic research (Charlton, Tooher, Rye, & Hennessy, 2014; Founds et al., 2011;
Ilekis, Reddy & Roberts, 2007). The disease seems to be resultant from a complex interplay of
maternal and fetal factors (Hermes et al., 2013).
A common pathophysiologic theory of preeclampsia involves abnormal implantation of
the placenta where trophoblasts insufficiently invade and remodel the uterine spiral arteries
resulting in inadequate oxygen delivery to the fetus (Warrington, George, Palei, Spradley, &
Granger, 2013). What is causative of this maladaptation remains unclear. It seems that the
insufficient remodeling of the spiral arteries leads to ischemia, which in turn increases
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angiogenic factors such as sFLT-1 and other inflammatory cytokines (Warrington et al., 2013).
The release of these inflammatory factors into maternal circulation may result in fibrin
disposition in the spiral arteries of the placenta, which can occlude blood to the fetus and result
in FGR (Alpoim et al., 2011). There is also a decrease in proangiogenic factors and an increased
production of reactive oxygen species. This in turn leads to maternal endothelial dysfunction
(Warrington et al., 2013). Subsequently, due to the increased production of endothelin-1 and
decreased availability of nitric oxide, extensive vascular abnormalities occur in end organs such
as the brain and kidneys, resulting in hypertension, neurologic disturbances and proteinuria
(Warrington et al., 2013).
Risk of CVD Based on Early Versus Late Onset Preeclampsia
Risk of CVD. Globally, one in three women dies of cardiovascular disease (CVD).
CVD presents itself differently in women than in men, and often goes undiagnosed, making early
identification of risk factors integral to the prevention of increased morbidity and mortality
(Rich-Edwards, Fraser, Lawlor & Catov, 2014). Obstetric history is a unique risk marker in
women that often goes unassessed (Spaan, Peeters, Spaanderman, & Brown, 2012). Typically
early onset preeclampsia has been associated with increased severity of symptoms as well as
worse maternal and neonatal outcomes than its late onset counterpart (Boyd et al., 2013; van Rijn
et al., 2013). A large prospective study by Mongraw-Chaffin, Cirillo, & Cohn (2010) revealed
that “cumulative cardiovascular disease death survival for women with early preeclampsia was
85.9% compared to 98.3% for women with late preeclampsia and 99.3% for women without
preeclampsia” (p.1). Women with early onset disease have been shown to have a 7-8 fold
increased risk of cardiovascular disease, whereas women with late onset disease have a twofold
increase risk (van Rijn et al., 2013).
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Shared risk factors. The link between pregnancy complications such as preeclampsia
and future cardiovascular disease is not well understood. Research has revealed shared risk
factors between cardiovascular disease and preeclampsia. Shared preeclampsia and CVD risk
factors include increased prepregnancy lipids, triglycerides, BMI, as well as sub clinical
elevation in blood pressure (Alsnes et al., Bushnell et al., 2014; 2014; Ray, Diamond, Singh &
Bell, 2006; Rich-Edwards et al., 2014; Roberts, Bodnar, Patrick & Powers, 2011). Other
underlying CVD risk factors such as metabolic syndrome may also play a role in the
development of preeclampsia (Founds et al., 2011; Smith et al., 2009). Risk factors such as
hypertension, diabetes and smoking seem to have more of an adverse effect on cardiovascular
health in women and young people than in men and the elderly (Spaan et al., 2012). In young
women, favorable cardiovascular profiles resulted in an 80% reduction in cardiovascular
mortality when compared to young women who had two or more cardiovascular risk factors
(Spaan et al., 2012). This points to the extreme importance of both primordial and primary
prevention of cardiovascular disease in this group of women. With an understanding that women
with a history of preeclampsia are at higher risk of CVD later in life, research aimed at exploring
novel risk factors shared between preeclampsia and CVD may be helpful. Research may be
helpful in revealing if pregnancy acts a stress test to expose women already at risk of CVD or
rather if preeclampsia provides added physiologic stress that is in fact causal (Osol & Bernstein,
2014). Additional research aimed at revealing risk factors of preeclampsia may help to establish
the relationship between pregnancy complications and chronic disease risk. This in turn will
help clinicians alter the health trajectories of women who have experienced pregnancies
complicated by preeclampsia. (Rich-Edwards et al., 2014).
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van Rijn (2013) and colleagues suggest that women with early onset preeclampsia had
two or more independent cardiovascular disease risk factors in addition to their preeclampsia
diagnosis. These authors also observed higher BMI’s in women with early onset preeclampsia,
however elevated BMI could only partially explain the increased cardiovascular risk associated
with early onset preeclampsia. In a recent study by Veerbeek et al. (2015), postpartum
modifiable cardiovascular risk factors did differ by preeclampsia subtype: early, late, and
pregnancy induced hypertension. The early onset group had an overall less favorable CVD
profile postpartum. Specifically, there were significant differences in postpartum glucose and
lipid levels in the early onset group. Interestingly, both early onset and PIH groups had higher
rates of hypertension postpartum than the late onset group (Veerbeek et al., 2015).
Postpartum Pathophysiologic Effects of Preeclampsia
Hermes et al. (2013) stated that at 2.5 years postpartum, women with a history of
gestational hypertension or late onset preeclampsia exhibit more cardiovascular risk factors and
have higher risk of hypertension than women who had a normotensive pregnancy. These
cardiovascular risk factors included “higher waist circumferences; higher BMI; higher systolic
and diastolic blood pressures; higher prevalence of metabolic syndrome; higher levels of
biochemical risk factors, including glucose, HbA1c, insulin, insulin resistance (HOMA), total
cholesterol, triglycerides, and hs-CRP; and lower levels of high density lipoprotein (HDL)
cholesterol” (Heremes et al., 2013, p. 474.e5).
Endothelial dysfunction. Endothelial dysfunction has been proposed to be a key factor
in the pathophysiology of preeclampsia and may be the link between preeclampsia and long-term
cardiovascular risk (Sandvik et al., 2013). Soluble fms-like tyrosine kinase (sFlt-1), and
placental growth factor are antiangiogenic factors produced by the placenta, and may cause the
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endothelial dysfunction that results from preeclampsia. Women with a history of preeclampsia
have been shown to have markers of endothelial dysfunction one year after the index pregnancy.
These markers of endothelial dysfunction were shown not to normalize until 11 years after the
index pregnancy (Oslund et al., 2013). Lao (2014) suggests that in preeclampsia there is a
decrease in endothelium-dependent dilatation. Vascular alterations, such as increases in the
thickness of the carotid intima- media, result in alterations in blood pressure such as “higher
brachial diastolic pressure, central systolic pressure, mean arterial pressure (MAP), and
peripheral vascular resistance (PVR)” (Lao, 2014, p.250). Aykas et al. (2015) also found that
alterations in the vascular structure and function associated with preeclampsia persisted after the
index pregnancy. Melchiorre, Sharma, & Thilaganathan, (2014) reported that major adverse
cardiovascular events occur at much higher rates in pregnancies affected by preeclampsia and
risk of stroke and myocardial infarction remains significant for >/= three years postpartum.
Although Oslund (2013) found normalization in endothelial dysfunction, women with a history
of preeclampsia remained at higher risk for dysrhythmias, heart failure as well as cardiac death.
Cardiac changes. In addition to vascular changes, cardiac changes have also been
shown to occur in patients with preeclampsia. In late onset preeclampsia, women had left
ventricular remodeling as well as myocardial damage, whereas women with early preeclampsia
seem to have more severe cardiac impairment, and in both groups, severe dysfunction and left
ventricular hypertrophy could still be found at 1 year postpartum although higher rates were
noted in the early onset group (Lao, 2014). In women who delivered preterm (<34) with
preeclampsia, risk of cardiac death was even greater. In these women with early preeclampsia,
one in seven would die from a cardiac event within three decades of delivery (Mongraw-Chattin
et al., 2010).
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Shared Pathway CVD and Preeclampsia
In order to bring light to the disparities in the cardiovascular care of women, gender
specific cardiovascular risk factors must be explored. Although much research supports the link
between preeclampsia and future CVD, the mechanism which connects the two is not clear.
Scantlebury and Hayes (2014) propose several different pathways by which preeclampsia may
increase risk of CVD
1)
2)
3)
4)
5)
6)

Increased risk of metabolic syndrome
Persistent endothelial dysfunction
Common underlying risk factors
Altered myocardial structure and function
Renal disease
Other non-classic risk factors

Non-classic biomarkers
A variety of biomarkers have been explored with an aim at improving prediction of
preeclampsia. Visser et al. (2014) completed a metanalysis and systematic review of the
literature looking at novel biomarkers that may predict cardiovascular risk. Due to the suggested
common pathophysiology between cardiovascular disease and preeclampsia, Visser et al. (2014)
hoped to better elucidate if these biomarkers could aid in preeclampsia prediction. The
biomarkers which these authors reviewed included:
“inflammation (intercellular adhesion molecule [ICAM], vascular cell adhesion molecule
[VCAM], interleukin-6 [IL-6], interleukin-10 [IL-10], and E-selectin), thrombosis
(homocysteine, von Willebrand factor [VWF], fibrinogen, fibronectin, endothelin, Ddimer, plasminogen activator inhibitor-1 [PAI-1], tissue plasminogen activator [tPA]), and
angiogenesis (vascular endothelial growth factor [VEGF], soluble Fms-like tyrosine
kinase-1 [sFLT-1], and tumor necrosis factor alpha ([TNF-a])” (Visser et al., 2014, p.
373e2).
The authors broke these biomarkers into categories, those that effected inflammation,
thrombosis, and angiogenesis (Visser et al., 2014). Levels of some of the specific biomarkers
listed above are unique based on blood type. Although these authors did not find significant
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differences in thrombotic biomarkers such as von Willebrand factor and fibrinogen in their
review, previous studies have revealed a shared pathophysiology between thrombosis and
preeclampsia and elevated levels of these markers in preeclamptic women. This shared pathway
could explain the restriction of blood flow and reduced placental perfusion noted in preeclampsia
(Visser et al., 2014). It has been shown that levels of VWF as well as other biomarkers vary
based on blood type (Franchini & Lippi, 2015). Thusly, it is biologically plausible that ABO
blood type may mediate the development of preeclampsia (Alpoim et al., 2013). Additionally,
since preeclampsia influences risk of future cardiovascular disease and ABO blood type has been
implicated in the development of both disease processes, this relationship must be further
explored.
Review of the Literature: Preeclampsia and ABO Blood Type
Introduction
Preeclampsia effects 3-8% of all pregnancies (Hutcheon et al., 2011). It is a global issue
and is related to significant maternal and neonatal morbidly and mortality. Rates of
preeclampsia have risen by 25% in the past two decades in the United States and it is listed as a
major contributor to prematurity (Ferrazzani et al., 2011; Wallis et al., 2008). Mothers
diagnosed with preeclampsia have increased risk of poor short and long-term outcomes
(Bushnell et al., 2014). Preeclampsia has been called the disease of theories and the
pathophysiology has yet to elucidated (Founds et al., 2011). It is hypothesized that different
subtypes of the disease may exist.
Preeclampsia is defined by ACOG (2013) as the new onset of hypertension >/=140mm
Hg systolic or >/=90mmHg diastolic after 20 weeks gestation, and proteinuria (>/=300mg in a
24-hour urine collection) or in the absence of proteinuria, platelets < 100,000 microliter, serum
creatinine > 1.1 or doubling of serum creatinine in the absence of renal disease, and elevated
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concentrations of blood liver transaminases to twice normal levels. When preeclampsia is
diagnosed prior to 34 weeks in pregnancy it is defined as early onset preeclampsia, when
occurring on or after 34 weeks gestation it is defined as late onset preeclampsia (Lisonkova, &
Joseph, 2013). Typically early onset preeclampsia has been associated with increased severity of
symptoms and more severe maternal and neonatal outcomes than late onset preeclampsia (Boyd
et al., 2013; van Rijn et al., 2013). ACOG (2013) recently called for more research into the
subtypes of preeclampsia in order to better determine if each subtype has a unique
pathophysiology or set of risk factors thus requiring tailored therapies and interventions.
Preeclampsia and Cardiovascular Disease
Previously it was thought that preeclampsia was in fact cured by the imminent delivery of
the baby. However, more recently, research has begun to support that preeclampsia is linked to
long-term risk of cardiovascular disease in affected women (Firoz & Melnik, 2011; Fraser et al.,
2012; Hermes et al., 2013; Mongraw-Chaffin, Cirillo, & Cohn, 2010; van Rijn, et al., 2013). The
risk seems to be further increased in women with early onset preeclampsia. Women who were
previously affected by early onset preeclampsia have been shown to have a 7-9 fold increased
risk of cardiovascular disease. Women with late onset preeclampsia has been shown to impart a
twofold increased risk of cardiovascular disease later in life in those who have been previously
affected (van Rijn, et al., 2013).
Currently, no evidenced based cardiovascular risk reduction programs have been
designed for women with preeclampsia, nor have screening strategies been created (ACOG,
2013; Firoz & Melnik, 2011). Although traditional cardiovascular interventions may be used,
there is no evidence to support their efficacy in women with preeclampsia (Firoz & Melnik,
2011). More research is needed to identify variables, which may increase a woman’s risk for
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preeclampsia, so prediction, prevention and treatment of preeclampsia can be improved.
Additionally, we continue to look for what mechanisms connect hypertensive disorders of
pregnancy to chronic cardiovascular disease later in life in women with a history of preeclampsia
so that cardiovascular interventions can be tailored to this population (Scantlebury, & Hayes,
2014). The following review of literature will explore the link between maternal ABO blood
type and preeclampsia.
Blood Type, Preeclampsia and CVD
In the early twentieth century scientist, Karl Landsteiner discovered the ABO blood
phenotype, which was the first genetic polymorphism detected in humans (Etemadi et al., 2015;
Franchini & Liumbruno, 2013). There are four ABO blood phenotypes, A, B, AB, and O.
Today ABO blood type is used in far more than in transfusion medicine alone (Franchini &
Lippi, 2015). ABO blood type can be the cause of illness such as the case in hemolytic disease
of the fetus and the newborn, or in case of hemolytic reactions that occur after transfusion or
transplantation (Franchini, & Liumbruno, 2013). ABO blood type has been shown to increase
the incidence of some disease processes, such as cardiovascular disease, cancer, venous
thrombus and resistance against certain pathogens (Hiltunen et al., 2009; Phaloprakarn &
Tangjitgamol, 2013; Seyfizadeh et al., 2014; Than et al., 2011). With the known link between
cardiovascular disease and preeclampsia blood type may be a biologically plausible moderator.
There has also been literature to suggest a correlation between maternal blood type and
preeclampsia. However, no current literature explores the correlation between ABO type blood
and preeclampsia subtype as currently defined by ACOG (2013). Pike & Dickins (1954) first
looked into the relationship between a woman’s blood type and preeclampsia and found that
women with type O blood may be at increased risk for developing preeclampsia. More recently,
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several other authors continue to support the relationship between blood type and preeclampsia,
however, these authors have pointed to women with non-O blood types as being at increased risk
of preeclampsia. Phaloprakarn & Tangjitgamol (2013) as well as other authors hypothesized that
the correlation between non-O blood phenotypes such as A, B and AB and preeclampsia may be
related to the fact that VWF is higher in non-O blood phenotypes, increasing the risk of
thrombus (Alpoim et al., 2012; Alpoim et al., 2011). More research is necessary in order to
better elucidate if different subsets of preeclampsia require different treatment and follow up and
if different racial and ethnic populations are at increased risk of preeclampsia related to blood
type distribution. The purpose of this author’s dissertation research will be to explore the
association between maternal blood type and preeclampsia subtype with an aim at improving
identification and screening of those at increased risk for future cardiovascular disease as well as
improving prediction, .
Methods Used to Conduct This Review
Search for Evidence
In order to identify literature relevant to preeclampsia and ABO blood phenotype CINAHL,
The Cochrane Collaboration and PubMed databases were searched. These databases were chosen
due to their inclusion of academic nursing, medical and allied health journals, books and other
scholarly texts. The following keywords were used in the review ABO blood group, Rh factor,
preeclampsia, and gestational hypertensive disorders.
Inclusion and Exclusion Criteria
Inclusion criteria include (a) research conducted on pregnant human subjects, (b) in
English (c) published between January 2000 and January 2016 (d) in academic, peer reviewed
journals. This time frame was used for the search due to the limited number of results returned
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using a five year search window. Dissertations, letters to the editor, and other unpublished works
were not included in the search, nor were solitary case studies. The initial search yielded 11
results, and the abstracts were reviewed to assess if each article met the aim of the review. One
additional article was found when searching gestational hypertensive disorders and ABO blood
group. The reference pages of selected articles were then reviewed to identify if there were other
articles that may not have been revealed in the original search. One additional article was
identified. Prior to completing the dissertation, the literature was searched in order to ensure the
review was up to date, one additional article was added to the review. Subsequently, fourteen
articles were included in the review.
Compilation of Evidence
Table of Evidence
The research literature was reviewed, synthesized and leveled using The U.S Preventive
Task Force Levels of Evidence (Appendix A). A table of evidence was created (Appendix B).
The table includes information on title, author name as well as level of evidence, aim of the
research, sample size, results and strengths and limitations of each study. All fourteen articles
are quantitative in nature and are one of the following designs, three systematic review and metaanalysis, five case-control studies, five cohort studies, and one cross-sectional design. These
designs were appropriate for this review, experimental designs, such as randomized control trials
do not lend themselves to this area of study.
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Critical Appraisal of the Evidence
Synthesizing the Evidence
Maternal blood type. Hiltunen et al. (2009) reported that non-O blood group was not
associated with preeclampsia; however, AB blood group was associated with higher rates of
subgroups of preeclampsia such as early and severe as well as preeclampsia with FGR. These
authors reported that O blood type was protective of pre-eclampsia with FGR (P=0.03) and in
their study came close to significance in the early pre-eclampsia group (P=0.08) (Hiltunen et al.,
2009). Lee, Zhang et al. (2012) stated that women with AB blood type had a higher incidence of
gestational hypertensive disorders, while blood group O had the lowest odds of both
preeclampsia and severe preeclampsia. Than et al. (2011) agreed, and reported that maternal
blood groups may be helpful in early assessment of those pregnancies at risk of IUGR.
Conversely, Alpoim et al. (2011) found that in their population, O and non-O blood types did not
differ in frequency between preeclamptic and normotensive pregnancies. In a meta-analysis,
Clark & Wu (2008) reported similar results to Alpoim et al. (2011). In another meta-analysis,
Alpoim et al. (2013) suggest that maternal type AB blood increased risk for preeclampsia. While
Phaloprakarn & Tangjitgamol, (2013) stated a 1.7 fold increased risk of preeclampsia for patients
with A and AB blood types. Hentschke and colleagues (2014) also reported no difference in
blood group distribution between preeclampsia and normotensive women. There is varied
evidence on the correlation between maternal blood type and preeclampsia. More research is
needed to clarify the association, as each study had differing population characteristics and were
done on patients of varying ethnicities.
ABO blood type and ethnicity. Genetic variants of ABO blood types have been shown
to be predictive of risk of hypertension in certain cultures in non-pregnant clients (Gasso et al.,
2012). Distribution of blood group varies based on ethnicity (Hiltunen et al., 2009). There are a
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limited number of studies found in the literature exploring the link between maternal blood type
and preeclampsia diagnosis; this makes it difficult to ascertain the link between blood type and
preeclampsia. The research reviewed was completed using various ethnic groups including the
Thai, Hungarian, Turkish, Scottish, Finnish, Swedish, Iranian, Ecuadorian and Brazilian
populations (Alpoim et al., 2012; Clark et al., 2007; Hiltunen et al., 2009; Lee, Zhang et al.,
2012; Phaloprakarn & Tangjitgamol, 2013; Seyfizadeh et al., 2014). Phaloprakarn &
Tangjitgamol (2013) found that in the Thai population women with A or AB blood types had
higher rates of preeclampsia. Type O blood type is the most common blood type found in both
the Thai population as well as the United States, whereas A is more common in both Japan and
other European countries (Phaloprakarn & Tangjitgamol, 2013). None of the studies reviewed
used American participants, which is an identified gap in the literature.
Von Willebrand Factor and FVIII. Differing ABO blood groups are associated with
varying plasma concentrations of Von Willebrand Factor (VWF) and FVIII (Than et al., 2011).
Plasma levels of VWF increase by blood type in the following order O>A>B>AB (Alpoim et al.,
2013). “Mediators of endothelial cell dysfunction, including relative nitric oxide deficiency,
fibronectin, von Willebrand factor, cell adhesion molecules, and cytokines, are upregulated in
preeclampsia” (Bilhartz et al., 2011, p.696). VWF is a marker of hypercoagulability and may
mediate platelet adhesion to the vessel wall particularly at sites of vascular injury (He et al.,
2012). Since preeclampsia has been associated with fibrin disposition in the placental
microvasculature it may be important to examine the role VWF plays in the development of the
disease (Alpoim et al., 2011). ADAMTS13 is shown to remove VWF from circulation, in a
deficiency of this substrate, VWF levels may rise, increasing the risk of thrombosis in the small
vessels (Alpoim et al., 2011). Alpoim et al. (2013) showed that subjects with AB blood type had
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higher levels of VWF as well as FVIII resulting in increased risk for thrombus formation.
However, when comparing O and non-O blood types, Alpoim et al. (2011) did not find differing
levels of ADAMTS13 levels. Finally, after correction for FVIII levels, Witsenburg and
colleagues (2005) did not find any difference between ABO blood types in terms of risk of
pregnancy complications such as hypertensive disorders of pregnancy and IUGR.
Platelets. Pregnancy is a hypercoagulable state; it is hypothesized that in preeclampsia
there is a deviation in the communication between the inflammation and coagulation cascades
(Han et al., 2014; Rich-Edwards et al., 2014). Preeclampsia diagnostic criteria list platelet count
as >100,000 per microliter in combination with blood pressure parameters as diagnostic of
preeclampsia (ACOG, 2013) and in high risk women aspirin therapy is recommended for
preeclampsia prevention (LeFevre, 2014). Platelets are formed from megakaryocytes in the bone
marrow and referent levels indicate a balance in homeostasis and thrombosis. The imbalance
that results between coagulation and anticoagulation factors in preeclampsia patients can result in
poor placental and maternal end organ perfusion due to microthrombosis (Han et al., 2014). In
addition to increasing coagulation, the increased platelet activation that occurs in preeclampsia
may also mediate inflammation (Gonçalves Freitas et al., 2014).
Blood type antigens A and B are expressed on platelets (Lee, Zhang et al., 2012).
Alpoim et al. (2011) postulated that the increased levels of Ultra Large VWF (ULVWF) seen in
preeclamptic patients might be related to occlusion of the renal and placental arterioles that often
occurs in this disease process. Interestingly, platelets do not adhere to smaller forms of VWF in
the circulation after ULVWF binds to ADAMTS13. This may result in platelets blocking the
microvascular of the placenta (Alpoim et al., 2011). Hiltunen et al. (2009) hypothesized that the
effect blood type has on preeclampsia could be mediated by prothrombitic mechanisms.
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PP13. Than and colleagues (2011) hypothesized that ABO blood type may influence
gene and environment interactions due to how it functio ns at what they deem the “cross-roads”
of the immune and coagulation systems (p. e21564). PP13 is a galectin, which functions at this
crossroads and may be available in varying amounts in different blood groups (Than et al.,
2011). Upon exploration, Than et al. (2011) reported that PP13 is an early marker for
preeclampsia. PP13 is produced by the placenta however, is released into maternal circulation
and works to bind other galactosides found on the ABO blood group antigen (Than et al., 2011).
It is thought that in severe preeclampsia, PP13 may be more readily shed. This in turn may result
in a maternal immune response, which is a suggested pathophysiolo gic basis for preeclampsia
(Lee, Zhang et al., 2012). In their study, Than et al. (2011) state that women with B blood type
had the highest serum levels of PP13 in all trimesters of pregnancy however, in this blood type,
red blood cells had the weakest ability to bind to PP13 (Than et al., 2011). In contrast, AB blood
type had the lowest serum levels of PP13 in the first trimester suggesting that PP13 more readily
binds to certain ABO antigens altering serum-circulating levels. Than et al. (2011) stated that
the proportion of individuals with AB and B blood type were low in their study so they could not
adequately evaluate their association with risk of preeclampsia however, this study reveals that
ABO antigens may play a unique role in preeclampsia risk by regulating the serum availability of
other biomarkers (Than et al., 2011).
Factor V Leiden. Both Factor V Leiden (FVL) and blood group are common heritable
influences, which may affect thrombotic risk (Alpoim et al., 2012; Clark et al., 2007; Hiltunen et
al., 2009). Other research has shown that FVL may be influenced by the inheritance of a non-O
blood type (Hiltunen et al., 2009). FVL has been associated with preeclampsia in previous
studies (Clark et al., 2007; Hiltunen et al., 2009). Hiltunen et al. (2009) report an increased risk
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for preeclampsia in those with FVL and FVL or FII G20210A combined, although this was not a
statistically significant increased risk. In a study by Clark et al. (2007), there was no influence of
either FVL or non-O blood type on risk of preeclampsia. Subsequently, based off their study,
Clark et al. (2007) do not recommend routine screening for FVL to assess for risk of thrombotic
events such as preeclampsia.
Interaction between blood type and other factors. Alpoim et al. (2013) and Than et al.
(2011) both report that how various blood types interact with different biologic and hemostatic
factors may be what increases risk of thrombotic disease in these patients. Phaloprakarn &
Tangjitgamol (2013) suggest that tumor necrosis factor-alpha and intracellular adhesion
molecule 1 tend to be more readily up regulated by the A allele, possibly increasing risk of
preeclampsia in both the A and AB blood type. Seyfizadeh et al. (2014) reported that serum
creatinine levels were significantly higher in AB blood type women in their sample. Since
elevated creatinine is a known risk factor for preeclampsia, it is possible that blood type has an
association with certain preeclampsia risk factors. Additionally, Lee, Zhang et al. (2012)
propose that each ABO blood type may have differing rates of occurrence of certain
cardiovascular risk factors such as hypocholesteremia, insulin resistance and endothelial damage
that subsequently increase risk of preeclampsia.
Rh factor. Lee, Zhang et al. (2012) discovered that Rh positive women also have a
slightly increased risk of developing preeclampsia than their Rh negative counterparts (Lee,
Zhang et al., 2012). Sezik and colleagues (2002) reported in their study, that subjects with O
negative blood had a higher risk of HELLP syndrome than other blood types. This risk was not
reported in women with type O blood independent of Rh type (Sezik et al., 2002). These authors
postulated that the Rh antigen or Rh incompatibility might be important factors in the
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development of this most severe form of preeclampsia. They also hypothesized that the
increased antibody load in O negative individuals could play a role in the increased incidence of
HELLP syndrome seen in this population (Sezik et al., 2002).
Than et al. (2011) did not report any difference in the bioavailability of PP13 based on
Rh type; no difference was still reported even when assessing levels of PP13 by ethnicity.
López-Pulles et al. (2010) also found no difference in rates of preeclampsia between Rh negative
and Rh-positive women in their study.
Summary of Research Conclusions
Implications on Clinical Practice
Identification of risk factors specific to preeclampsia may allow clinicians to better
understand the pathophysiology of the disease, and create an effective risk factor algorithm to
identify women at risk for preeclampsia prior to conception (Alpoim et al., 2012). Globally,
preeclampsia is associated with increased morbidity and mortality. Identifying biomarkers that
promote early detection as well improve scientists understanding of the pathophysiology of
preeclampsia is necessary in order to improve outcomes (Alpoim et al., 2011). Alpoim et al.
(2011) suggests that monitoring FVIII, VWF and ADAMTS13 may be relevant. Phaloprakarn &
Tangjitgamol (2013) suggest that tumor necrosis factor-alpha and intracellular adhesion
molecule 1 tend to be more readily up regulated by the A allele. These inflammatory markers
have also been associated with cardiovascular disease, further pointing to blood type as a
mediator between the two disease processes.
As research continues to advance the science surrounding preeclampsia and with work
toward prophylaxis, the idea of a specific screening algorithm is alluring (Jørgensen, Hedley,
Gjerris, & Christiansen, 2014). With this said, it is important to create an algorithm that has a
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high detection rate and low false positive rate (Jørgensen, et al., 2014). Research on biochemical
markers such as ABO blood type should continue, in order to reach scientific consensus as to
whether or not blood group would be a valuable addition to a screening algorithm. A screening
algorithm could allow for early recognition of patients at risk for preeclampsia, providing
practitioners with the opportunity to utilize prophylaxis or increase antepartal monitoring in
order to improve pregnancy outcomes. Finally, even if ABO Blood type is not significantly
different between preeclampsia subtypes, collection of data on various biomarkers by
preeclampsia subtype may help to clarify or refute potential etiologic pathways (Myatt et al.,
2014).
Limitations of the Review
Overall, there were a limited number of studies that have examined the association between
blood type and preeclampsia. Many of the studies reviewed were retrospective in nature which
may not allow for identification of potential confounders (Polit & Beck, 2012). Additionally,
many of the studies had relatively small sample sizes and were completed on diverse ethnic
populations. Since blood type varies by ethnicity, results are difficult to compare (Hiltunen et al,
2008; Lee, Zhang et al, 2012; Than et al., 2011). In 2013, there was a change in preeclampsia
diagnostic criteria (ACOG, 2013). Due to the differing diagnostic criteria utilized as well as
definitions of subtypes utilized, it is difficult to compare studies. Finally, none of the studies
included information on neonatal and paternal blood type. Due to a postulated immunologic
pathophysiology of preeclampsia, an interaction between fetal and/or paternal antigens and
maternal ABO blood phenotype could also play a role in preeclampsia development.
Review of Literature: Cardiovascular Disease and ABO Blood Type
Introduction
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Cardiovascular disease is a complex disease with a variety of risk factors (Lee, Lin et al.,
2012). Cardiovascular disease is a vexing problem in the United States and around the globe.
Thirty seven percent of deaths of women in the United States are said to be related to
cardiovascular disease (Freibert, Mannino, Bush & Crofford, 2011). Scientists and health care
providers continue to look for risk factors, which may improve early identification and treatment
of those at risk. Since ABO blood type has been linked to increased susceptibility to certain
disease processes, such as preeclampsia and has been associated with varying levels of clotting
factors that increase risk of thrombus formation and cardiovascular risk it is important to explore
further explore this association (Jassim, 2012).
Having a non-O blood type has been associated with nearly 6% of total deaths and as
many as 9% of cardiovascular deaths (Etemadi et al., 2015; Franchini, & Liumbruno, 2013).
Lee, Lin et al. (2012) postulated that since ABO blood type is inherited and premature coronary
artery disease is often linked to inherited risk factors, ABO blood groups could mediate this risk.
It is well established that ABO blood type increases risk of venous thrombus as ABO antigen
expression determines levels of VWF and FVIII (Franchini & Lippi, 2015). Individuals with O
blood types have 25% increased rates of VWF and FVIII, which is often protective of venous
thrombus (Franchini & Lippi, 2015). Many studies suggest that the affect ABO blood type has
on both hemostasis and plasma lipid levels influence other cardiovascular outcomes such as
myocardial infarction and coronary heart disease (Franchini & Lippi, 2015). Accordingly, the
following review of literature was completed in order to explore research on the relationship
between ABO blood type and poor cardiovascular outcomes.
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Methods Used to Conduct This Review
Search for Evidence
In order to identify literature relevant to cardiovascular disease and ABO blood
phenotype CINAHL and PubMed databases were searched. These databases were chosen due to
their inclusion of academic nursing, medical and allied health journals, books and other scholarly
texts. The following keywords were used in the review, ABO blood group and cardiovascular
disease.
Inclusion and Exclusion Criteria
Inclusion criteria were research conducted (a) on human subjects (b) age 19 and older,
(c) in English (d) published in the past five years, (e) in academic, peer-reviewed journals.
Dissertations and other unpublished works were not included in the search, nor were solitary
case studies. The initial search yielded 75 results, and the abstracts were reviewed to assess if
each article met the aim of the review. All articles included in the review used stroke,
cardiovascular disease or atherosclerosis as the main outcome. Fourteen met the inclusion
criteria for this literature review.
Compilation of Evidence
Table of Evidence
The research literature was reviewed, synthesized and leveled using The U.S Preventive
Task Force Levels of Evidence (Appendix A). A table of evidence was created (Appendix C).
The table includes information on title, author name as well as level of evidence, aim of the
research, sample size, results and strengths and limitations of each study. All fourteen articles
are quantitative in nature and are one of the following designs; one meta-analysis, six casecontrol studies, five cohort studies, and two cross-sectional design. These designs were
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appropriate for this review, experimental designs, such as randomized control trials do not lend
themselves to this area of study, as you cannot ethically manipulate blood type.
Critical Appraisal of the Evidence
Synthesizing the Evidence
ABO blood type. Gong et al. (2014b) found that having type A blood was significantly
associated with cardiovascular disease even after adjustment for common cardiovascular risk
factors. Additionally, type A blood was associated with more severe coronary atherosclerosis
than other blood types (Gong et al., 2014b). Lee, Lin et al. (2012) reported in their study that
participants with type A blood had significantly higher rates of coronary artery disease (CAD) as
well as CAD that was more severe than in those with other blood types. This study also revealed
type A blood to be an independent risk factor for both men and women with early onset CAD
(Lee, Lin et al., 2012).
Etemadi et al. (2015) reported that those with non-O blood types had increased risk of
total mortality, with most mortality being attributable to cardiovascular disease. In their
metanalysis, He et al. (2012) noted a statistically significant difference in rates of CAD between
blood groups, reporting that non-O subjects where at a significantly higher risk of developing
coronary heart disease than those with an O blood type. Chen et al. (2014) also reported an
association between non-O blood type and significant CAD although when analyzed by sex, the
association was significant in men but not in women in their sample. Gong et al. (2014b)
discovered that non-O blood types were an independent risk factor for CAD and MI.
Of all blood types, AB had the highest risk of CHD, followed by blood groups B and A
(He et al., 2012). This risk remained, even after adjusting for other cardiovascular risk factors
and when excluding diabetic patients (He et al., 2012). Karabuva, Carević, Radić, and Fabijanić
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(2013) described that coronary artery disease occurred more often in males less than age 50 with
type AB blood. A study by Zakai and colleagues (2014) discovered similarly, stating that AB
blood type is a risk factor for stroke even after adjustment for age and race. On the contrary, in
their study population of Bengali East Indians, Biswas et al. (2013) discovered that participants
with AB blood type had decreased rates of coronary heart disease, compared with those with
type O blood. In the review, only one study, Sode, Allin, Dahl, Gyntelberg, and Nordestgaard
(2013) did not find an association between myocardial infarction and blood type.
Rh factor. Only two studies in the review included Rh factor as a variable. When
studying Turkish participants, Etemadi et al. (2015) found no association between Rh factor and
CVD, even when assessing for interaction between Rh factor and ABO blood type, no interaction
effect was noted. In their metanalysis He et al. (2012) also did not find an association between
Rh status and poor cardiovascular outcome.
ABO as a mediator of CVD. Several studies performed mediation analysis in order to
assess the role ABO blood type plays in mediating risk of CVD (Gong et al., 2014a; He et al.,
2012). He et al. (2012) noted an interaction effect between BMI and ABO blood type. In obese
or overweight non-O blood type women, blood type had a stronger relationship to CHD risk than
in those women with BMI <25. This interaction was not seen in men (He et al., 2012). Gong et
al. (2014a) explored CRP as an inflammatory mediator to CAD and MI. Gasso et al. (2014)
found that ABO blood type might predict ACE plasma activity, which in turn could mediate
CVD risk. The relationship between ACE plasma activity and blood type could prove relevant
when designing risk models used to predict hypertension or when determining efficacy of ACE
inhibitor pharmacotherapy (Gasso et al., 2014). Finally, since ABO antigens are also expressed
on platelets, which play a role in both coagulation and inflammation, platelets may be an
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important mediator of association between blood type and cardiovascular risk (Karabuva,
Carević, Radić, & Fabijanić, 2013). Sode et al. (2013) reported that reduced activated partial
thromboplastin time was seen in non-O versus O blood type, which further supports the role of
coagulatory factors as mediator of cardiovascular risk.
Cardiovascular risk factors. Research has explored the link between ABO blood type
and traditional cardiovascular risk factors. As described above He et al. (2012) revealed that
BMI mediated CHD risk. In a study by Gong and colleagues (2014b), participants with blood
group O had less traditional cardiovascular risk factors then those with blood type A and more
severe coronary lesions. Conversely, Jassim (2012) found in their study that blood group O had
higher levels of glucose, total cholesterol and higher blood pressures. Biswas et al. (2013)
reported that just over 28% of participants with O blood type had a family history of
cardiovascular disease.
Karabuva, Carević, Radić, and Fabijanić (2013) found that in the participants they
studied with coronary artery disease, those with type B blood had lower HDL levels but did not
find any difference in self-reported CAD risk factors among all blood types. Finally, Zakai et al.
(2014) reported that participants with blood type AB had higher rates of diabetes than all other
blood types; however, this association was non-significant when adjusted for race.
Cardiovascular pathogenesis. Each of the studies explored different cardiovascular end
outcomes. Some explored acute cardiovascular events such as MI, while other studies looked at
CAD as a chronic inflammatory process. Karabuva, Carević, Radić, and Fabijanić (2013)
explored coronary artery disease as a chronic inflammatory process and discovered there to be no
relationship between ABO blood type and magnitude of atherosclerotic lesions. These authors
also reported no significant difference in distribution of ABO blood types among patients with
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CAD versus healthy controls nor was there any difference in distribution of cardiovascular risk
among blood types (Karabuva, Carević, Radić, & Fabijanić, 2013). Due to the known increased
levels of VWF by blood type and subsequent risk of venous thromboembolism, Sode et al.,
(2013) also explored the interaction between ABO blood type, FVL and prothrombin mutations.
Sode et al. (2013) discovered that there was not a consistent association between ABO blood
type and MI. Other studies in this review have suggested a link between more acute
cardiovascular events and blood type, particularly cardiac events that occur at a younger age and
in women (Lee, Lin et al., 2012).
Genetic factors. In a recent Genome Wide Association Studies (GWAS) Reilly et al.
(2011) set out to determine what genetic factors predispose participants to plaque rupture or
myocardial infarction in participants with coronary atherosclerosis versus coronary disease
without plaque rupture or MI. ABO was identified as a locus for MI in patients who had
identified angiographic CAD (Reilly et al., 2011). Reilly and colleagues (2011) reported that
“ABO GWAS signal for myocardial infarction in patients with angiographic CAD is mediated
by the glycotransferase-deficient isoform that encodes the ABO blood group O phenotype” (p.
7). Subsequently, the higher risk of thrombus at time of MI in non-O blood types, even in those
with less extensive atherosclerotic plaques, seems to be a related to an interaction between non-O
ABO glycotransferase activity and coronary thrombus rather than atherosclerosis (Reilly et al.,
2011). Thus, in patients with angiographic CAD, blood type O is protective of MI. With an
understanding of the genetic loci that exist for CAD, Wauters et al. (2013) took the work of
Reilly and colleagues (2011) further and explored genetic variants of CAD. With an
understanding that the development of CAD is heritable and complex, there may be genetic
factors that overlap and subsequently mediate different pathologic cardiovascular outcomes. .
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Inflammation. ABO antigens are expressed on endothelial cells and platelets, and play a
role in motility, adhesion and proliferation of these cells (Karabuva, Carević, Radić, & Fabijanić,
2013). Subsequently, ABO antigens play a role in the inflammatory process. Gong et al.
(2014a) report a higher prevalence of systemic inflammation in non-O blood types. Recent
GWAS have linked the ABO locus to “circulating levels of soluble intercellular adhesion
molecule-1, soluble P-selectin, soluble E-selectin, and angiotensin-converting enzyme”
(Karabuva, Carević, Radić, & Fabijanić, 2013, p. 351). Interleukin-6 (IL-6) and tumor necrosis
factor (TNF) have also been found to be mediators between blood type and cardiovascular
disease (Gong et al., 2014a). Gong et al. (2014a) discussed the association between the ABO
gene and C-reactive protein which is a marker of inflammation often elevated in CAD and MI.
C-reactive protein was found to be higher in non-O blood types and mediated the risk of CAD
and MI, in these blood types (Gong et al., 2014a).
Cholesterol. Genetic studies have revealed that ABO blood types are inherited from
chromosome 9 locus 9p34 (Gong et al., 2014b). This chromosomal locus controls cholesterol
balance and non-O blood types have increased cholesterol absorption (Chen et al., 2014; Gong et
al, 2014b; Lee et al., 2012). Other GWAS studies have shown differing levels of plasma lipids
based off blood type, and a recent study estimated that 10% of CHD risk in non-O blood types is
mediated by low-density lipoprotein cholesterol levels (Chen et al., 2014; Etemadi et al., 2015).
Thusly, ABO blood types influence on cardiovascular disease may be mediated at least in part by
cholesterol (Chen et al., 2014). Chen et al (2014) found that those with O blood types had lower
levels of total cholesterol and LDL cholesterol than all other blood types, with mean levels
among other blood types to be roughly the same.
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More specifically, studies by Etemadi et al (2015), and Lee, Lin et al. (2012) all reported
that those with type A blood had higher total cholesterol and LDL. Etemadi et al (2015) reported
that those with type B blood had lower lipid levels. However, in their study, overall, blood
glucose was the only significant variable and non-O blood groups had higher blood glucose
levels (Etemadi et al., 2015). These authors did not believe higher plasma lipid levels in type A
individuals can alone explain the increased mortality in non-O persons because, lipids levels in
AB and B type individuals were actually lower than those with O type blood (Etemadi et al.,
2015). Lee, Lin et al. (2012) found similarly, and reported that the “association of blood group
A and CAD/MI was independent of atherogenic lipid profiles” (p. 1819). In a study by Biswas
and colleagues (2013), AB blood type had the highest levels of HDL with lowest HDL levels in
individuals with O blood type.
Conversely, when analyzing LDL levels, highest levels were found in participants with O
blood type with lowest levels in those with AB blood type (Biswas et al., 2013). Although these
findings are contradictory to all other studies in the review this may be related to the ethnicity
and genetics of the population they studied.
Summary of Research Conclusions
Implications on Clinical Practice
The majority of the studies reviewed found subjects with non-O blood types to be at
higher risk of cardiovascular disease than those with O blood types. Several studies found
subjects with AB blood types in particular to be at higher risk of cardiovascular events than all
other blood types (Chen et al., 2014; Etemadi et al., 2015; Gong et al., 2014a; Gong et al. 2014b;
He et al., 2012; Karabuva, Carević, Radić, & Fabijanić, 2013; Lee, Lin et al., 2012; Zakai et al.,
2014). Etemadi et al. (2015) reported, total mortality is increased in non-O blood types and

50

much of this was attributable to cardiovascular risk. The association between non-O blood type
and cardiovascular risk may be related to the 25-30% increase in VWF and FVIII in these
individuals. The increase in these blood proteins in non-O individuals may result in increased
platelet adhesion and subsequent plaque formation. It may be important for health care providers
to consider blood type when screening individuals for heart disease risk. In addition to earlier
identification, an understanding of how biomarkers differ by blood type may allow from the
design of more individualized therapies for the prevention and treatment of CVD.
Limitations
It is well established that frequencies of blood type vary in different
ethnicities/populations. The studies in the review were completed on individuals from Chinese
(4), Iranian (1), Iraqi (1), Taiwanese (1), European backgrounds (UK, Belgian, Danish) (2),
Croatian (1), Spanish (1) Indian (1), as well as individuals from the United States (2). Since
studies did not include individuals from all ethnicities, findings from the review may not be
generalizable. Additionally, the small sample size of some of the studies and lack of
representation of more rare blood types in certain populations may also make it difficult to
generalize the findings.
Cardiovascular endpoints were not well defined in all studies. Studies reviewed a variety
of cardiovascular outcomes including MI, stroke and both acute and chronic CAD. Differences
in the associations found between blood types in some of the studies could be related to the
pathophysiology of the cardiac outcome being studied. Interestingly only one study focused on
individuals with early onset cardiovascular disease (Lee, Lin et al., 2012). Early onset CVD may
have a different pathogenesis than atherosclerotic lesions that accumulate with age and
subsequently may not stem from the some pathologic background. It may be possible that ABO
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blood type plays a more significant role in modulating the outcome in acute coronary events
versus coronary events that are considered chronic.
Although A, B, AB and O are the most common blood groups; there are ABO subgroups
as well. Subgroups are determined when there are noted to be decreasing amounts of antigens on
the RBC’s as well as in secretors in the saliva (Franchini & Liumbruno, 2013). Subgroups are
most common on the A allele, with the two most common subgroups being A1 and A2.
Approximately 80% of blood type A or AB are classified as being part of A1 subgroup
(Franchini & Liumbruno, 2013). The other 20% are classified at A2 (Franchini & Liumbruno,
2013). Since in most studies individuals with type A or AB blood were shown to be at highest
risk of cardiovascular sequela, further refining research to examine the subgroups of the A allele
may be helpful in identifying those who are at highest risk for the development of cardiovascular
disease.
Conclusion
Certain ABO blood types have been shown to be convey higher risk of certain disease
processes. ABO blood type may mediate the development of certain cardiovascular pathology.
Most studies in the review implicate non-O blood types with the development of CVD, with
individuals with blood type A and AB at most cardiovascular risk. The authors of these studies
hypothesize that the 25-30% increase in VWF and FVIII in non-O blood types may contribute to
the increased cardiovascular risk due to the increase in platelet adhesion and plaque formation.
Other authors explored the link between ABO blood type, inflammatory markers and
cardiovascular risk. Interestingly, both markers of coagulation and inflammation have been
explored in the preeclampsia literature and seem to play a role in the pathogenesis of this disease
as well. Cardiovascular disease continues to be the leading cause of death in women and even
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with new treatments, rates of CVD in women is not decreasing at the same rate as it is in men.
With that said it is important to consider uniquely female risk factors for CVD. Exploration of
risk factors shared between preeclampsia and CVD, such as ABO blood type, may allow for
earlier identification of women at risk of both outcomes and help to more clearly define the
pathophysiology of preeclampsia.
Preeclampsia, ABO and CVD
In both reviews of the literature, there were similar themes noted. Although results
varied, in both reviews, non-O blood type was most frequently cited as increasing risk of both
CVD and preeclampsia. With individuals with blood type AB being at highest risk of both
outcomes. However, most of the studies in both reviews did not find an association between Rh
factor with either CVD or preeclampsia. Since ABO antigens are expressed on platelets,
platelets were implicated in both reviews as mediators in the risk of development of both disease
processes. In the literature review exploring ABO blood type and CVD, increased cholesterol
absorption as well as increased blood glucose levels were seen in non-O individuals as well as
increased rates of other traditional cardiovascular risk factors such as increased BMI (Etemadi et
al., 2015, He et al., 2012; Gong et al., 2012b). These risk factors have also been proposed as
preeclampsia risk factors (Lee et al., 2012; Bodnar, Ness, Markovic, & Roberts, 2005).
Finally, inflammatory mediators were implicated in increasing risk of both CVD and
preeclampsia. Traditional cardiovascular risk factors, such as cholesterol absorption and BMI, as
well as coagulation factors also seem to vary based on blood type. These factors have also been
implicated in the development of both CVD and preeclampsia. Subsequently it is possible that
blood type mediates this relationship between the two disease processes due to its role in
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modulating cardiovascular risk factors as well as levels of inflammatory and coagulation factors
that may increase risk for both disease processes.
Conclusion
ABO is expressed on a variety of different tissues, blood components and bodily fluids
(Seyfizadeh et al., 2014). ABO blood phenotype has been linked to increases in inflammation
and coagulation due to differing levels of inflammatory markers and blood clotting proteins that
have been implicated in both preeclampsia and cardiovascular disease (Gong et al., 2014a;
Franchini & Lippi, 2015; Visser et al., 2014). Since preeclampsia leads to increased risk of
cardiovascular disease and has been linked to many simila r pathologic mechanisms it may be
important to consider if ABO blood type mediates increased risk of preeclampsia. Research on
the role of ABO blood type in the development of preeclampsia has yielded inconsistent results.
However, several of the studies reviewed revealed an association between non-O blood types and
preeclampsia diagnosis, specifically, AB blood type (Hiltunen et al., 2008; Lee et al., 2012;
Phaloprakarn & Tangjitgamol, 2013).
Chapter Summary
Preeclampsia continues to threaten the health of women. Implications of the disease are
far reaching and also include poor neonatal outcomes and increased cardiovascular risk later in
life. With an understanding that preeclampsia is a cardiovascular risk factor unique to women,
the importance of the use of a feminist theoretical framework was discussed. The
pathophysiology of preeclampsia is not clear; however, it has been proposed that there are
different subtypes of the disease. The role that blood type plays in the development of both
cardiovascular disease and preeclampsia was explored, and commonalities were discovered in
the research on the association between blood type and both disease processes. With an
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understanding that each preeclampsia subtype may have a distinct pathophysiology, further
research is necessary to explore the role blood type plays in the development of preeclampsia
subtype.
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Chapter 3
Methods
Chapter Introduction
Recently, much literature has been published on the relationship between pregnancy
complications and risk of chronic disease. Upon further review of the literature, recent evidence
has revealed an association between preeclampsia and future cardiovascular disease. The
pathophysiology of preeclampsia has yet to be elucidated. Preeclampsia has been called the
disease of theories because the exact etiology of the disease remains largely unknown (Founds et
al., 2011). Currently, there is evidence to support that the disease is heterogeneous in nature and
varying subtypes of the disease may exist (Barton, & Sibai, 2008; Founds, et al., 2011).
Pathophysiologic, genetic, metabolic, immunologic, and inflammatory causes have all been
postulated (Charlton, Tooher, Rye, & Hennessy, 2014; Founds, et al., 2011; Ilekis, Reddy &
Roberts, 2007). Due to the heterogeneous nature of the disease, it is important to consider that
the pathophysiology may also be different amongst subtypes (Barton, & Sibai, 2008). Blood
type has also been postulated to increase risk of both cardiovascular disease and preeclampsia
(Biswas et al., 2013; Etemadi et al., 2015; Franchini, & Liumbruno, 2013; Gong et al., 2014; He
et al., 2012; Jassim, 2012; Lee et al., 2012). Due to this shared risk factor, blood type, the
following study was designed in order to explore the association between maternal blood type
and preeclampsia subtype.
More data is needed to better clarify differences in biophysical and biochemical markers
of women affected by the early and late preeclampsia subtypes. Data from this study has the
potential to allow for more effective diagnosis, treatment, and management of patients with
preeclampsia through a better understanding of risk factors of each preeclampsia subtype. Since
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both cardiovascular disease and preeclampsia may be associated with blood type, further
examination of risk factors shared between the two disease processes is necessary in the hope of
establishing a clearer pathophysiologic basis for preeclampsia (Biswas et al., 2013; Bushnell et
al., 2014).
The purpose of this study is to investigate the association between maternal ABO blood
type and preeclampsia subtype with an aim at improving prediction and diagnosis as well as
further exploring risk factors shared with cardiovascular disease. Furthermore, since
preeclampsia is said to be heterogeneous in nature, a secondary aim of this study is to better
describe variables that increase risk of each subtype. A case-control study was conducted to
investigate the magnitude of association between ABO blood type and the development of each
preeclampsia subtype. The study compared women with both subtypes of preeclampsia to a
control group of women without preeclampsia.
This chapter will thoroughly describe the research design and sampling method used in
this study. Furthermore, this chapter describes operational definitions utilized for each variable
as well as the eligibility criteria utilized for both preeclampsia subtypes as well as the control
groups. Finally, measurement tools, the data management plan as well as an outline of how data
was analyzed is described.
Research Design
Case control studies provide the opportunity for retrospective assessment of an outcome,
examining differences in predictor variables between cases, those with the outcome criteria and
controls. Case control studies are valuable in instances when it is not ethical or feasible to
conduct an experiment (Shadish et al., 2002). This design has also been shown to be efficient
and less expensive than other designs particularly when studying rare outcomes (Hulley et al.,
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2013). Although preeclampsia is not rare, this study will be specifically assessing the early onset
subtype of preeclampsia, which is relatively uncommon compared to its late onset counterpart.
In their study, MacKay, Berg & Atrash (2001) established the prevalence of early onset
preeclampsia to be 0.8%.
Although case control studies cannot yield information on incidence, they provide an
excellent methodology by which to obtain descriptive information about those cases that meet
outcome criteria, and allows scientists to estimate the strength of association between the
independent and dependent variables (Hulley et al., 2013; Lewallen, & Courtright, 1998). In
case control methodology the outcome variable is typically dichotomous (Shadish et al., 2002).
Although the main association of interest in this study is ABO blood type, the case control
design will allow for the assessment of other variables that may influence the development of
each subtype of preeclampsia. A case control study designed to assess the association between
blood type and preeclampsia subtype will provide data that may be foundational to more costly
and time-consuming longitudinal studies that could assess the shared relationship between
preeclampsia and ABO blood phenotype and increased future cardiovascular risk (Lewallen, &
Courtright, 1998).
Weaknesses of the design include an increased risk for bias that must be addressed
(Hulley et al., 2013; Lewallen, & Courtright, 1998). Sampling bias occurs when cases are
unrepresentative of the risk factor being studied. In this study, there is limited concern over
sampling bias as all pregnant women are followed regularly for prenatal care and are routinely
screened for preeclampsia per standard obstetrical practice. During the chart review, if a subject
was found not have attended prenatal care, they were not included in the study. The predictor
variable being studied (ABO phenotype) is represented in the entire population and is commonly
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tested in all pregnant clients at their first prenatal visit and again at delivery. Additionally, due to
the retrospective nature of case control studies there may be concerns with measurement error,
subsequently clear descriptions of how each variable was measured are described in this chapter
(Hulley et al., 2013). All data was extracted from electronic health databases so there was no
concern over inaccuracy related to poor maternal recall and the majority of the data was recorded
prior to the occurrence of the outcome under study. Finally, strict criteria were used to define
both case and controls groups (Lewallen, & Courtright, 1998).
Conceptual Framework
There are four major human blood groups A, B, O and AB (Seyfizadeh et al., 2014).
Current research supports that ABO blood phenotypes are now far more useful than in
hematology and transfusion medicine alone (Franchini & Lippi, 2015). It seems that blood
phenotype may be linked to risk of cancer, cardiovascular disease as well as a variety of
infectious disease (Biswas et al., 2013; Franchini & Lippi, 2015). ABO antigens are expressed
differently on the red cell surface as well as in a “variety of human cells and tissues, including
epithelium, sensory neurons, platelets, and vascular endothelium” (Franchini & Lippi, 2015, p.
1). Each blood type has differing levels of coagulation factors, such as VWF and Factor VIII.
Non-O groups have approximately 25% higher levels of VWF than type O individuals (Franchini
& Lippi, 2015). Individuals with non-O blood phenotypes have been shown to be at increased
risk for venous thrombosis, arterial thrombosis, myocardial infarction and ischemic stroke
(Franchini & Lippi, 2015). Thus, the link between alteration in hemostasis seen in certain blood
types as well as preeclampsia supports the biologic plausibility of this study.
Feminism provides an ideal philosophical framework by which to explore this problem.
Although this study is highly pathophysiologic, the lens of the researcher frames the research

59

questions posed, how data is extracted and interpreted. With that said, there is also an
engendered component to cardiovascular disease. Women experience different cardiovascular
signs, symptoms and risk factors than their male counterparts. Studying sex specific
cardiovascular risks factors such as preeclampsia may help to improve opportunities for early
detection and prevention of heart disease in young women.
Research Question and Hypothesis
The primary aim of this study was to assess the association between ABO blood type and
preeclampsia subtype. After a thorough review of the literature, variables were identified and the
following research questions were formulated. The research questions addressed in this study
included:
Research Question 1
What are the maternal characteristics of women with preeclampsia and with each preeclampsia
subtype?
Hypothesis 1: Individuals with early onset preeclampsia will have more traditional
cardiovascular risk factors such as, higher body mass index (BMI), chronic hypertension and
diabetes. Additionally, more subjects in the early onset subtype will be of African American
race, lower socioeconomic class.
Research Question 2
Is there an association between preeclampsia subtype and ABO blood phenotype?
Hypothesis 2: Women with non-O blood types will have greater odds of early-onset
preeclampsia, compared to those with O blood type.
Research Question 3
What is the association between preeclampsia subtype and Rh type?

60

Hypothesis 3: Rh factor will not be associated with preeclampsia or preeclampsia
subtype.
Research Question 4
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation and
preeclampsia development?
Hypothesis 4: ABO blood type will be associated with platelet count at >/= 28 6/7 week
in each preeclampsia subtype.
Research Question 5
What is the association between ABO blood type and fetal growth restriction in preeclamptic
women?
Hypothesis 5: ABO blood type will be associated with fetal growth restriction in women
with preeclampsia.
Research Question 6
What factors are significantly associated with preeclampsia and preeclampsia subtype?
Hypothesis 6: Traditional clinical and sociodemographic risk covariates such as
increased BMI, nulliparity, lower socioeconomic status, Black race, extremes in maternal age
will increase odds of preeclampsia and early onset preeclampsia subtype. Non-O blood types
will have increased odds of preeclampsia and preeclampsia early onset subtype.
The findings from the study could contribute to a more clear understanding of the
pathophysiologic basis of each preeclampsia subtype as well as a better understanding of the
association between preeclampsia and future cardiovascular disease risk. Additionally, although
currently there is no reliable risk-screening model for preeclampsia, this study may provide
knowledge about biophysical characteristics of women with each preeclampsia subtype so that
health care providers can consider the need for early pregnancy surveillance in certain sub
groups of women.
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Measurement Tools
Gel Agglutination
When blood type is determined, technologists are assessing the presence of specific
antigens on the red blood cell (RBC) and antibodies in the plasma. When the A antigen is
present the client is type A, when the B antigen is present the client is type B and when both are
present the client has AB blood type. When neither A or B antigen are present the client is typed
as O. The ABO type is unique in that there is an inverse relationship between the antigens found
on the RBCs and the antibodies found in the plasma/serum. Each blood specimen is tested for
both antigens and antibodies (personal communication, B. Steiber, January 29, 2016).
In the study site laboratory, gel agglutination is used as their primary testing
methodology. Certified Clinical Laboratory Scientists complete all testing. Gel methodology
has been shown to be more sensitive than tube methodology, as the reactions are stronger
(personal communication, Steiber, B, January 29, 2016). Gel agglutination assay is used “for the
detection of A, B, and D and for ABO serum grouping, indirect antiglobulin tests (IATs), and
direct antiglobulin tests (DATs)” (Langston, Procter, Cipolone, & Stroncek, 1999, p. 300). Six
microtubules are held in a cassette. Each microtubule has gel in a column that may be neutral or
contain a reagent. Reactants are then added to each microtubule (Langston, Procter, Cipolone, &
Stroncek, 1999). The RBC’s are tested with two antibody reagents for anti-A and anti-B, each of
which has specificity for one antigen. Antibodies in the plasma/serum are tested with RBC
reagents known to be A1 cells and B cells.
Using the same sample of blood as above, Rh factor testing is completed at the same time
as ABO blood typing described above and the appropriate anti-Rho(D) reagent is included in the
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gel cassette. The presence or absence of Rh antigen on the sample’s red blood cells is
determined by testing the sample with antibody reagent anti-D.
Regardless of the test performed, the gel cassette is spun for 10 minutes in the centrifuge.
This is necessary so that the RBCs, whether agglutinated or not, layer in the appropriate area.
The strength of agglutination reaction is then graded (+1, +2, +3, +4) by the Certified Clinical
Laboratory Scientist in order to determine the presence or absence of agglutinatio n in each of the
microtubules. The presence of agglutination determines a positive reaction (personal
communication, Steiber, B, January 29, 2016).
The majority of prenatal ABO testing is routine. For routine samples, the Ortho ProVue®
is used to complete gel agglutination testing. Prior to utilizing the Ortho ProVue®, the machine
is validated by comparing results from the ProVue® to manually tested specimens which were
completed according to Blood Bank protocols. The instrument is tested daily with reagents as
well as patient specimens in order to achieve 100% accuracy in ABO and Rh blood typing.
Platelet Measurement
In the study site laboratory, platelet counts are completed using an automated blood cell
analyzer called the Sysmex XE-series. Utilization of impedance technology has resulted in a
dramatic improvement in precision in platelet counts. The Sysmex counts platelets using
electronic resistance detection enhanced by hydrodynamic focusing (WellSpan Lab Services,
2012). The study sites laboratory services, cellular microscopy policy CM-IOP-27 outlines
principles, care and procedures governing the Sysmex XE series.
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Variables
Preeclampsia
Diagnostic criteria of preeclampsia is defined by ACOG (2013) as the new onset of
hypertension (>/=140mm Hg systolic or .>/=90mmHg diastolic) on two occasions at least 4
hours apart after 20 weeks, and proteinuria (> 300mg in a 24-hour urine collection). In the
absence of proteinuria the patient may have any one or more of the following in order to meet
preeclampsia diagnostic criteria:
● platelets < 100,000 microliter
● serum creatinine > 1.1 or doubling of serum creatinine in the absence of renal
disease
● elevated concentrations of blood liver transaminases to twice normal levels
● pulmonary edema
● new onset of cerebral or visual disturbances (ACOG, 2013, p. 4).
Early and late onset. Myatt et al. (2014) reports that a better understanding of
preeclampsia subtypes will lead to a more clear understanding of the pathophysiology of
preeclampsia and subsequently improved diagnostic prediction. In this study, two preeclampsia
subtypes were assessed, early and late onset. Early onset preeclampsia is defined by ACOG
(2013) and the ISSHP as occurrence of preeclampsia before or at 33 weeks gestation, while late
onset preeclampsia occurs at 34 weeks or later (Lisonkova, & Joseph, 2013; Myatt et al, 2014).
Additionally, since perinatal morbidity is much higher when delivery occurs prior to 34 weeks,
using this gestational age for designation of subtypes proves important (Myatt et al., 2014).
Previous research on early and late preeclampsia subtypes utilized timing of delivery to
classify subjects, or did not describe how subjects were classified into each subtype. Myatt et al.
(2014) recommends using onset of preeclampsia clinical symptoms rather than timing of delivery
to define each subtype as symptoms may have been clinically present days to weeks before
delivery. Prenatal records of each case were reviewed in order to assess gestational age when
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preeclampsia diagnostic criteria was documented. Since it is accepted practice to record blood
pressures and urine protein at all obstetrical visits, both the prenatal record as well as the hospital
inpatient record were reviewed as most cases of preeclampsia were confirmed in the inpatient
setting. The exactness of this may be affected due to timing of antenatal visits during pregnancy
(Myatt et al., 2014). Since this study involves gestational age as a variable it is important to
elucidate method and accuracy of dating. It is common practice at the study site for all women
to have first trimester dating ultrasounds to confirm dating. Cases in which preeclampsia
occurred in the postpartum period were not included in this study as this may be a separate
subtype of the disease.
Major Independent Variables
ABO blood type. Myatt et al. (2014) calls for researchers to begin to explore differences
in laboratory findings between preeclampsia subtypes. ABO blood type was chosen as a variable
in this study due to the cardiovascular and thrombotic risk associated with certain blood types.
There are four major human blood groups A, B, O and AB (Franchini & Lippi, 2015; Seyfizadeh
et al., 2014). Blood type is ordered to be drawn as part of prenatal labs on all pregnant clients at
their first prenatal visit. ABO was documented as a categorical variable.
Rh factor. Rh factor is the major Rh antigen and when it is present the client is deemed
Rh positive, when the Rh antigen is not present the client is Rh negative. The Rh antigen is
present in 85% of the population in the United States (Blood Typing Systems, 2013). When
blood type is drawn as part of prenatal labs on all pregnant clients at their first prenatal visit, Rh
status is included. Rh factor was documented as a dichotomous categorical variable.
Platelets. Platelets are a component of the blood that aid in the clotting process.
According to ACOG (2013) preeclampsia diagnostic criteria, in the absence of proteinuria,
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platelet levels less than 100,000 per microliter can be diagnostic of preeclampsia, if hypertensive
criteria exist. In preeclampsia, thrombocytopenia reveals systemic disease. Platelet and
thrombin activation, have been listed as possible pathogenic mechanisms in the development of
preeclampsia (Han et al., 2014). In this study, maternal platelet count was documented at three
different time periods throughout the subjects pregnancy, less than 20 6/7 weeks gestation (first
prenatal lab work), between 21 and 28 6/7 weeks gestation, and greater than 29 weeks gestation
(admission for delivery). Platelet count was documentated as a continuous variable.
Maternal body mass index (BMI). Prepregnancy BMI has been linked to both
preeclampsia and CVD risk (Bodnar et al., 2005; Roberts et al., 2011). Additionally, women
with non-O blood types have been shown to have a greater number of traditional cardiovascular
risk factors, such as elevated BMI (He et al., 2012). BMI is calculated at the prenatal teaching or
first obstetrical visit and is calculated by the electronic health record by taking the persons
weight in kilograms divided by the square of their height in meters. Weight is typically
measured on a standing scale and height may be self-reported or confirmed by the nurse on the
standing scale if the patient is unsure of their height at the time of the intake visit. If a
prepregnancy BMI or weight was documented in the prenatal history and physical, this data was
utilized. Otherwise only weights measured prior to the end of the first trimester (<13 weeks)
were used to calculate maternal BMI’s so as to obtain a BMI as close to a prepregnancy as
possible. BMI was documented as a continuous variable.
Race. There are differing distributions of blood type by racial and ethnic group (Racial and
Ethnic, 2013). Risk of preeclampsia is also shown to be increased in certain race (Lisonkova, &
Joseph, 2013; Paré et al., 2014)). Below are the racial groups listed in the hospital database.
Each participant’s race is self-declared and was abstracted from the Premier® database. This
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variable was recoded due to small numbers in many of the racial categories to include White,
Black and Other.
A.
B.
C.
D.
E.
F.
G.

Asian
Black or African American
Native Hawaiian or Other Pacific Islander
White
Declined-Other
Declined
Unknown to patient
Maternal socioeconomic class. Socioeconomic status may reflect the access to

resources of the women in this study. Other studies have used years of education and income as
a proxy’s for socioeconomic status (Shavers, 2007). Due to its availability in the database
utilized in this study, maternal insurance type was used as a proxy for maternal socioeconomic
status. Insurance type was collected as a categorical variable. The following insurances types
were listed in the Premier

®

database (1) Commercial Indemnity (Private) (2) Managed Care

Non-Cap (Private); (3) Medicaid Managed Care Non-Cap (Public) (4) Medicaid Traditional
(Public) (5) Medicaid Traditional (TR) (Public) (6) Medicare Traditional (Public) 7) Self Pay (8)
Unknown (9) Other Government Payers (Public). These were recoded into a dichotomous
variable, public and private insurance.
Maternal age. Maternal age was calculated as the number of years completed at the time
of delivery of the pregnancy. Maternal age was listed on the electronic delivery found in the
electronic health record. Age was documented as a continuous variable. Lisonkova, & Joseph,
(2013) list extremes in maternal age (<18 or >35) as a risk factor for preeclampsia. In teen
pregnancy, researchers have hypothesized that the risk of preeclampsia is elevated due to the
immaturity of uterine and cervical blood supply. This in turn may result in increased
prostaglandin production and subsequent inflammatory response, which may affect blood

67

pressure (Aliyu et al., 2010). Researchers have also hypothesized that poor dietary intake of
certain nutrients such as vitamins C and E, calcium, zinc as well as essential fatty acids, which
have been associated with preeclampsia, particularly in developing countries, could be causative
of preeclampsia in teens. In teens, their own growth and bodies’ need for nutrients may result in
nutrient deprivation of the fetus (Aliyu et al., 2010). Aliyu et al. (2010) also adds that teenage
mothers are often nulliparous, and non-white, both of which are risk factors of preeclampsia,
which in turn could exaggerate the risk of preeclampsia in this age group (Aliyu et al., 2010).
Alternatively, it is has been proposed that the increased risk of preeclampsia in older mothers
may be due to aging endothelium which does not adapt as well to the hemodynamic demands
placed on the maternal vascular system during pregnancy (Rich-Edwards et al., 2014)
Smoking. Interestingly, smoking has been shown to be protective of preeclampsia and may
confer a 50% reduction in risk (Hutcheon et al., 2011; Savitz, Danilack, Engel, Elston, &
Lipkind, 2014). This association is dose dependent and if smoking is stopped early in
pregnancy, there is no protective effect. This association was not seen with snuff (Hutcheon et
al., 2011). This variable was collected by review of the prenatal record in the electronic health
record and was dichotomized for data collection, as either “yes” or “no.” Women who reported
not smoking at their prenatal intake visit were considered nonsmoking. If a woman had a
positive smoking status documented in her prenatal record by her health care provider at the first
prenatal visit, then women were considered smokers.
Parity. Nulliparity is a risk factor of preeclampsia. The “primipaternity hypothesis
suggests that risks of preeclampsia are increased among women who have limited exposure to
their partner’s sperm” (Hutcheon et al., 2011’ p. 394). Although there has been some debate
over this hypothesis, supporters site higher rates of preeclampsia in women who consistently use

68

barrier contraception, and the three fold higher risk of preeclampsia in women who conceived
following intracytoplasmic sperm injection for azoospermia, with sperm obtained surgically as
evidence of this hypothesis (Hutcheon et al., 2011). Nulliparous women have three times higher
risk of preeclampsia than do multiparous women. (Hutcheon et al., 2011). The lower rates of
preeclampsia seen in multiparous women further support this hypothesis (Hutcheon et al., 2011).
Parity will be documented as a dichotomous categorical variable, nulliparous or multiparous.
Nulliparous women were those who had no documented history of a term or preterm birth in the
electronic delivery log.
Gestational age at birth. At the study site, first trimester ultrasound is routinely
performed in order to calculate estimated date of confinement. First trimester ultrasound,
improves gestational age accuracy and subsequently allowed for more accurate identification of
preeclampsia subtype. As per standard of practice, first trimester ultrasound is obtained to
confirm dating by measuring fetal crown rump length (Myatt et al., 2014). If a dating ultrasound
completed before 7 weeks gestation calculates a due date that is ≥ 3 days different from the due
date that was calculated using the last menstrual period, then the due date was changed in the
electronic health record to correspond with the ultrasound report. If a dating ultrasound
completed before 10 weeks gestation calculates a due date that is ≥ 5 days different from the due
date that was calculated using the last menstrual period, then the due date will be changed to
correspond with the ultrasound report. If a dating ultrasound completed before 13 weeks
gestation calculates a due date that is ≥ 7 days different from the due date that was calculated
using the last menstrual period, then the due date will be changed to correspond with the
ultrasound report (personal communication, S. Bennett, February 9, 2016). If a patient presents
after 13 weeks and dating has not yet been confirmed, biometry based on fetal biparietal
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diameter, abdominal circumference, and femur length is utilized to calculate gestational age. In
this case, if the due calculated is ≥ 11 days different from the due date which was calculated
using the patients last menstrual period, then ultrasound dating would be used (Myatt et al.,
2014). Gestational, age was extracted from the delivery record. This variable will be
documented as a continuous ratio level variable. If gestational age was in question at delivery,
the case was not included in the study. Based off assigned estimated date of delivery, an
obstetrical wheel was used to confirm gestational age at onset of preeclampsia symptomology in
order to appropriately assign each case to the correct subtype.
Sex of the infant. There is a strong incidence of sexual dimorphism particularly related
to disorders of an inflammatory nature (Myatt et al., 2014). A male fetus has been associated
with increased risk of preeclampsia ; however, a female fetus has been associated with the early
subtype (Myatt et al., 2014). Lisonkova, & Joseph, (2013) reported an association between
pregnancy with a male fetus and late onset preeclampsia. In this current study, the sex of the
infant was extracted from the electronic delivery record and was coded as a dichotomous
categorical variable.
Infant birthweight. Myatt et al. (2014) calls for birth weight to be recorded in all
studies on preeclampsia. Fetal growth restriction (FGR) is a common complication of
preeclampsia, often associated with the more severe early onset subtype (Kucukgoz Gulec et al.,
2013. A growth-restricted infant is characterized by “a reduced birthweight in relation to its
length” (Owen, Ogah, Bachmann, & Khan, 2003, p. 411). More specifically, FGR is
documented when an infant’s “birth weight and/or birth length is below the 10th percentile for
gestational age” (Zohdi et al., 2012 p. 2). All infants are weighed shortly after birth on electronic
scales by registered nurses. Birth weight was documented in the electronic health record in
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grams, it was initially measured as a continuous ratio level measurement. Infant birthweight was
then recoded into birthweight percentiles to assess for rates of growth restriction within
subgroups and controls. A fetal biometry calculator which takes into account gestational age and
birthweight was used to calculate birthweight percentile. The calculator can be accessed at
http://perinatology.com/calculators/exbiometry.htm. The calculator utilizes the Hadlock (1991)
equation. This variable was then dichotomized in order to represent those infants with growth
restriction (< 10th percentile) and those without growth restriction (> 10 th percentile)
(Unterscheider et al. 2013).
Comorbid conditions. Comorbid illnesses to include chronic hypertension (CHTN),
preexisting diabetes (DM) and gestational diabetes (GDM) will be collected as dichotomous
categorical variables. Chronic hypertension, preexisting diabetes and gestational diabetes are
known risk factors for both CVD as well preeclampsia (Lisonkova, & Joseph, 2013; Paré, 2014).
In other studies, ABO blood type has been shown to increase risk for diabetes and other
cardiovascular disease risk factors (Chen et al., 2014; Gong et al, 2014b; Karabuva, Carević,
Radić, & Fabijanić, 2013; Lee et al., 2012). Subsequently, ABO blood type may mediate the
development of these comorbid conditions which in turn may increase risk for preeclampsia. In
this current study, CHTN, DM and GDM were initially identified by ICD 9 code and then
confirmed upon chart review.
Subjects and Setting
Location
Due to accessibility, the electronic health record (EHR) from a large suburban ethnically
diverse community hospital in south central Pennsylvania was used for data collection. The city
where the hospital is located has a population of 43,935. In 2015, 3,164 births occurred at this
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institution. There is only one other small community hospital in this county. This hospital is
considered a tertiary referral center for several other small hospitals in surrounding counties
subsequently; the majority of high-risk pregnancies are delivered at this hospital due to its NICU
and high-risk obstetrical facilities. Thus, utilizing other hospitals in the area would not increase
access to clients with the desired outcome. Because the study site is a referral center, more cases
of early onset preeclampsia delivered at this institution, as these cases often require early
delivery of the pregnancy and utilization of NICU services that are not offered by other hospitals
in the area.
Inclusion and Exclusion Criteria
Inclusion criteria for controls included:







Female clients
Singleton pregnancies
Presented for delivery at the study site between November 2014 and March 2016
ABO blood typing complete
No diagnosis code for preeclampsia
Live births

Exclusion criteria for controls included:





Incomplete ABO blood typing
Women who did not deliver at the study site between the defined time period.
Women pregnant with multiples
Women with a history of preeclampsia

Inclusion criteria for cases included






Female clients
Singleton pregnancies
Presented for delivery at the study site between January 2012 and June 2016
ABO blood typing complete
Initially must have intrapartum ICD 9 for preeclampsia (Appendix D)
documented in their medical record. Then upon chart review must have met
ACOG (2013) diagnostic criteria for preeclampsia.

Exclusion criteria for cases will include:
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Incomplete ABO blood typing
Women who did not deliver at the study site between January 2012 and June
2016
Women who delivered prior to 20 weeks gestation
Women pregnant with multiples
Women who did not meet preeclampsia diagnostic criteria when chart review
completed

ICD 9 codes were used to exclude women in both the case and control groups with a multiple
gestation (Appendix D). Women did not have more than one pregnancy included in the study.
Women who delivered more than one pregnancy during the study period only had the first
pregnancy included in the sample.
Although considered risk factors of preeclampsia, the decision was made to include
subjects with comorbidities such as diabetes, gestational diabetes and chronic hypertension in
both the case and control groups. Typically, with a case control study, you need to exclude diseases
known to be associated with the exposure of interest. Since determination of ABO blood type
predates any disease process it was determined that individuals with these conditions should
remain in both groups. Additionally, literature supports that ABO blood type may predispose
individuals to certain comorbid condition and cardiovascular risk factors, which in turn may
increase risk of these comorbid conditions (Chen et al., 2014; Etemadi et al., 2015; Gong et al.,
2014a; Gong et al. 2014b; He et al., 2012; Karabuva, Carević, Radić, & Fabijanić, 2013; Lee et
al., 2012; Zakai et al., 2014). Subsequently, if these subjects were excluded from the sample,
there may be a loss of an important subset of individuals whom blood type already matters in
terms of their health status and subsequently may bias the results to the null.
Sample Size
Sample size was calculated using openepi.com. OpenEpi® is free, open source software
that can be used to calculate epidemiologic statistics (Dean, Sullivan, & Soe, 2004). In order to
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complete the sample size calculation “the desired confidence level, power, a hypothetical
percentage of exposure among the controls, and either an odds ratio or a hypothetical percentage
of exposure among the cases” must be entered into the statistical software (Dean, Sullivan, &
Soe, 2004). In OpenEpi® “results are presented using methods of Kelsey, Fleiss, and Fleiss with
a continuity correction” (Dean, Sullivan, & Soe, 2004). The results using the Kelsey method
were utilized for sample size determination in this study (Appendix E).
Many similar studies reviewed on this topic did not discuss how they calculated sample
size. The power selected for use in the sample size equation was from a study by Shamsi et al.
(2010) who reported using a power of 80% with an alpha level of 0.05 and an effect size of 0.3.
In the current study, the exposure variable is non-O blood type. The distribution of ABO
blood type in the United States for all races is O 44%, A 42%, B 10% and AB 4% (“Racial and
Ethnic Distribution,” 2013) with non-O blood types accounting for 56% of all blood types.
A review of the literature was completed in order to find a percentage of non-O blood
type exposure among cases of preeclampsia. There were only two articles identified in the
literature that clearly listed the prevalence of blood type in cases of preeclampsia Hiltunen et al.,
(2009) and Spinillo, Capuzzo, Baltaro, Piazzi, & Iasci (1995). Each uses varying definitions of
preeclampsia, and none use the strict definitions of early and late preeclampsia utilized in this
study. None of the articles reviewed discussed prevalence of blood type by early or late onset
preeclampsia subtype.
After reviewing these articles, Hiltunen (2009) was utilized to calculate sample size.
Hiltunen (2009) used a total of 248 cases that fulfilled the diagnostic criteria for pre-eclampsia
and 679 controls. In this article the sample consisted of preeclampsia cases and then was
analyzed by subsamples 1) severe pre-eclampsia, 2) early pre-eclampsia, and 3) pre-eclampsia
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with intra-uterine growth restriction (IUGR). Primigravid women with preeclampsia were also
analyzed separately. However, Hiltunen (2009) only reported blood type distribution for the
entire preeclamptic sample. Hiltunen (2009) reported a 70.96% prevalence of non-O blood type
in preeclamptic subjects. Sample size was calculated using Openepi.com. In order to add power
to the study, two controls were added for every case (Lewallen, & Courtright, 1998). A sample
size of 126 early cases, 126 late cases, and 252 controls, is able to detect an odds ratio of 1.9 with
a power of 80% at a significance level of 5%. Subsequently, each subtype is adequately powered
to detect differences.
Matching. Finally, the decision was made to not utilize matching in the design of the
study. “Matching should be considered only for risk factors whose confounding effects need to
be controlled for but that are not of scientific interest as independent risk factors in the study”
(Wachoider, Silverman, McLaughlin, & Mandel, 1992, p. 1043). Because all variables
considered for matching are clinical risk factors of preeclampsia, the PI chose not to match on
these variables, as they were of scientific interest. Additionally, matching can shrink the sample
and subsequently create difficulty in meeting sample size requirements; this was of concern
particularity in relation to the overall difficulty in finding early onset cases. Since none of the
preeclampsia clinical risk factors under study are predictors of exposure to the primary risk
factor under investigation (ABO Blood type), other than race, confounding was not a concern
(Wachoider et al., 1992). Rose & van der Laan, (2009) cite that confounders can be adjusted for
in the analysis if necessary. In this sample, there were no statistically significant differences in
race (p=.145) and or maternal age (p.279) between the preeclampsia subtypes and controls.
Data Collection
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Initially, data was abstracted from the electronic delivery log on all deliveries between
November 2014-March 2016. Subjects with multiple gestations were excluded as well as the
second delivery of subjects who had more than one delivery during this time period. This group
of patients was assessed for preeclampsia cases that met inclusion criteria. From the remaining
subjects who had live births a randomly selected control group was created using excel.
Recognizing the rarity of preeclampsia, particularly early onset preeclampsia, the search for
preeclampsia cases needed to be expanded to include cases identified by the Premier® database
using ICD-9 codes for preeclampsia between January 2012-June 2016 (Appendix D).
The electronic health record of each consecutive preeclampsia case was reviewed to
ensure that each subject met preeclampsia diagnostic criteria until the sample size requirement
was met for both the early and late onset subtypes. Accuracy of data collection surrounding
preeclampsia diagnosis can prove difficult and multiple methods exist. A strength of this study
is the strict criteria which was utilized in order to determine a case of preeclampsia. Many
population birth cohort studies utilize large data sets consisting of birth certificate data and
extract data using diagnostic codes. Diagnostic codes can be used to extract data from electronic
sources, however, Brown et al. (2013) reported that coding was only accurate 54% of the time in
meeting the diagnostic criteria set forth by ACOG surrounding preeclampsia. Since this study is
assessing the consequences ABO blood type has on preeclampsia risk, the accuracy of
preeclampsia diagnosis is imperative. Accurate classification of subjects improves the chances
of finding real exposure differences between groups. The exacting way in which cases were
identified improves the statistical power of the analysis particularly when compared to larger
studies that may have utilized less sensitive measures for identifying cases of preeclampsia
(Klemmensen, Olsen, Østerdal & Tabor, 2007).
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Protection of Human Subjects
This investigator, as required by the study site, completed WCG® research training. Prior
to beginning data collection, this investigator obtained IRB approval from the study site and a
IRB deferral request was submitted and approved by the University of Wisconsin-Milwaukee.
The primary investigator also sought approval from the Women’s and Children’s Service Line
Administration at the study site. A HIPPA waiver was requested and approved as this study
posed minimal harm to patients. Ethical research principles were followed in order to assure
ethical treatment of data.
Procedures
Study site laboratory procedures were assessed and were confirmed that they met quality
standards for accuracy in blood typing as well in determining platelet count. Blood bank type
and Rh processes were assessed with the manager of the Blood Bank at the study site. Policies
and adherence to federal regulations surrounding blood banking were ensured.
Detailed data were collected on a wide variety of biophysical, laboratory as well as sociodemographic variables. Although all variables were extracted from the electronic health record,
not all data was extracted using the same methodology. Appendix F outlines from which
database each variable was extracted. The electronic delivery log, electronic health record and
the Premier® database were all used to extract data. Data extracted from the Premier® database
was merged with data from the electronic delivery log in order to create a cohesive data set.
Data collected from the Premier® database was collected by a population health data analyst at
the study site as access to the Premier® database is restricted. The ICD 9 codes commonly
utilized for preeclampsia were searched in the Premier® database in order to extract documented
cases of preeclampsia from the electronic health record during the defined time-period.
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Preeclampsia diagnosis and gestational age at diagnosis were confirmed through chart review in
order to separate preeclamptic subjects by appropriate subtype. The electronic chart of each
subject was then reviewed to gather data on early pregnancy BMI, platelet counts during three
gestational time periods, infant birthweight, and to confirm smoking status as well as comorbid
conditions of interest (GDM, CHTN, DM). Although identified preliminary by ICD 9 code,
diagnosis of GDM, DM and CHTN were also confirmed during chart review in both cases and
controls. Within the electronic health record, the prenatal chart of each control subject was also
reviewed in order to confirm they had no history of preeclampsia.
Since data is often documented in multiple locations within the electronic health record,
a subsample of cases and controls were assessed in order to attempt to standardize the data
collection process. A data collection procedure was formalized, documented and reviewed with
a research assistant. A paid research assistant who is a registered nurse at the study site and
familiar with the electronic health record was utilized to collect chart data on control subjects
only. She was paid through the Harriet Werley Doctoral Research Award, which the principal
investigator received in 2016.
Data Management and Analysis
Patient data was extracted from patient charts, the electronic delivery log as well as the
Premier® database and was stored in a password protect hospital based secured share drive.
Statistical analysis was performed using SPSS version 23. Initially data was examined for
missing data as well as outliers, and data was cleaned. Missing data was replaced using the
number 8888. The data was screened and cleaned in order to check for errors. Minimum and
maximum values were assessed as well as number of missing cases for each variable. Any errors
or inconsistencies in the data were corrected. Assumptions for statistical tests were checked.
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The data was analyzed in order to answer each research question.
Research Question 1
What are the maternal characteristics of women with preeclampsia and with each preeclampsia
subtype?
Descriptive statistics were performed for each group, early preeclampsia, late
preeclampsia and controls and were used to describe the sample. Initially the categorical
variables, maternal ABO blood type, Rh factor, parity, smoking, race, socioeconomic status,
infant outcome and infant gender were assessed for frequencies and a table was created to
compare data on both cases and controls. Continuous variables such as maternal age, infant
birthweight, gestational age and BMI were checked for skewness, normality and outliers. Means
and standard deviations were calculated on all continuous variables. Chi square test of
independence was estimated for categorical variables of interest. Independent-samples t-test
were run to determine statistically significant differences between the mean scores for
continuous variables in the preeclampsia and control groups. One-way ANOVA was utilized
when assessing continuous variables against preeclampsia subtypes and controls, in order to
determine significant differences in the mean scores across the three groups.
Research Question 2
Is there an association between preeclampsia subtype and ABO blood type?
The main aim of the study is the association between preeclampsia subtype and ABO
blood type. Initially, Chi square test for independence was estimated to assess association
between ABO blood type, and both preeclampsia and preeclampsia subtypes. This test was also
completed excluding individuals with comorbidities from the sample. When assessing ABO
blood type and preeclampsia subtype because the table is larger than 2 x 2, Pearson chi square
and Cramer’s V were reported. The analysis was also performed to assess the association
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between Non-O and O blood types and preeclampsia and preeclampsia subtypes. When
assessing Non-O and O blood types and preeclampsia a 2 x 2 table was created, subsequently the
Yate’s continuity correction value and phi coefficient were reported as appropriate.
Next, logistic regression was performed and odds of developing preeclampsia for each
preeclampsia subtype was calculated based of ABO blood type. Logistic regression aims to
assess the independent contribution of predictor variables in predicting an outcome (Hulley et al.,
2013). After assumptions of logistic regression were checked, an unadjusted binary logistic
regression was run assessing the association between preeclampsia and ABO blood type. Race
was then added to the model and the regression rerun. Odds ratios of each ABO blood type with
95% confidence intervals (CI) were reported.
Next, multinomial logistic regression was utilized to assess the association between ABO
blood type and preeclampsia subtypes. This statistical test was chosen because there are more
than two nominal outcomes: early preeclampsia, late preeclampsia, and controls. Because, these
groups are unordered it makes them ideal for multinomial logistic regression (Kwak, & ClaytonMatthews, 2002). Multinomial regression creates multi-equation models and allows for the
comparison of one group to a reference group, in this case the controls (Meyers, Gamst, &
Guarino, 2013). The control group was set as the reference category. When running the
regression, it was confirmed that all cells in the model were populated. Odds ratios with 95%
confidence intervals (CI) were reported for significant blood types only. The regression was
then performed adjusting for race.
Research Question 3
What is the association between preeclampsia subtype and Rh type?
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In order to answer research question three, Chi square test for independence was
estimated in order to assess the association between Rh factor and preeclampsia as well as
preeclampsia subtype. When assessing Rh factor and preeclampsia a 2 x 2 table was created,
subsequently the Yates continuity correction value and phi coefficient were reported. When
assessing Rh factor and preeclampsia subtype, Pearson chi square and Cramer’s V were reported
as appropriate. This analysis was also complete when excluding subjects with comorbidities.
Research Question 4
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation, and
preeclampsia development?
A two way between groups ANOVA was performed to assess if ABO blood type
moderates the relationship between preeclampsia subtype and platelet count at >/= 28 6/7 weeks
gestation. Levene’s test was assessed for equal variances and a more stringent p value was used
as appropriate, and t values were reported appropriately. Both main and interaction effects are
reported. Additionally, mediation analysis was run to determine if the relationship between
maternal ABO blood type (predictor) and preeclampsia subtype (outcome) is mediated by
platelet count at > 28 6/7 weeks gestation.
Research Question 5
What is the association between ABO blood type and fetal growth restriction in preeclamptic
women?
Chi square test for independence was estimated to assess the relationship between fetal
growth restriction (FGR) and ABO blood type in preeclamptic women. Binary logistic
regression was also performed. Odds ratios and 95% confidence intervals were reported for
significant results.
Research Question 6
What factors are significantly associated with preeclampsia and preeclampsia subtype?
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In order to address the most influential preeclampsia risk factors associated with each
preeclampsia subtype, another regression was run which included all clinical risk factors in the
model. The decision was made to not utilize stepwise regression due to the inherent flaws in this
method, particularly since clinical risk factors of preeclampsia are well established in the
literature and served as a conceptual model for the development of the model (Field, 2015).
First, binary logistic regression was run using all clinically significant independent risk factors
which data was collected on (Portney & Watkins, 2009). Variables determined in the review of
literature as risk factors for preeclampsia were utilized in the model regardless of significance in
this study. Binary logistic regression was performed to examine the association between
socioedemographic and clinical covariates and preeclampsia including BMI, maternal age at
delivery, sex of the neonate, smoking status at antenatal enrollment, maternal race, insurance
type, parity and gestational diabetes. P-values ≤ 0.05 were considered statistically significant.
Maternal BMI and age were mean centered prior to being included in the regression modeling.
Because these variables (BMI and age) cannot have a true value of zero, these variables were
mean centered in order to improve the interpretability of the output. Odds ratios with 95% CI’s
that were statistically significantly associated with preeclampsia were reported. ABO blood type
was then added to the model to determine how much variability ABO blood type accounts for in
the model. A table was created and odds ratios with 95% CI’s that were statistically significantly
associated with preeclampsia were reported.
Secondly, multinomial logistic regression was used to examine the association between
covariates of interest and preeclampsia subtype. Initially, the same sociodemographic and
clinical covariates were included in the model. Odds ratios and 95% confidence that were
statistically significantly associated with preeclampsia subtype were reported. Values of p<0.05
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were considered significant (Lewallen & Courtright, 1998). Significant variables in the final
model were described. Confidence intervals were assessed and significant variables described
did not contain the value of 1.0 in the confidence interval (Portney & Watkins, 2009). Since
multiple independent variables were included in the regression model, the odds ratio described
was corrected due to each individual variables influence on each other, and the adjusted values
were reported (Portney & Watkins, 2009). ABO blood type was then added to the model to
determine how much of the variability in preeclampsia subtype ABO blood type explained. A
table was created and odds ratios with 95% CI’s that were statistically significantly associated
with preeclampsia subtype were reported.
Supplementary Analysis
Mediation analysis. PROCESS which is a statistical program created by Andrew Hayes
was downloaded to SPSS version 23 in order to perform the mediation analysis (Field, 2015).
Mediation occurs when a relationship between a predictor and outcome can be explained through
a third variable (Fields, 2015). In mediation, the predictor (X) should predict both the outcome
(Y) and mediator (M). The mediator (M) also predicts the outcome (Y) variable. Subsequently
when a mediator is present, the relationship between the predictor and the outcome may differ
(Fields, 2015). Simple mediation analysis was performed to assess if the relationship between
ABO blood type (X) and preeclampsia subtype (Y) was related to a third variable BMI (M).
Since the literature supports that individuals with certain blood types may be more at risk for
certain cardiovascular risk factors such as increased BMI (He et al., 2012), and since obesity is a
known risk factor of preeclampsia, it is plausible that increased BMI mediates the relationship
between ABO and preeclampsia (Bodnar et al., 2005; Roberts et al., 2011 , ). A conceptual model
was created and both the indirect and direct effects were reported.
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Chapter Summary
The goal of this case control study was to assess risk factors of each preeclampsia
subtype, looking specifically at the strength of association between ABO blood phenotype and
the development of preeclampsia. This chapter defines the variables included in the study,
provides an overview of the sample as well as the data collection methods that were utilized in
this dissertation study. An overview of data analysis methods was also provided.
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Chapter 4
Study Findings
Chapter Introduction
Both blood type and pre-eclampsia subtype have been established as risk factors for
cardiovascular disease, yet understanding of the role that blood type may play in shaping preeclampsia subtype remains limited. For this reason, examination of whether blood type is
associated with pre-eclampsia subtype is needed to clarify whether the onset of specific preeclampsia subtypes may represent an important physiologic link between blood type and later
life CVD. The purpose of this hospital- based case-control study was therefore to explore the
association between preeclampsia subtype and maternal ABO blood phenotype.
First, descriptive statistics and sample characteristics are presented for the preeclampsia
group in its entirety, each preeclampsia subtype, and controls. Next, the primary results for each
research question are presented. Chi square test for independence were reported in order to
examine associations among categorical variables (Research Questions (RQ’s) 1, 2, 3, 5). Two
way between groups ANOVA was performed (RQ 4) and both main and interaction effects were
reported. Both binary logistic and/or multinomial logistic regression were used to address RQs
2, 5, and 6 and odds ratios and 95% confidence intervals were reported. Additionally, in RQ 6,
Nagelkerke, Cox, and Snell R2 (and change in these values) are reported to represent an estimate
of variance explained in each model. All analyses were conducted in SPSS version 23. Finally,
a supplementary analysis of the data was performed using mediation analysis in order to assess if
the relationship between ABO blood type (X) and preeclampsia subtype (Y) was related to
maternal BMI (M).
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Research Questions and Hypotheses
The following are the research questions addressed in the study:
Research Question 1
What are the maternal characteristics of women with preeclampsia and with each preeclampsia
subtype?
Hypothesis 1: Individuals with early onset preeclampsia will have more traditional
cardiovascular risk factors such as, higher body mass index (BMI), chronic hypertension and
diabetes. Additionally, more subjects in the early onset subtype will be of African American
race, lower socioeconomic class.
Research Question 2
Is there an association between preeclampsia subtype and ABO blood type?
Hypothesis 2: Women with non-O blood types will have greater odds of early-onset
preeclampsia, compared to those with O blood type.
Research Question 3
What is the association between preeclampsia subtype and Rh type?
Hypothesis 3: Rh factor will not be associated with preeclampsia or preeclampsia
subtype.
Research Question 4
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation, and
preeclampsia development?
Hypothesis 4: ABO blood type will be associated with platelet count at > 28 6/7 week in
each preeclampsia subtype.
Research Question 5
What is the association between ABO blood type and fetal growth restriction in preeclamptic
women?

86

Hypothesis 5: ABO blood type will be associated with fetal growth restriction in women
with preeclampsia.
Research Question 6
What factors are significantly associated with preeclampsia and preeclampsia subtype?
Hypothesis 6: Traditional clinical and sociodemographic risk covariates such as
increased BMI, nulliparity, lower socioeconomic status, Black race, extremes in maternal age
will increase odds of preeclampsia and early onset preeclampsia subtype. Non-O blood types
will have increased odds of preeclampsia and preeclampsia early onset subtype.
Results
Sample Characteristics
The following are descriptive statistics for each group. The sample included women with
the early onset preeclampsia subtype (≤ 33 6/7 weeks) (n=126), the late onset preeclampsia
subtype (≥34 0/7 weeks) (n=126) and a control group (n=259) of normotensive women. Women
in the control group did not have a current or previous history of preeclampsia.
Research Question 1
What are the maternal characteristics of women with preeclampsia and with each
preeclampsia subtype?
Table 1 provides descriptive statistics for the preeclampsia group in its entirety as well as
controls.
Preeclampsia. Although the main aim of this study was to assess preeclampsia subtypes
association to ABO blood phenotypes, the preeclampsia group will be described in its entirety in
Table 1. Since many previous studies on this association did not assess by preeclampsia subtype,
this author felt it important to also evaluate this relationship and describe the sample in this way.
The mean age of women with preeclampsia was 27.7 (SD =6.0 years). Women in this group had
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a mean BMI 30.34 (8.4 =SD). Subjects were also categorically assigned a weight classification
according to their BMI. In the preeclampsia group, 42% of women were considered obese (BMI
> 30). The mean gestational age at delivery for the preeclampsia group was 34.8 (SD= 3.9
weeks). The group was mainly White (77.8), 8.5% were Black, 13.7% were other race. The
“other race” category consisted of those that identified as Asian (n=2) or Native Hawaiian
(n=12); subjects from these races were a very small component of this “other” category. The
majority of the “other” racial category were individuals who either declined to report their race,
or reported other race (n=65). During the chart review, it was noted that study subjects who
declined to document their race or self-classified as other race tended to be Hispanic.
Preeclamptic women overall were more often multiparous (54%) and gave birth to more male
(53.2%) than female infants (46.8%). The birthweight percentiles of infants born to mothers in
this group were also assessed for frequency of growth restriction (<10% percentile). In the
preeclampsia group, 36.1% of infants experienced some degree of growth restriction.
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Table 1
Characteristics of Preeclampsia Subjects (n=252) versus Controls (n=259)
Preeclampsia
Controls
Characteristic
n
%
n
%
p
Race
White
African American
Other Races
Parity
Nulliparous
Multiparous
Insurance Type
Public
Private
Neonatal Outcome
Live Birth
Fetal Death
Neonatal Death
Season of Birth
Winter
Spring
Summer
Fall
Infant Sex
Male
Female
BMI
Underweight
Normal
Overweight
Obese
Smoker
ABO Blood Type
A
B
AB
O
RhD
Neg
Pos
FGR

.595
193
21
34

77.8
8.5
13.7

190
23
43

74.2
9
16.8
.032

116
136

46
54

94
165

36.3
63.7
.621

104
124

45.6
54.4

103
137

42.9
57.1

249
1
2

98.8
0.4
0.8

259
0
0

100
---

*

.495
72
73
45
62

28.6
29
17.9
24.6

90
66
45
58

34.7
25.5
17.4
22.4
.615

133
117

53.2
46.8

131
128

49.2
50.8
<.001

7
58
65
94
59

3.1
25.9
29
42
23.4

9
112
63
61
45

3.7
45.7
25.7
24.9
17.4

95
32
13
106

37.7
15.1
5.2
42.1

100
32
5
122

38.6
12.4
1.9
47.1

29
223
91

11.5
88.5
36.1

32
227
31

12.4
87.6
12

.113
.156

.874

BM I= Body M ass Index FGR=Fetal Growth Restriction
* statistical significance not calculated due to low frequencies
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<.001

Early onset. The data was further analyzed by preeclampsia subtype and is reported in
Table 2. The early onset group consisted of women who met preeclampsia diagnostic criteria on
or before 33 6/7th week in pregnancy. The mean gestational age at delivery of the early onset
preeclampsia group was 31 weeks and 6 days (SD=3.09 weeks) however, gestational age at
delivery varied from 21 weeks and 6 days to 37 weeks and 4 days (Table 3). Ages of women in
the group ranged from 17-46 years of age, with a mean age of 28.2 years (SD=6 years). Early
pregnancy BMI of women in the group ranged from 16 to 55.3, with a mean BMI of 31.7 (SD=
8.15) with 51.4% falling into the obese category (BMI>30). The majority of the early onset
subgroup was White (73.8%). Blacks accounted for 12.7% of the early onset group. The
majority of women in the early onset subtype were multiparous (63.5%). These women gave
birth to more female infants (54.0%). Although the overwhelming majority of women in this
subtype had live births (97.6%), there was one fetal death and two documented neonatal deaths.
Fetal or neonatal deaths did not occur in either the late onset subtype or the control group. Over
a quarter of women in the early onset subtype were smokers (27%). Blood type distribution in
the early onset subtype was as follows, A (31.7%), B (19.8%), AB (4.8%), (O 43.7%). Rhpositive women made up the majority of the subtype (91.3%), with 8.7% of the group having
Rh-negative blood types. Growth restriction most effected infants born to mothers with early
onset preeclampsia, with 55.6% of infants in this subtype weighing less than the 10 percentile for
their gestational age.
Late onset. The late onset subtype consisted of women who had documented
preeclampsia diagnostic criteria on or after the 34 0/7 weeks of pregnancy. Characteristics of
this subtype are documented in Table 2. The mean gestational age at delivery was 37 weeks and
6 days (SD=1.89 weeks), however, gestational age at delivery ranged from 34 weeks and 2 days
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to 41 weeks and 3 days. The late onset subtype consisted of more nulliparous women then
multiparous women, 55.6% vs. 44.4%. The majority of infants born in the late onset subtype
were males (60.8%). Mean maternal age was similar to the early subtype, 27.13 (SD= 6 years).
Early pregnancy BMI for the late subtype was 29.11 (SD= 8.45), BMI’s ranged from 17.8 to
66.5. In the late onset subtype, the highest frequency of women had a normal BMI (BMI 18.524.9) (35.7%), however this was closely followed in the frequency by women in the obese
category (BMI >30) (33%). This subtype was also predominately White (82%), however
consisted of 4.1% Black subjects. Blood type distribution for the late onset subtype was as
follows A (43.7%), B (10.3%), AB (5.6%) and O (50.5%). Rh-negative women of any blood
type made up 14.3% of the group.
Controls. Control subjects (n=259) had no current or previous history of preeclampsia,
characteristics of this group can be found in Table 2. The mean gestational age at delivery was
39 weeks and 2 days (SD=1.72 weeks) with an average birthweight of 3359gms (SD=543.4
grams). Many more of the women in the control group were multiparous (63.7%). The ratio of
male to female infants was roughly even (49.2% vs 50.8%). Mean maternal age at delivery was
similar to the late group, 27.7 years (SD=5.56 years). Of all groups, the controls had the lowest
mean early pregnancy BMI, 26.5 (SD=6.8). BMI in this group ranged from 15.00 to 53.00.
Most women in this group fell into the normal BMI category (BMI 18.5-24.9) (45.7%).
Similarly, to the other groups, the control group was also predominately White (74.2%). Black
subjects represented 9% of the control group. Of all the groups, controls had the lowest
percentage of smokers (17.4%). In the United States blood type distribution is as follows, 44%
O, 42% A, 10% B, and 4% AB. Distribution of blood type within the control group was as
follows, A 38.6%, B 12.4%, AB 1.9% and O 47%. In the control group, 12.7% had Rh-negative
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blood types, 87.6% were Rh positive. In the control group, 12% of infants were growth
restricted.

92

Table 2
Characteristics of Early (n=126) Late (n=126) and Control (n=259) Subjects
Late
Controls
Early
Characteristics
n
%
n
%
n
%
Race
White
93 73.8
100
82
190 74.2
Black
16 12.7
5
4.1
23
9
Other Races
17 13.5
17 13.9
43 16.8
Parity
Nulliparous
46 36.5
70 55.6
94 36.3
Multiparous
80 63.5
56 44.4
165 63.7
Insurance Type
Public
61 52.1
43 38.7
103 42.9
Private
56 47.9
68 61.3
137 57.1
Neonatal Outcome
Live Birth
123 97.6
126 100
259 100
Fetal Death
1
0.8
0
-0
-Neonatal Death
2
1.6
0
-0
-Season of Birth
Winter
36 28.6
36 28.6
90 34.7
Spring
40 31.7
33 26.2
66 25.5
Summer
26 20.6
19 15.1
45 17.4
Fall
24
19
38 30.2
58 22.4
Infant Sex
Male
57 45.2
76 60.8
131 49.2
Female
68
54
49 39.2
128 50.8
BMI
Underweight
3
2.8
4
3.5
9
3.7
Normal
17 15.6
41 35.7
112 45.7
Overweight
33 30.3
32 27.8
63 25.7
Obese
56 51.4
38
33
61 24.9
Smoker
34
27
25 19.8
45 17.4
ABO Blood Type
A
40 31.7
55 43.7
100 38.6
B
25 19.8
13 10.3
32 12.4
AB
6
4.8
7
5.6
5
1.9
O
55 43.7
51 40.5
122 47.1
RhD
Neg
11
8.7
18 14.3
32 12.4
Pos
115 91.3
108 85.7
227 87.6
FGR
70 55.6
21 16.7
31
12
BM I= Body M ass Index FGR=Fetal Growth Restriction
* statistical significance not calculated due to low frequencies
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p
.145

.001

.106

*

.275

.047

<.001

.088
.062

.380

<.001

Comparison of preeclampsia to controls. Table 1 provides Chi square test for
independence results for each variable. A Chi-square test for independence (with Yates
Continuity Correction) indicated a significant association between parity and preeclampsia, x 2 (1,
N= 511) =4.6, p=.032, phi=-.099. Additionally, a Chi-square test for independence (with Yates
Continuity Correction) indicated a significant association between growth restriction and
preeclampsia, x 2 (1, N= 511) =39.64, p <.001, phi=0.283. An independent samples t test was
conducted to compare age, BMI, gestational age and birthweight between preeclampsia patients
and controls. All variables were significant at the p <.001 level except for maternal age which
was not significant (p=.566) (Table 3).

Table 3
Means of Age BMI , GA and Infant Birthweight Preeclampsia
Preeclampsia (n=252)
Variable
M (SD)
95% CI
Age
27.7(6)
[26.9, 28.4]
BMI
30.34(8.4)
[29.3, 31.5]
GA
34.8(3.9)
[34.3, 35.3]
Birthweight
2381.4 (957.3) [2261.1 , 2501.6]

versus Controls
Control (n=259)
M (SD)
95% CI
27.9 (SD 5.6)
[27.3, 28.6]
26.8 (SD 7.1)
[25.6, 27.4]
39.3(SD 1.7)
[39.1, 39.5]
3359(SD 543.4) [3292.7, 3525.6]

Note BMI= Body Mass Index; GA =Gestational Age

Comparison of preeclampsia subtypes. Participants were divided into three groups,
according to onset timing of preeclampsia (early ≤ 33 6/7 weeks, late ≥ 34 0/7 weeks, and
controls (no preeclampsia)). A Chi-square test for independence indicated a significant
association between preeclampsia subtype and infant sex x2 (1, n= 509) = 6.13, p= .047,
Cramer’s V= .11 as well as between preeclampsia subtype and parity x2 (1, N= 511) = 14.45,
p=.001, Cramer’s V = .168. One-way between-groups analysis variance was conducted to
explore significant differences in the mean scores of BMI and maternal age across each
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p
.566
<.001
<.001
<.001

preeclampsia subtype and controls. There was a statistically significant difference in BMI for
the three groups: F (2,468) =15.3, p<.001. Because a significant difference was found, post hoc
comparisons using the Tukey HSD test where performed in order to reveal exactly where
differences in BMI exist between groups. Post hoc comparison revealed that mean BMI scores
for all groups were significantly different from each other. There was not a statistically
significant difference in age across the three groups (Table 4). Since preeclampsia subtypes are
defined based on gestational age, which would result in expected differences in mean birthweight
and gestational age, these variables were not compared, as this would not provide any clinically
significant findings. Mean gestational age and birthweights for each group were reported earlier
in the chapter.
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Table 4
Means of Age and BMI by Preeclampsia Subgroup
Early (n=126)
Variable
M (SD)
95% CI
Age
28.2 (SD 6) [27.2, 29.3]
BMI
31.7 (SD 8.1) [30.1, 33.2]
Note: BMI=Body Mass Index

Late (n=126)
M (SD)
95% CI
27.13 (SD 6) [26.1, 28.2]
29.11 (SD 8.4) [27.5, 30.7]

Control (n=259)
M (SD)
95% CI
27.7 (SD 5.6) [26, 28.4]
26.5 (SD 6.8) [25.6, 27.4]

p
.279
<.001

Comorbidities in each preeclampsia subtype and controls. Data on common
comorbidities such as chronic hypertension (CHTN), gestational diabetes (GDM), and
preexisting diabetes (DM) were collected on subjects in all three groups (early preeclampsia, late
preeclampsia and controls). The early onset preeclampsia subset had subjects with the most
comorbidities, CHTN (27%), DM (9.5%) and GDM (19.0%). Of the late onset preeclampsia
subtype, 15.1% had CHTN, 10.3% had GDM, and 3.2% had DM. No subjects in the control
group had DM and one had CHTN. A Chi square test for independence also identified a
significant association between gestational diabetes and preeclampsia subtype x 2 (2, N= 511)
=7.54, p= .023, Cramer’s V= .121.

Table 5
Prevalence of Comorbidities by Early Preeclampsia (n=126), Late Preeclampsia (n=126)
and Controls (n=259)
Preeclampsia Subtype
Early
Late
Control
n
%
n
%
n
%
p
No CHTN
92
73
107 84.9
258 99.6
*
CHTN
CHTN
34
27
19 15.1
1
.40
No Diabetes
114 90.5
122 96.8
259 100
*
Diabetes
Diabetes
12
9.5
4
3.2
0
0
No GDM
102
81
113 89.7
234 90.3 .023
GDM
GDM
24
19
13 10.3
25
9.7
Note: CHTN=Chronic Hypertension and GDM=Gestational Diabetes
* denotes that significance level not reported due to low frequencies

Research Question 2
Is there an association between preeclampsia subtype and ABO blood phenotype?
In order to assess the association between preeclampsia subtype and maternal ABO blood
phenotype a Chi square test for independence was estimated. Although some expected cell
frequencies were small, only 16.7% of the contingency table cells had expected cell frequencies
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less than 5, subsequently not violating this assumption (Field, 2015). A Chi square test for
independence indicated no significant association between ABO blood type and preeclampsia
subtype, x 2 (6, N=511)=11.99, p= .062, Cramer’s V= .108. Additionally, no significant
difference was noted when assessing controls versus the preeclamptic group as a whole (p=.156).
The percentage of Non-O versus O blood types did not significantly differ by preeclampsia
subtype (p=.456) or within the preeclampsia group as a whole (p=.29).
Exclusion of comorbidities. Since many previous studies excluded individuals with
comorbid conditions, the decision was made to rerun the analysis without comorbid conditions
included in order to be able to compare data with other studies to see if results were consistent.
When subjects with comorbidities (CHTN, GDM and preexisting diabetes) are excluded
(n=108), from the sample, ABO blood type continues not to be significantly associated with
preeclampsia x2 (3, n= 403) = 6.94, p= .72, Cramer’s V= .132. However, after excluding
subjects with comorbidities from both the control group and each preeclampsia subtype, the
Chi-square results were statistically significant indicating an association among ABO blood type
and preeclampsia subtype, x 2 (6, n= 403) =24.06, p= .001, Cramer’s V= .173 (Table 6). The
early onset subtype was much more likely to have a B blood type (31%) than those with late
onset preeclampsia (9.3%) or controls (12%). Frequency of the AB blood type was fairly even
between early (4.2%) and late (5.2%) preeclampsia subtypes. The control group consisted of
less subjects with the AB blood type then both the early and late subtypes (2.1%)(p=.33).
When analyzing the sample with comorbidities excluded, non-O versus O blood type,
was statistically significantly associated with preeclampsia subtype x 2 (3, n= 403) = 6.92, p=
.031, Cramer’s V= .131. However, there was not a statistically significant association when
analyzing the preeclampsia group x2 (1, n= 403) = 2.69, p= 0.101, phi= .09.
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Table 6
ABO Blood Type and Preeclampsia Subtype Comorbidities Excluded
Preeclampsia Subtype
Early (n=72)
Late (n=97)
n
%
n
%
ABO
A
25
34.7
40
41.2
Blood
AB
3
4.2
5
5.2
Type
B
23
31.9
9
9.3
O
21
29.2
43
44.3

Control (n=234)
n
%
92
39.3
5
2.1
28
12
109
46.6

p
.001

Binary Logistic Regression. Binary logistic regression was performed to further assess
the association between ABO blood phenotype and preeclampsia. Initially the model included
ABO blood phenotype as the predictor. Maternal ABO blood type was not significant in
predicting preeclampsia status x 2 (3, N=511) =5.35 p=.148, indicating that the model including
ABO blood phenotype alone was unable to distinguish between preeclamptic subjects and
controls. The model as a whole explained 1% (Cox and Snell R squared) to 1.4% (Nagelkerke R
squared) of the variance in preeclampsia status and correctly classified 53.4% of preeclampsia
cases. As shown in Table 7, of the four blood types, only one was statistically significantly
associated with preeclampsia. Of the blood types, AB was associated with the greatest odds of
preeclampsia (OR= 2.99, 95% CI 1.03, 8.67). This indicates that women with an AB blood type
had an almost three times the odds of preeclampsia, compared to those with O blood type. This
model was re-run including race as a control variable given the relationship between race and
blood type. After controlling for race, the results remain consistent; AB blood type was
significantly associated with preeclampsia (OR= 3.03, 95% CI 1.04, 8.80).
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Table 7
Summary of Logistic Regression ABO Blood Type and Preeclampsia
Wald
Predictor
B
SE
OR
95% C.I.
statistic
O
0.09
0.20
A
1.09 [0.75, 1.60]
0.21
1.10
0.54
AB
2.99 [1.03, 8.67]
4.08
0.31
0.27
B
1.37 [0.80, 2.34]
1.31

p
.177
.648
.043
.255

p<.05

Multinomial logistic regression. Multinomial logistic regression was performed to
further assess the association between ABO blood type and preeclampsia subtype (early and
late). Maternal ABO blood type was not significantly associated with preeclampsia subtype x 2
(6, N=511) =11.81 p=.066, indicating that the model including ABO blood phenotype alone was
unable to distinguish between subjects with each preeclamptic subtype and controls. The model
as a whole explained 2.3% (Cox and Snell R squared) to 2.6% (Nagelkerke R squared) of the
variance in preeclampsia status. As shown in Table 8, of the four blood types, only blood type
AB was statistically significantly associated with late onset preeclampsia (OR= 3.35, 95% CI:
1.02, 11.05). Although none of the blood types were statistically significantly associated with
early onset preeclampsia, it is important to note that B blood type is trending towards being
significantly associated with early onset preeclampsia in this model (p=.078). After controlling
for race, results remained consistent; only AB blood type was statistically significantly
associated with late onset preeclampsia (OR=3.41, 95% CI, 1.03, 11.29).

100

Table 8
Summary of Multinomial Logistic Regression ABO Blood Type
and Preeclampsia Subtype
Predictor
Early

Late

O
A
AB
B
O
A
AB
B

Wald
statistic

B

SE

OR

95% C.I.

p

-0.12
0.98
0.55

0.25
0.63
0.31

.89
2.66
1.73

[0.55, 1.44]
[0.78, 9.10]
[0.94, 3.21]

0.23
2.44
3.12

.629
.118
.078

0.27
1.21
-0.03

0.24
0.61
0.37

1.32
3.35
.97

[0.83, 2.09]
[1.02, 11.05]
[0.47, 2.00]

1.34
3.94
0.01

.246
.047
.938

p <.05

Research Question 3
What is the association between preeclampsia subtype and Rh type?
A Chi square test for independence was estimated to assess the relationship between Rh
factor and preeclampsia subtype. Rh type was not significantly associated with preeclampsia
subtype, x 2 (2, N=511) = 1.94 p= .38, Cramer’s V= .062 by preeclampsia subtype. It was also
not significant when assessing preeclampsia versus controls (p= .874). After exclusion of
comorbidities, Rh type continued not to be significant when assessed by subtypes (p=.51) and in
the preeclampsia group as a whole (p= .65).
Research Question 4
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation, and
preeclampsia development?
A two way between groups ANOVA was performed to assess if ABO blood type
moderates the relationship between preeclampsia and platelet count at >28 6/7 weeks gestation.
The two grouping variables (preeclampsia subtype and blood type) as well as the interaction
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between the two were used to predict platelet count. The Levene’s Test of Equality of Error
Variances was significant (p=.028), this suggests that the variance of platelet count across groups
was not equal, subsequently a more stringent significance level was used (p=.01) when
interpreting results. There were no statistically significant main effects noted for either blood
type or preeclampsia subtype. The interaction effect between maternal ABO blood type and
preeclampsia subtype was not significant F (6, 482) =.845, p=.536, meaning that the influence of
preeclampsia subtype on platelet count does not depend on maternal blood type. Although nonsignificant, Figure 1 depicts estimated marginal means of platelet counts at greater than 28 6/7
weeks gestation by each preeclampsia subtype and ABO blood type.

Figure 1 Estimated Marginal Means of Platelets > 28 weeks

Mediation analysis. Mediation analysis was performed using PROCESS 2.16 (Hayes,
2016). PROCESS “uses an ordinary least squares or logistic regression-based path analytic
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framework for estimating direct and indirect effects” of variables in a mediated model (Hayes,
2016). Mediation attempts to determine if a relationship between a predictor variable and an
outcome variable can be explained by their relationship to a third variable (Field, 2015) (Figure
2). Literature supports that ABO antigens are reflected on the platelet surface, subsequently
mediation analysis was run to determine if the relationship between maternal ABO blood type
(predictor) and preeclampsia subtype (outcome) is mediated by platelet level at > 28 6/7 weeks
gestation. Blood type did not significantly predict preeclampsia subtype b=1.47, t = .76, p =.44
additionally, there was no significant indirect effect noted of ABO blood type on preeclampsia
subtype through platelet count at >28 6/7 weeks gestation b= .0008, BCa CI [-.0013, .0085]

Platelet level >28
6/7
b= 1.47

b= .001 p= .37

p= .44

Maternal ABO
Blood Type

Preeclampsia
subtype

Figure 2 Mediation Analysis Platelets > 28 6/7
Direct effect, b=-.004, p=.87
Indirect effect, b=.0008 , 95% CI [-.001, .008]

Research Question 5
What is the association between ABO blood type and fetal growth restriction in preeclamptic
women?
A Chi square test for independence was performed to assess the relationship between
ABO blood type and fetal growth restriction (FGR) in preeclamptic women only. This test
indicated a significant association between FGR and ABO blood type in preeclamptic subjects x 2
(3, n=252) = 19.52, p <.001, Cramer’s V =.278. Table 9 depicts frequency of FGR by maternal
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ABO blood type in preeclamptic subjects. In preeclamptic women with the B blood type, almost
66% of the subjects had a growth-restricted fetus. No significant association was noted when
comparing O versus Non-O blood types (p=.99). Logistic regression was performed in order to
assess the odds of developing growth restriction amongst women with each preeclampsia
subtype. The model including ABO blood type was statistically significant x 2 (3, n=252) =
19.04, p=<.001, indicating that the model was able to distinguish between preeclampsia subjects
with growth restriction and those without. The B blood type was the only blood type that was
statistically significantly associated with growth restriction in preeclamptic women. Women
with the B blood type had three times the odds of having a growth-restricted fetus than did
women with other blood types (OR=3.44, 95% CI 1.58, 7.50).

104

Table 9

Association of ABO Blood Type to Fetal Growth Restriction in Preeclamptic Subjects (n=252)

Variable

A

105

FGR

n
24

%
25.3

n
4

No FGR

71

74.7

9

Note FGR =Fetal Growth Restriction

ABO Blood Type
AB
%
30.8
69.2

B

O

n
25

%
65.8

n
38

%
35.8

13

34.2

68

64.2

p

<.001

Research Question 6
What factors are significantly associated with preeclampsia and preeclampsia subtype?
preeclampsia subtype?
Initially, binary logistic regression was performed to test the association between
preeclampsia and other well-documented risk factors of preeclampsia. An initial model
containing eight independent variables (BMI, maternal age at delivery, sex of the neonate,
smoking status at antenatal enrollment, maternal race, insurance type, parity and gestational
diabetes diagnosis), was statistically significant x 2 (9, n=419) =43.93 p<.001, indicating that the
model was able to distinguish between participants with preeclampsia and those without. The
model as a whole explained between 10% (Cox and Snell R squared) to 13.3% (Nagelkerke R
squared) of the variance in preeclampsia status and correctly classified 64% of preeclampsia
cases. The sensitivity of this model or the ability of the model to identify cases of preeclampsia
was 51.3%. The specificity of this model or the ability of the model to correctly identify those
that did not have preeclampsia was 75%. Four of the variables were statistically significantly
associated with preeclampsia, nulliparity (OR=1.68, 95% CI 1.08, 2.61), maternal early
pregnancy BMI (OR=1.07, 95% CI 1.04, 1.11), smoking (OR=1.79, 95% CI 1.07, 3.02) and
Black race (OR= .456, 95% CI .209, .995).
Binary logistic regression was rerun including ABO blood type into the model. This
model contained ABO blood type and the same eight independent variables used in the previous
model (BMI, maternal age at delivery, sex of the neonate, smoking status at antenatal enrollment,
maternal race, insurance type, parity and gestational diabetes diagnosis). The full model
containing all variables including ABO blood type was statistically significant x 2 (12, n=419) =
51.01, p=<.00, indicating that the model was able to distinguish between participants with
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preeclampsia and those without. Including ABO blood type explained an additional 1.5-2% of
the variability in preeclampsia group and the model as a whole explained an 11.5% (Cox and
Snell R squared) to 15.3% (Nagelkerke R squared) of the variance in preeclampsia status and
correctly classified 63.7% of preeclampsia cases. The sensitivity of this model or the ability of
the model to identify cases of preeclampsia was 51.3%. The specificity of this model or the
ability of the model to correctly identify those that did not have preeclampsia was 74.6%. Four
of the variables were statistically significantly associated with preeclampsia, nulliparity, maternal
early pregnancy BMI, smoking, and AB blood type (Table 10). The strongest odds of
preeclampsia was for AB blood type (OR= 4.93 95% CI 1.26, 19.38), such that individuals who
had an AB blood type had almost five times greater odds of preeclampsia, controlling for all
other factors in the model. When including ABO blood type into the model, the specificity and
sensitivity of the model remained the same and there was not an improvement in the
classification of preeclamptic subjects.
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Table 10
Summary of Logistic Regression Analysis Preeclampsia with ABO Blood Type
95% C.I.for
Variable
O
A
AB
B
BMI
White
Black
Other Races
GDM
Smoking
Nullipara
Age
Insurance
Sex of Baby

B

S.E.

-.002
1.60
.29
.07

.23
.70
.33
.02

-.78
-.63
.10
.58
.53
-.03
.006
.12

.41
.33
.35
.27
.23
.02
,24
.21

Wald

df

p

5.99
.00
5.23
.76
21.17
6.15
3.69
3.58
.08
4.61
5.39
.02
.00
.32

3
1
1
1
1
2
1
1
1
1
1
1
1
1

.112
.991
.022
.384
.000
.046
.055
.058
.781
.032
.020
.144
.979
.572

Odds
Ratio

Lower

Upper

1.00
4.93
1.33
1.07

.63
1.26
.70
1.04

1.57
19.38
2.53
1.11

.46
.53
1.10
1.78
1.70
.97
1.01
1.130

.21
.28
.56
1.05
1.09
.93
.63
.74

1.02
1.02
2.16
3.01
2.65
1.01
1.61
1.70

Note. CI=confidence interval for odds ratio

Multinomial logistic regression. Multinomial logistic regression was performed to
assess the association of well-documented preeclampsia risk factors on each preeclampsia
subtype (early and late). This model contained eight independent variables (BMI, maternal age
at delivery, sex of the neonate, smoking status at antenatal enrollment, maternal race, insurance
type, parity and gestational diabetes diagnosis). The full model containing all variables was
statistically significant x 2 (16, n=417) =44.17, p=<.000 and was a good fit based off nonsignificant Pearson and deviance statistics. The model as a whole explained between 14.2%
(Cox and Snell R squared) to 16.4% (Nagelkerke R squared) of the variance in preeclampsia
subtype and correctly classified 56.1% of subjects.
Three variables were statistically significantly associated with early onset preeclampsia,
smoking, White race and BMI. In this study, White individuals were almost three times more
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likely to have early preeclampsia (OR= 2.7, 95% CI: 1.11, 6.72). The effect of smoking was
positive, (OR= .53, 95% CI .29, .97), so those that did smoke were roughly 50% less likely to
develop early onset preeclampsia. For every one unit increase in BMI there is roughly an 8%
increase in risk of early preeclampsia (OR= 1.08, 95% CI 1.04, 1.12).
The association of both parity and BMI were statistically significant with late onset
preeclampsia. Nulliparous women had two times greater odds of late onset preeclampsia (OR=
2.1, 95% CI .1.25, 3.65). For every 1-unit increase in BMI there is roughly a 7% increase in
odds of late preeclampsia (OR= 1.06. 95% CI 1.03, 1.11).
Multinomial logistic regression was rerun including ABO blood type into the model.
This model contained maternal ABO blood type and the same eight independent variables used
in the previous model (BMI, maternal age at delivery, sex of the neonate, smoking status at
antenatal enrollment, maternal race, insurance type, parity and gestational diabetes diagnosis).
The full model containing all predictors was statistically significant x 2 (24, N=418) = 74.81
p<.001 and was a good fit based off non-significant Pearson and deviance statistics. Including
ABO blood type explained an additional 2.2% -2.6% of the variability in preeclampsia subtype
and the model as a whole explained an 16.4% (Cox and Snell R squared) to 18.8% (Nagelkerke
R squared) of the variance in preeclampsia subtype and correctly classified 56.8% of subjects
(early 24%, late 17.9%, controls 87.9%). When including ABO blood type into the model, the
model remained significant however, there was only a small improvement in the classification of
subjects with each preeclamptic subtype (56.1% vs 56.8%).
As shown in Table 11, only four of the variables were statistically significantly associated
with early onset preeclampsia, AB blood type, smoking, White race and BMI. The strongest
association was between AB blood type and early-onset preeclampsia (OR=5.41, 95% CI 1.19,
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24.55). This indicated that participants who had an AB blood type have five times greater odds
of early onset preeclampsia, controlling for all other factors in the model. In this study, White
individuals were almost three times more likely to have early preeclampsia (OR=2.9, 95% CI:
1.16, 7.26). Smoking was also statistically significantly associated with early onset preeclampsia
(OR=.528, 95% CI .286, .974). For every one unit increase in BMI there is roughly an 8%
increase in risk of early preeclampsia (OR=1.08, 95% CI 1.04, 1.12).
The association of both parity and BMI remained statistically significantly associated
with late onset preeclampsia. Nulliparous women had two times greater odds of late onset
preeclampsia (OR=2.2, 95% CI .1.25, 3.65). For every 1-unit increase in BMI there is roughly a
7% increase in odds of late preeclampsia (OR=1.07. 95% CI 1.03, 1.11). AB blood type was
trend-level in the late onset group (p=.053).
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Table 11
Summary of Multinomial Logistic Regression Analysis Preeclampsia Subtype and ABO Blood Type
95% CI
Predictor
Early

Late

Blood Type A
Blood Type AB
Blood Type B
Insurance
White
Black
GDM
Smoking
Sex of Baby
Nullipara
BMI
Age
Blood Type A
Blood Type AB
Blood Type B
Insurance
White
Black
GDM
Smoking
Sex of Baby
Nullipara
BMI
Age

B

S.E

Wald

df

p

.01
1.69
.66
-.19
1.07
.60
-.22
-.64
.15
.28
.08
-.02
-.001
1.52
-.18
.21
.28
-1.23
.001
-.48
-.40
.28
.02
-.04

.29
.77
.38
.29
.47
.59
.41
.31
.26
.28
.02
.03
.39
.79
.44
.30
.39
.73
.43
.33
.26
.28
.02
.03

.00
4.79
2.99
.42
5.20
1.01
.29
4.18
.34
1.00
18.61
.37
.00
3.73
1.60
.51
.51
2.85
.00
2.08
2.29
7.67
12.14
2.94

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

.982
.029
.084
.516
.023
.316
.590
.041
.559
.317
.000
.545
.997
.053
.689
.474
.475
.091
.999
.150
.131
.006
.000
.086

Odds
Ratio
1.007
5.414
1.927
.827
2.904
1.812
.804
.528
1.164
1.325
1.079
.985
.999
4.574
.837
1.239
1.322
.292
1.001
.620
.674
2.148
1.067
.957

Lower

Upper

.569
1.194
.916
.468
1.162
.567
.363
.286
.699
.764
1.042
.938
.575
.979
.351
.690
.614
.070
.435
.324
.404
1.250
1.029
.910

1.782
24.554
4.053
1.464
7.258
5.790
1.780
.974
1.939
2.297
1.117
1.034
1.735
21.381
1.997
2.225
2.847
1.219
2.303
1.188
1.124
3.690
1.106
1.006

Note. CI=confidence interval for odds ratio
BM I and Age are mean centered

Supplementary Analysis
Body mass index. A supplementary analysis was performed in order to assess if BMI
mediates the development of preeclampsia. Previous literature supports the relationship between
ABO blood type and cardiovascular risk factors, however, due to the small number of subjects in
the control group with CHTN (n= 1) and DM (n=0), the mediation effect of these variables could
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not be assessed. Mediation analysis was run to determine if the relationship between maternal
ABO blood type (predictor) and preeclampsia (outcome) is mediated by maternal early
pregnancy BMI. Blood type did not have a significant direct effect on BMI, additionally, there
was no significant indirect effect noted of ABO blood type on preeclampsia subtype through
BMI b= -0.02, BCa CI [-0.023, .005] (Figure 3). Even when excluding women with
comorbidities from the sample, no mediation effect was noted.
.

BMI
b =0.31, p= 0.24

b=-0.025, p=<.001

Maternal ABO
Blood Type

Preeclampsia

Figure 3 Mediation Analysis BMI
Direct effect, b=-0.01, p=.73
Indirect effect, b=-0.02, 95% CI [-0.02, 0.005]

Chapter Summary
This chapter reports the results of the study. Descriptive statistics for subjects with
preeclampsia as well as controls were reported. Descriptive statistics were also reported by
preeclampsia subtype. Data was analyzed according to each research question with the main aim
of the study to assess the relationship between ABO blood type and preeclampsia subtype. Both
logistic and multinomial regression modeling were performed. The findings of this study
suggest that blood type may play a role in the development of each preeclampsia subtype
particularly in individuals without preexisting and other comorbid conditions of pregnancy.
Preeclamptic subjects with B blood type had three times the odds of having a growth-restricted
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fetus. Logistic regression, revealed that even when controlling for race, AB blood type was
statistically significantly associated with increased odds of preeclampsia and late onset
preeclampsia specifically. Finally, the inclusion of ABO blood type in a model with other
clinical risk factors of preeclampsia did not improve the specificity and sensitivity of the model
and no improvement was see in the classification of preeclamptic subjects.
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Chapter 5
Discussion, Conclusion, Recommendations
Chapter Introduction
The pathophysiology of preeclampsia remains unclear. Scientists believe there may be
multiple subtypes of the disease, which have varying pathophysiology. Biomarkers must be
explored in order to better elucidate the pathophysiologic basis of each preeclampsia subtype.
Assessing the association between commonly collected biomarkers such as blood type and
preeclampsia may prove valuable in risk identification. This chapter provides a discussion of the
results of this study. A hospital-based case control study of 511 subjects was completed with the
main aim of examining the association between maternal ABO blood type and preeclampsia
subtype. Each research question is subsequently addressed. The results are compared and
contrasted to existing literature on the topic. Finally, strengths and limitations of the study are
presented as well as implications for clinical practice and policy and suggestions for further
research.
Research Question 1
What are the maternal characteristics of women with preeclampsia and with each preeclampsia
subtype?
Description of Study Groups
Clinical risk factors. Although not the primary aim, this study provided rich descriptive
data of each preeclampsia subtype. Since many studies do not evaluate preeclampsia in relation
to distinct early and late subtypes, this current study provided a unique opportunity to collect
data on differences between these two preeclampsia subtypes. Due to the number of clinical and
sociodemographic variables on which data was collected, these variables are discussed
individually below.
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In this study, maternal age was not significant for preeclampsia subtype (p=.279) or
preeclampsia (p=.566). Maternal age continued not to be significant when assessed categorically
(<18 years, 18-34 years, >35 years) (p=.763). Lisonkova, & Joseph, (2013) cite maternal age
<20 years as a risk factor for early onset preeclampsia and reported that older maternal age > 35
years, was associated with preeclampsia, but not a specific subtype. However, Trogstad,
Magnus, and Stoltenberg (2011) states that research is conflicting on whether maternal age is a
risk factor of preeclampsia.
Infant sex. Results of this current study were in line with previous research, more infants
born to preeclamptic women were male than controls (53.2% v 49.2%) although this difference
was not significant (p=.615). However, in this current study there was a significant difference in
infant sex when assessed by preeclampsia subtype (p=.047). In this study, 54% of the early
onset subtype had a female infant versus 39.2% in the late onset subtype and 50.8% in the
control group. There seems to be a complex and not well understood interaction between the
fetus and maternal physiology. Fetal sex has been shown to have an impact on a variety of
maternal obstetrical outcomes (Jaskolka, Retnakaran, Zinman, & Kramer, 2016). A recent
systematic review by Jaskolka and colleagues (2016) reported male fetal sex only to be a
maternal risk factor for preeclampsia in the non-Asian population. Previous research has shown
that carrying a female fetus is associated with early onset or more severe preeclampsia subtypes
which is in line with results from this dissertation study (Myatt et al., 2014; Zheng, Deng, Zhong,
& Shi, 2016).
Race. Although maternal race was not significant by subtype (p= .145), there were far
more Black subjects in the early onset subtype (12.7%) then in the late onset subtype (4.1%) and
the control group (9%). This may point to the fact that race may influence the severity of the

115

disease, since the early onset subtype is often considered more severe due to its associated higher
rates of maternal and neonatal morbidity and mortality.
Overall data has been conflicting on the significance of race by preeclampsia subtype.
Data from this study is in contrast to Trogstad et al. (2011) which lists African American race as
risk factor of preeclampsia. Pare' et al. (2014) reported that African American race was not a
risk factor for early onset preeclampsia. Conversely, Lisonkova, & Joseph (2013) reported that
African American race was a risk factor for early onset preeclampsia. Tucker, Berg, Callaghan,
and Hsia (2007) reported that although non-Hispanic black women did not have a higher
prevalence of preeclampsia than white women did, they did have much higher case-fatality rates.
Results on race garnered from this study may be related to the lack of diversity within the sample
overall. Community demographics reported on the 2010 census revealed the racial make-up of
the community where this current study was completed to be 88.54% White, 5.6% Black and
5.86% other race which includes Asian and Native Hawaiian or Pacifica Islander
(Demographics, 2010). Due to the lack of racial diversity in the community overall, a larger
sample size may be necessary to detect true subtype differences by race. However, the
differences in racial make-up of each preeclampsia subtype and controls in this current study
does support that race may in some way mediate severity of the disease.
Parity. Rates of nulliparity were significantly different between preeclampsia subtype
and controls (p <.001). Interestingly, rates of nulliparity were comparable between early
preeclamptic subjects and controls (36.5% v 36.3%), however; subjects with late onset
preeclampsia had the highest rates of nulliparity (44%) of all the groups. Rates of multiparity
were significantly higher in the early onset subtype (63.5%) than the late onset subtype (44.4%)
(p=.004). Data from this current study, further supports the heterogeneous nature of this disease,
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possibly suggesting that the pathophysiology of late onset preeclampsia may have an
immunologic component, possibility related to “primipaternity hypothesis” (Hutcheon et al.,
2011, p. 394). Since rates of multiparity were significantly higher in the early onset subtype, it
could point to higher rates of preeclampsia reoccurrence in the early onset subtype. This in turn
could suggest a different pathophysiologic basis for the early subtype. Data on preeclampsia
recurrence was not collected in this current study; future research should be done assessing the
association between preeclampsia recurrence and maternal ABO blood type.
Body mass index. Body mass index was significantly different by preeclampsia subtype.
The early onset preeclampsia subtype had the highest mean early pregnancy BMI (M=31.7,
SD=8.15) and 51.4% of subjects in this subtype were in the obese category (BMI > 30)
compared to the late onset subtype (33%) and control group (24.9%) which were much more
comparable in terms of BMI.
It is well documented that obesity substantially increases the risk of preeclampsia;
Bodnar et al. (2005) reported that women with a body mass index (BMI) of 30 have threefold
higher odds of developing preeclampsia. Roberts et al. (2011) reported that obesity increased
risk of both the early and late subtypes of preeclampsia. In this study, data was collected on
maternal prepregnancy or early pregnancy (<13 weeks gestation) BMI. Roberts et al. (2011)
postulate that since both preeclampsia and obesity share a similar dyslipidemic profile, possibly,
obese women with the most abnormal lipids are at the highest risk of preeclampsia. In this
study, lipid profiles on each patient were not collected. Research supports that dyslipidemic
profiles may differ by blood type (Etemadi et al., 2015; Lee et al, 2012). Future research should
aim to compare lipid profiles by ABO blood type of women in each preeclampsia subtype as this
my help to further differentiate the pathophysiologic basis of each preeclampsia subtype and

117

provide some clarity about the association between preeclampsia and long-term risk or
cardiovascular disease.
Since obesity is one of the only modifiable risk factors of preeclampsia, this study further
supports the need for health care providers to provide education and counseling on preconception
and interconception weight loss in order to help women reach a healthy weight prior to
pregnancy. Since women with the early onset subtype had higher rates of both multiparty and
obesity than both the late onset subtype and controls, it is important for providers to have
conversations about interconception weight loss and management in order to prevent
complications in future pregnancies. The provision of evidence based and culturally appropriate
programs to women of reproductive age on weight management and physical activity may have
significant implications for maternal and neonatal obstetrical outcomes.
Smoking. Due to the retrospective nature of this study, it is difficult to determine how
much and how often subjects smoked. There were more smokers in both preeclamptic subtypes
than in the control group. Rates of smoking between the preeclampsia subtypes and controls was
not significant (p=.088), subjects with early onset preeclampsia had the highest rates of smoking
(27%). In the regression when all other clinical risk factors were included, smoking was
protective of early onset preeclampsia, (OR= .53, 95% CI .29, .97), so those that did smoke were
roughly 50% less likely to develop early onset preeclampsia. There was no significant
association with the late onset subtype. This result was similar to other studies (Hutcheon et al.,
2011; Savitz et al., 2014). However, this association has been shown to be dose dependent, and
if smoking is stopped early in pregnancy, there is no protective effect. In this current study,
smoking data was collected based off documentation of smoking status early in pregnancy so the
amount each women smoked was difficult to quantify.
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Gestational diabetes. Researchers have documented that preexisting disease such as
chronic hypertension and diabetes are risk factors for preeclampsia (Bartsch et al., 2016). As
expected, the highest rates of the comorbidities studied (GDM, HTN, DM) were seen in subjects
with early onset preeclampsia. Rates of gestational diabetes were significantly different between
the preeclampsia subtypes and control group (p=.023) with the highest rates of GDM seen in the
early onset preeclampsia subtype (19%). In the early onset subtype, 22 subjects delivered
between 21 and 28 weeks. Although some subjects in the early onset subtype may have had
early prenatal glucose testing due to clinical risk factors such as BMI > 30, history of GDM or
previous infant > 8’13oz, because testing for GDM typically occurs at 28 weeks of gestation, it is
possible, that due to rates of prematurity in this subtype, numbers of subjects with GDM may
have been far higher in this group and gone undiagnosed (WellSpan High Risk Standing Order
Set, 2016). Rates of GDM in the late onset and control group were comparable (10.3% v 9.7%).
A study by DeSisto, Kim & Sharma (2014) using data from the Pregnancy Risk Assessment
Monitoring System (PRAMS) found prevalence of GDM might be as high as 9.2% which was
similar to controls in this study (9.7%). Rates of GDM in women with the early onset
preeclampsia subtype were over twice that of controls. This supports the need for the provision
of pointed patient education at the time of GDM diagnosis on signs and symptoms of
preeclampsia, as preeclampsia seems to occur earlier in this patient group.
Chronic hypertension. More subjects in the early onset subtype (27%) had CHTN than
in the late onset (15.1%) or the control group (0.4%). Rates of CHTN between the early and late
onset preeclampsia subtypes were significantly different (p=.03). This further supports the
increased severity of the disease in women with CHTN. Providers should be aware of ACOG
(2013) and the United States Preventive Task Force (2014) guidelines for the use of aspirin
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therapy for preeclampsia prophylaxis in women with CHTN. The use of aspirin therapy
beginning as early as 12 weeks gestation may help to decrease risk of preeclampsia in these highrisk women. Additionally, recent research has shown that women with early onset preeclampsia
have 7-9 times increased risk of CVD later in life (van Rijn et al., 2013). In this current study,
the higher rates of obesity and chronic hypertension seen in the early preeclampsia subtype could
further support that the link between early onset preeclampsia and CVD risk may be potentiated
by the increased rates of cardiovascular risk factors seen in this subtype rather than physiologic
alterations that occur from preeclampsia. Further longitudinal studies are needed in this area.
Neonatal outcome. There were three fetal (n=1)/neonatal (n=2) deaths in the early onset
preeclampsia subtype. However, there were no occurrences of fetal or neonatal death in the late
onset or control groups. Subsequently, statistical significance was not reported on this variable.
However, it is important to consider the clinical significance of this finding. It is well
established that the early onset subtype is associated with significant perinatal morbidity and
mortality (Hutcheon et al., 2011; Lisonkova, & Joseph, 2013). This may be related to the earlier
gestational age at birth however, the increased morbidity and mortality in the early subtype may
also be related to other pathophysiologic changes that occur in subjects with this subtype that
require further study.
Seasonality. In this current study, infant month of birth was classified according to season
(winter, spring, summer, and fall). The current study did not support the seasonality of
preeclampsia and found no difference in the seasonal rates of the disease by subtype (p=.275).
Literature on preeclampsia supports the seasonality of the disease. In non-tropical climates such
as the U.S., increased rates of preeclampsia have been seen in the winter months (Tepoel, Saftlas,
& Wallis.2011). Interestingly, in a metanalysis by Tepoel et al. (2011) three of 14 studies
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reviewed also did not support the hypothesis that preeclampsia is seasonal in nature; two of the
three were also hospital based case control studies. A larger sample size may be necessary to
detect seasonal differences.

Research Question 2
Is there an association between preeclampsia subtype and ABO blood phenotype?
Preeclampsia subtype (early, late) trended towards being significantly associated with
ABO blood phenotype when assessed by individual blood type (A, B, AB, O) (p=.062). In this
current study, when analyzing the frequency of each blood type within each preeclampsia
subtype, it was noted that 19.8% of the early onset subtype had a B blood type. This was
considerably more than in the late onset preeclampsia subtype (10.32%) and control group
(12.36%) and trended towards statistical significance (p=.06). Both the AB (p=.133) and A
blood types (p=.147) were also not significantly associated with preeclampsia subtype when
analyzed individually. Additionally, this author did not find non-O blood type to be significantly
associated with preeclampsia (p=.29) or preeclampsia subtype (p=.46).
Excluding comorbidities. Interestingly, when excluding individuals with comorbidities
such as GDM, CHTN and DM, ABO blood type was significantly associated with preeclampsia
subtype (p= .001). Subsequently, there seems to be a stronger relationship between blood type
and preeclampsia subtype in healthy individuals than in those with comorbidities. It is possible
that in healthy individuals, the pathway to preeclampsia development is influenced by blood
type’s effect on the regulation of biomarkers of coagulation and inflammation whereas the
increased risk of preeclampsia in individuals with comorbid conditions may follow a different
pathophysiologic pathway. Due to the low number of individuals with CHTN and DM in the
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control group, mediation analysis was not performed. In future studies, mediation analysis could
be done in order assess the role various biomarkers play in mediating the development of
preeclampsia subtype in women with and without comorbidities and of different blood types.
This could be done in order to better assess if there are different pathophysiologic pathways that
lead to the development of preeclampsia in previously healthy women.
There have been conflicting results in studies that have explored the association between
ABO blood type and preeclampsia. The results of this current study were similar to those of
other authors in the literature review (Alpoim et al., 2012; Hiltunen et al., 2009; Hentschke et al.,
2014) and did not find non-O blood types to be associated with preeclampsia. Results on the
association between blood type and preeclampsia have varied, and it is difficult to synthesize the
literature on ABO blood type and preeclampsia as studies have used varying inclusion criteria.
Some studies in the literature review chose to exclude subjects with comorbidities or multiparous
women from their sample (Alpoim et al., 2011; Hiltunen et al., 2009; Lee, Zhang et al., 2012;
Spinillo et al., 1995). In this current study, in order to address the possible confounding effect of
comorbid conditions, subjects with comorbidities (CHTN, DM and GDM) were included in both
the case(s) and control groups. Lee, Zhang et al. (2012) also chose to include women with
preexisting hypertension and diabetes in their study and did not find any evidence of
confounding.
Logistic regression. Binary logistic regression was performed to further assess the
association between ABO blood phenotype and preeclampsia. Maternal ABO blood type was
not significant in predicting preeclampsia, however, AB blood type was statistically significantly
associated with the greatest odds of preeclampsia (OR 2.99, 95% CI 1.03, 8.67). Even when
adjusting for race, subjects with AB blood type continued to have three times the odds of
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developing preeclampsia (OR 3.03, 95% CI 1.04, 8.80). Similar results were reported when
examining the association between blood type and preeclampsia subtype. Interestingly, even
when controlling for race, AB blood type (OR 3.41, 95% CI, 1.03, 11.29) was statistically
significantly associated with the greatest odds of late onset preeclampsia, no blood type was
statistically significantly associated with early onset preeclampsia.
This current study supported the findings of other studies on this topic, which also
reported that women with AB blood type have the highest odds of preeclampsia of all blood
types. In these studies, odds ratios ranged from 1.0 to 2.4 (Alpoim et al., 2012; Clark & Wu,
2008; Hiltunen et al., 2009; Lee & Zhang et al., 2012; Phaloprakarn & Tangjitgamol, 2013). The
main aim of these previous studies was to examine the association between ABO blood type and
preeclampsia as a homogenous group. To this authors knowledge, this study is the first to
describe an association between late onset preeclampsia and AB blood type.
Rationale for the association between preeclampsia and AB blood type may be related to
the increased levels of Von Willebrand factor noted in non-O blood phenotypes. Individuals
with non-O blood types have been shown to have a 25% increase in VWF and FVIII above their
O blood type counterparts and plasma levels of VWF increase by blood type in the following
order O>A>B>AB (Alpoim et al., 2012). It is plausible that the higher levels of these
coagulation factors may increase the risk of thrombus (Alpoim et al., 2012; Alpoim et al., 2011).
Researchers have postulated that the increased risk of thrombus in individuals with non-O blood
types may result in increased risk of micro-thrombus in the placental vasculature subsequently
decreasing placental blood supply (Alpoim et al., 2011). Future research should be done to
examine if levels of VWF vary by blood type and each preeclampsia subtype.
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In addition to varying level of coagulation factors, blood type has been shown to play a
role in inflammation and immunity as well as the regulation of other biochemical markers
(Alpoim et al., 2011; Franchini & Lippi, 2015; Hiltunen et al., 2009; Lee et al., 2012;
Phaloprakarn & Tangjitgamol, 2013). Seyfizadeh et al. (2014) reported that serum creatinine
levels in blood type AB were higher than all other blood groups. Increasing serum creatinine
level is considered a diagnostic marker of increasing preeclampsia severity, and could play a role
in the pathophysiology of the disease (ACOG, 2013). Future research should address the
association between levels of biomarkers of preeclampsia seventy such as serum creatinine, and
maternal blood type.
Research Question 3
What is the association between preeclampsia subtype and Rh type?
Rh factor was not significantly associated with preeclampsia (p=.87) or preeclampsia
subtype (p=.38) even when controlling for comorbidities (p=.51). However, the early onset
preeclampsia group had the lowest frequency of Rh-negative women (8.73%) as compared to the
late onset group (14.3%) and controls (12.4%). In this current study, 87.64% of the control
group was Rh positive, this is similar to population based results which report that 85% of the
population is Rh positive (“Blood Typing Systems,” 2010). The results of this current study
were in line with Shamsi et al. (2010) and López-Pulles et al. (2010) who both also reported no
significant association between Rh factor and preeclampsia. Two studies in the review of
literature did report an association between Rh factor and preeclampsia. Sezik et al. (2001)
stated that O Rh negative women had a higher risk of HELLP syndrome. Lee and Zhang et al.
(2012) also reported that Rh-positive women had a small increased risk of preeclampsia (OR
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1.07, 95% CI 1.03-1.10). More research may be necessary to assess if Rh status plays a role in
the severity of the disease and in differing populations.
Research Question 4
What is the association between ABO blood type, platelet count at > 28 6/7 weeks gestation, and
preeclampsia development?
In this study, blood type did not moderate platelet level at admission for delivery in
preeclampsia subtypes and controls. The interaction effect between maternal ABO blood type
and preeclampsia subtype was not significant F (6, 482) =.845, p=.54, nor were there statistically
significant main effects noted for either blood type or preeclampsia subtype. The estimated
marginal means of platelet levels at > 28 6/7 weeks gestation in both the early and late
preeclampsia subtype followed a similar pattern by blood type. The mean platelet count in
women with B blood type was noted to be less than that of other blood types, although not
statistically significant. Additionally, although not statistically significant, the higher platelet
counts noted in subjects with AB blood type may also be clinically significant (Figure 1).
ABO antigens are expressed on a variety of human cells and tissues including platelets
(Karabuva, Carević, Radić, & Fabijanić, 2013). Subsequently, it is important to consider the role
blood type may play in mediating platelet count. The endothelial damage that occurs in cases of
severe preeclampsia causes increased turnover of platelets resulting in decreased platelet count
(Özdemirci et al., 2016). The diagnostic criteria of preeclampsia is defined by ACOG (2013) as
the new onset of hypertension (≥140mm Hg systolic or .≥90mmHg diastolic) after 20 weeks
gestation on two occasions at least four hours apart, and proteinuria (≥300mg in a 24-hour urine
collection). In the absence of proteinuria, if the patient has a platelet count < 100,000 per
microliter, the diagnosis of preeclampsia can be made. A decrease in platelet count to <100,000
per microliter also marks increasing severity of the disease. Data from this current study
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supports the need for future research to explore the relationship between blood type and levels of
other laboratory markers associated with severe features of preeclampsia such as platelets, liver
enzymes, and serum creatinine.
Furthermore, other laboratory measures of platelets may better test their relationship to
both ABO blood type and preeclampsia subtype. Han et al. (2014) and Myatt (2009) also did not
find an association between platelet count and development of preeclampsia, but did find that
mean platelet volume was significantly greater in women who developed preeclampsia. Other
platelet indices, especially mean platelet volume (MPV), may be better indicators of
preeclampsia severity than platelet count (Han et al., 2014; Myatt, 2009).
Research Question 5
What is the association between ABO blood type and fetal growth restriction in preeclamptic
women?
In this current study, in women with preeclampsia, FGR was significantly associated with
ABO blood type (p=<.001). Of the blood types, subjects with B blood type had the highest rates
of FGR. In women with preeclampsia, 66% of those with a B blood type experienced FGR.
Preeclamptic women with the B blood type had three times the odds of having a growthrestricted fetus than did women with other blood types (OR 3.44, 95% CI 1.58, 7.50).
Hiltunen et al. (2009) also discovered an association between blood type and growth
restriction in preeclamptic women, however in their study; preeclamptic subjects with AB blood
type had higher rates of growth restriction. Although fetal growth restriction is no longer
considered diagnostic of preeclampsia, it may point to increasing severity of the disease (Fox,
Huang & Chasen, 2008). The American College of Obstetricians and Gynecologists (2013) Task
Force Statement on Hypertension in Pregnancy recommends that preeclamptic women
experiencing growth restriction should be monitored closely. These results further support that B
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blood type may in some way be associated with increasing severity of preeclampsia and women
with this blood type may require close monitoring of fetal growth as well as other severe features
of the disease. Further research should examine the pathophysiologic mechanism that mediates
the development of growth restriction in individuals with the B blood type.
Research Question 6
What factors are significantly associated with preeclampsia and preeclampsia subtype?
Preeclampsia. Initially, binary logistic regression was performed to test the association
between preeclampsia and other well-documented risk factors of preeclampsia. The initial
model containing eight independent variables (BMI, maternal age at delivery, sex of the neonate,
smoking status at antenatal enrollment, maternal race, insurance type, parity and gestational
diabetes diagnosis) was statistically significant x2 (9, n=419) =43.93 p<.001. Binary logistic
regression was rerun to include ABO blood type and the same eight independent variables used
in the previous model. This model was also statistically significant, x 2 (12, n=419) = 51.01,
p=<.00, however, including ABO blood type only explained an additional 1.5-2% of the
variability in preeclampsia group. The addition of ABO blood type did not provide much
improvement when classifying preeclampsia subjects. However, controlling for all other factors
in the model, subjects with AB blood type had almost five times greater odds of preeclampsia
(OR=4.93 95% CI 1.26, 19.38). The confidence intervals reported are wide, indicating that the
sample size of individuals with AB blood type were rather small. Subsequently, results of this
analysis should be interpreted cautiously.
Preeclampsia subtype. Multinomial logistic regression was performed to test the
association between preeclampsia subtype and other well-documented risk factors of
preeclampsia. The initial model containing eight independent variables (BMI, maternal age at
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delivery, sex of the neonate, smoking status at antenatal enrollment, maternal race, insurance
type, parity and gestational diabetes diagnosis) was statistically significant x 2 (16, n=417)
=44.17, p=<.000. There were different variables statistically significantly associated with each
preeclampsia subtype. Smoking, White race, and BMI were statistically significantly associated
with early onset preeclampsia, while nulliparity and BMI were statistically significantly
associated with late onset preeclampsia.
Multinomial logistic regression was rerun to include ABO blood type as well as the eight
clinical risk factors used in the previous model. The model remained significant however; there
was only a small improvement in the classification of subjects within each preeclamptic subtype.
When all clinical risk factors are included in the model, AB blood type significantly predicts
membership in the early onset preeclampsia subtype (OR=5.41, 95% CI, 1.19, 24.55) and was
trend-level in the late onset group (p=.053). The other variables that were significant prior to the
inclusion of blood type into the model remained the same by subtype. This suggests that the
utility of blood type as a risk factor for preeclampsia (regardless of onset) is weak after
considering the other risk factors collected in the study, which is further supported by the small
amount of variability accounted for in the model by ABO blood type. ABO blood type may not
be a valuable addition to a preeclampsia-screening algorithm that already includes common
clinical risk factors of preeclampsia. With this said, it is important to consider the role ABO
blood type has in the regulation of other biomarkers of inflammation and coagulation that may
influence the development of each preeclampsia subtype. Than et al. (2011) reported that
Placental Protein 13 (PP13) an early biomarker of preeclampsia, binds differently to each ABO
blood type. Subsequently, serum levels of PP13 may prove to be a better predictor of
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preeclampsia, and this may explain the association between ABO blood type and preeclampsia
when other variables are not in the model.
Strengths and Limitations
To this author’s knowledge, this current study demonstrated for the first time an
association between AB blood type and late onset preeclampsia subtype in women in the United
States even after controlling for race. Subjects with AB blood had three fold-increased risk of
late onset preeclampsia. Varying definitions of preeclampsia subtypes used in the literature have
made it difficult to synthesize the outcomes of studies reviewed. The inclusion of older research
in reviews may lead to further difficulty in synthesizing outcomes due to recent changes in
preeclampsia diagnostic criteria.
Recognizing the heterogeneity of the disease, Myatt et al. (2014) called for researchers to
begin to examine preeclampsia by the subtypes, early and late onset. Myatt (2014) suggests that
researchers should carefully examine medical records for the onset of preeclampsia
symptomology rather than simply using gestational age at delivery to signify subtype
membership. A strength of this study is that preeclampsia was studied by subtype rather than
studying preeclampsia as a homogenous group. Additionally, subjects were classified into
preeclampsia subtypes based on the documented onset of subjective and/or objective
preeclampsia diagnostic criteria rather than gestational age at delivery. Chart review was used to
assess for strict ACOG (2013) diagnostic criteria in order to determine subtype membership
(early onset ≤ 33 6/7 weeks, late onset ≥ 34 0/7). Other studies have used diagnostic codes to
confirm preeclampsia cases, and used gestational age at delivery as a proxy to classify
preeclampsia subtype, which could result in subtypes being diluted due to lack of stringent
classification criteria. Confirming preeclampsia diagnosis was time consuming, but improved
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the overall reliability of the study as compared to studies that utilized diagnostic codes for
inclusion without a formal chart review to confirm the diagnosis (Brown et al., 2013; Savitz et
al., 2014).
The study was adequately powered to detect differences in O versus non-O blood type by
preeclampsia subtype. Many previous studies in this area chose to use subsample analysis to
assess differences between preeclampsia subtypes, subsequently achieving the appropriate
sample size for both early and late onset subjects is a strength of this study.
In order to further improve the overall reliability of the data gleaned, prior to beginning
data collection, the blood bank was visited and their procedures for calibration and
documentation of blood type were assessed for quality. Additionally, standardized data
collection procedures were utilized when abstracting information from the EHR
It is necessary to address the limitations of this study and the applicability and
generalizability of the findings. Many of the variables included in the study were measured by
self-report, such as parity and ethnicity. Although this could potentially affect accuracy of the
data, collection of data by self-report for these measures is appropriate, as it is standard practice
(Gorber, Tremblay, Moher, & Gorber, 2007). It is unknown if height was consistently measured
or collected by self-report, as this varies by obstetrical practice, this may affect the reliability of
the data on this variable (Gorber et al., 2007). Additionally, due to the retrospective nature of
this study, in terms of measurement of variables, weight measurements were not collected from
scales that were known to be regularly calibrated. However, all health care personnel who
obtained this data are trained on how to obtain these measurements, although it is unknown about
the rigor of teaching and monitoring the practices of these tasks.
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A small sample from one hospital in one geographic region was utilized for this study,
and a majority of the subjects were White so the findings may not be generalizable to other
populations. Additionally, due to the fact that the hospital is a referral center, cases, particularly
those with the early onset preeclampsia subtype, may have followed a different referral pattern
than controls. To this author’s knowledge, no other studies have been conducted in the U.S with
the primary aim to assess the relationship between preeclampsia subtype and ABO blood type.
Since blood type varies by ethnicity this study fills an important gap in the literature.
Recommendations
Recommendations for Clinical Practice
Preventative therapy. Research exploring biophysical characteristics and biochemical
markers associated with each subset of preeclampsia is integral to the discovery of the distinct
pathophysiologic mechanisms which drive the onset timing and severity of this heterogeneous
disease. Without a clear understanding of the pathophysiology of preeclampsia, the creation of
targeted therapies has proven difficult. Recent evidence has shown use of aspirin may be helpful
in prevention of preeclampsia particularly in high-risk women (Bujold et al., 2010). In patients
with preeclampsia, it seems that aspirin improves trophoblast invasion of the uterine spiral
arteries as well as the cytokine profile, and may decrease cell death and increase production of
placental growth factor (Middeldorp, 2014). Literature supports increased levels of certain
inflammatory cytokines and procoagulation factors by blood type (Franchini, Mengoli, & Lippi,
2016), and due to the variation in platelet count and FGR noted by blood type in this study, it
may be valuable to assess if aspirin therapy is more effective in high-risk women with certain
blood types.
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Early identification. In this study, 66% of preeclamptic women with a B blood type
experienced FGR; preeclamptic women with B blood type had three times the odds of having a
growth-restricted fetus. This suggests that health care providers should carefully assess for FGR
in preelamptic women with the B blood type. Additionally, the trend in lower platelets in the B
blood type could also serve as a proxy for risk of increased severity of the disease. This also
supports the need to closely monitor pregnant clients with B blood types early in pregnancy for
manifestations of preeclampsia. Early in pregnancy, providers may want to begin to educate
women with B blood type about the signs and symptoms of preeclampsia and keep this
association in mind if these patients report non-descript symptoms that could be associated with
preeclampsia. Furthermore, research currently supports that low dose aspirin therapy started
earlier in pregnancy (<16 weeks) is more effective particularly in reducing risk of FGR and
severe preeclampsia (Roberge et al, 2016). Subsequently, blood type could be useful in
identifying women at risk for poor outcomes early in pregnancy and thus allow for earlier
initiation of aspirin therapy.
Cardiovascular risk. ABO blood type, specifically non-O blood type, has been shown
to increase cardiovascular risk (Etemadi et al., 2015; Gong et al., 2014; He et al., 2012; Jassim,
2012; Lee, Lin et al., 2012). With an understanding that preeclampsia not only effects
pregnancy, but also influences the lifelong cardiovascular health of a woman and her offspring,
an understanding of risk factors shared between both diseases could provide a foundation for the
development of programs and therapies aimed at decreasing risk of long-term cardiovascular
sequela in these women (Herrera-Garcia, & Contag, 2014). When adjusting for race only, this
study revealed an association between AB blood type and both preeclampsia, and specifically
late onset preeclampsia. Cardiovascular research also supported the link between AB blood type
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and poor cardiovascular outcomes (He et al., 2012; Karabuva, Carević, Radić, & Fabijanić,
2013; Zakai et al. 2014). Health care providers should consider targeting women with AB blood
type earlier in their lifespan in order to assess for cardiac risk and provide cardiopreventative
strategies.
`

Maternal weight management. Although not the main aim of this study, BMI was

consistently statistically significantly associated with increased odds of developing preeclampsia
and each preeclampsia subtype. With an understanding of the increased maternal and neonatal
morbidity and mortality associated with preeclampsia this study further supports the importance
of education on and support towards achieving a healthy weight prior to and between
pregnancies (Malnory & Johnson, 2011).
Policy Recommendations
Documentation. Although this study yielded interesting statistical results, clinically
relevant results were also gleaned during the extensive chart review and data collection process
that may have implications for practice. It is well documented that the clinical signs and
symptoms of preeclampsia are often non-descript (You, Wolf, Bailey, & Grobman, 2012). Upon
chart review, women reported “not feeling right,” and many reported headache as a clinical
symptom. Cerebral disturbance as a symptom was often difficult for providers to interpret as
many women had a history of migraines that made it difficult to determine if the headache was a
marker of increasing preeclampsia severity or simply the patient’s medical history. Additionally,
in an effort to confirm preeclampsia diagnosis a 24-hour urine specimen was often ordered. This
seemed to delay diagnosis (Townsend, R., O’Brien & Khalil, 2015). Chart review revealed that
maternal diagnosis of preeclampsia was not consistently documented in the history and physical
of the newborns born to preeclamptic women. With an understanding of the association between
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preeclampsia and risk of hypertension in these offspring, documentation of birth history proves
important to assessing future health and complications in infants born to preeclamptic women
(Founds, 2014; Geelhoed et al., 2010; Herrera-Garcia, & Contag, 2014).
Cardiovascular risk education. Finally, during documentation review, a few charts
revealed provider documentation, on conversations with the subject on the association between
preeclampsia and long-term cardiovascular risk. The majority of electronic health records of
preeclampsia cases which were reviewed did not have documentation on education related to the
association between preeclampsia and long-term cardiovascular health. Recent literature has
shown that many obstetricians and primary care physicians are not aware of the association
between preeclampsia and future cardiovascular disease in previously affected women (Young,
Hacker & Rana, 2012). In a study by Young, Hacker & Rana, (2012) “only 9% of internists and
38% of obstetrician- gynecologists were providing cardiovascular risk reduction counseling to
women with a history of preeclampsia” (p. 1). The AHA (2014) reported that many more
women with a history of preeclampsia experienced a cardiovascular event in the 10 years
following delivery then those women with uncomplicated pregnancies (Bushnell et al., 2014).
Best practices on when and how to educate women on the association between CVD and
preeclampsia are not known. However, based on the risk of poor cardiovascular outcomes in the
decade following the index pregnancy, and AHA recommendations for follow up, providers need
to ensure women are educated on this association soon after delivery so women can begin close
follow up with their PCP and institute cardiopreventive strategies (Celi et al., 2013).
Screening algorithms. It seems that an ideal preeclampsia screening algorithm would
need to be done in the first trimester, as any preventive intervention would also need to be
provided early in pregnancy when placentation occurs. Since abnormal placentation may be a
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key component of the pathophysiology of preeclampsia, the timing of effective screening tests is
important to consider (Townsend et al., 2015). Although, providers and policy makers are
working to promote early recognition and standardized treatment plans for preeclampsia,
currently there is currently no valid screening algorithm for preeclampsia. In this current study,
when including ABO blood type into a model with other clinical risk factors of preeclampsia,
ABO blood type did not increase the sensitivity or specificity of the model. Furthermore, when
in the model with other clinical risk factors of preeclampsia, AB blood type only increased odds
of early onset preeclampsia, and each preeclampsia subtype had different variables that were
significantly associated with the outcome. Subsequently, it is also important to consider that
subtypes of preeclampsia may have differing etiology, and one single screening algorithm may
not be appropriate in order to capture all women at risk of preeclampsia. Mikat et al. (2012)
suggests that early detection requires three main components, each that complements the other
when assessing risk. These components include biophysical markers, biochemical markers, and
maternal medical history (Mikat et al., 2012). Mikat et al. (2012) stated that when using
maternal history alone for early preeclampsia detection, only 30% of women are detected with a
5% false positive rate. More research is needed in order to discover biomarkers specific to each
preeclampsia subtype in order to improve prediction.
Recommendations for Further Research
The primary aim of this study was to determine if maternal ABO blood type was
associated with preeclampsia subtype. The subtypes of preeclampsia that were explored were
related to timing of onset, early (≤ 33 6/7 weeks gestation) versus late (≥ 34 0/7 weeks
gestation). There are other preeclampsia subtypes discussed in the literature, such as, proteinuric
and non-proteinuric preeclampsia and preeclampsia with FGR and preeclampsia without FGR.
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Future research should be done to explore if there is an association between these other
preeclampsia subtypes and ABO blood type.
Previous studies on the association between ABO blood type and preeclampsia have been
done in various racial and ethnic populations. Articles in the review of literature consisted of
studies done in Thai, Hungarian, Turkish, Scottish, Finnish, Swedish, Iranian, Ecuadorian and
Brazilian populations (Alpoim et al., 2012; Clark et al., 2007; Hiltunen et al., 2009; Lee, Zhang
et al., 2012; Phaloprakarn & Tangjitgamol, 2013; Seyfizadeh et al., 2014). Since blood type
varies by ethnicity, it is important to explore this association in various populations.
Additionally, since serum levels of certain inflammatory, thrombotic, and angiogenic markers
such as VWF, PP13, and Tumor necrosis factor, that may mediate the development of
preeclampsia subtype, vary by blood type and ethnicity, further study is necessary to explore this
association. This may help to clarify the role maternal ABO blood phenotype plays in the
development of each preeclampsia subtype, and support why results are inconsistent in studies
on ABO blood type and preeclampsia, as the association between certain inflammatory cytokines
and blood type may vary by ethnicity (Franchini, Mengoli, & Lippi, 2016)
Data on fetal and paternal blood type should be included in future research on the
association between maternal ABO blood type and preeclampsia in order to determine if
differences in maternal and fetal or paternal blood type mediate an immune reaction which
predisposes women to either preeclampsia subtype (Phaloprakarn & Tangjitgamol, 2013). Due
to the high rates of multiparty noted in the early onset subtype in this current study, it may also
be important for further studies to examine rates of preeclampsia recurrence by ABO blood type.
In this current study, markers of severity such as growth restriction and lower platelet
levels were seen more often in individuals with the B blood type. Although early onset
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preeclampsia is often considered the more severe of the subtypes, women with both subtypes of
the disease can have preeclampsia with severe features (Boyd et al., 2013; van Rijn et al., 2013).
Women who have met the basic criteria for preeclampsia are classified as having severe features
if their systolic blood pressure is >/= 160 mmHg or diastolic is >/= 110 mmHg on two occasions
at least 4 hours apart, have platelet counts less than 100,000 per microliter, impaired liver
function, renal insufficiency, pulmonary edema, or cerebral or visual disturbance (ACOG, 2013).
Further research should be conducted to assess if certain severe features occur more commonly
in each ABO blood phenotype.
Summary and Conclusion
Preeclampsia has been studied in biologic, immunologic, genetic and pathophysiologic
research (Charlton, Tooher, Rye, & Hennessy, 2014; Founds et al., 2011; Ilekis, Reddy &
Roberts, 2007). The disease seems to result from a complex interplay of maternal and fetal
factors (Hermes et al., 2013). There is a growing body of evidence that has begun to explore the
role of ABO blood phenotypes in the development of disease. Scientists now recognize the
influence ABO blood type plays in the body’s inflammatory and hemostatic responses
(Franchini, & Bonfanti, 2015).
Although there were significant limitations to the study, this study provides a unique
contribution to the literature on blood type and preeclampsia. Current research supports that
preeclampsia is heterogeneous in nature and must be studied as such (Founds et al., 2011; Myatt
et al., 2014). This current study utilized strict definitions that delineated preeclampsia by
subtype (early and late), instead of assessing preeclampsia as a homogenous group.
Subsequently, this study may better explain blood type’s association with each preeclampsia
subtype (early and late). Similar to other studies with this aim, subjects with the AB blood type
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had roughly three times higher odds of preeclampsia. This study added to literature and reported
that subjects with AB blood type had three times the odds of late onset preeclampsia than
subjects with other blood types. Since AB blood type is the rarest of all blood types, larger
studies done in the United States which utilize strict data collection procedures and assess
preeclampsia by subtype are necessary to confirm this relationship. Preeclampsia may provide
an early opportunity to identify women at risk for cardiovascular disease (Smith, Pudwell, &
Roddy, 2013). Further exploration of risk factors, such as blood type, which are shared between
preeclampsia and cardiovascular disease, may help in the development of interventions which
could decrease long-term cardiovascular risk in these women.
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Appendix A: U.S Preventive Services Task Force Levels of Evidence

I: Evidence obtained from at least one properly designed randomized, controlled trial or metaanalysis of randomized, controlled trials.
II‐1: Evidence obtained from well‐designed controlled trials without
randomization.
II‐2: Evidence obtained from II well‐designed cohort or case–control analytic
studies, preferably from more than one center or research group.
II‐3: Evidence from multiple time series with or without the intervention.
III: Opinions of respected authorities, based on clinical experience, descriptive
studies or reports of expert committees

U.S. Preventive Services Task Force. (1996). Guide to clinical preventive services (2nd ed.).
Baltimore: Williams and Wilkins.
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Appendix B: Evidence Table ABO Blood Phenotype and Preeclampsia
Title of
article
Author
Level of
Evidence
Alpoim et al
(2012)

161

Preeclampsia
and ABO
blood groups:
a systematic
review
and metaanalysis

Research Aim

A systematic review
of the literature for
published studies
investigating whether
ABO blood groups
could influence PE
developing

Sample

Two studies met eligibility
criteria
N=992 women with PE
N= 883 healthy pregnant
women
Total n = 1,875

Research
Design

Systematic
review
MetaAnalysis

Level I

Alpoim et al
(2012)
ADAMTS13,
FVIII, von

Results

Strengths/Limitations

Significant
overall effect
when comparing
pregnant women
of blood group
AB versus nonAB ones for the
risk of PE
(OR 2.42; 95 %
CI 1.63–3.58)

Very small only found
two studies that meet
inclusion criteria

No significant
findings for any
other blood type

FVIII activity, VWF
and ADAMTS13
plasma levels,
according to O and
“non O” blood

N= 55 pregnant with sPE
N=35 normotensive
pregnant

case-control
study

FVIII activity
and VWF
levels were
significantly
higher in sPE

Large group of severe
preeclamptic patients
in study
Utilized >/= 2 g of
prorteinuria as
diagnositic
Diagnostic criteria of
PE has changed since
publication
Reports >/= 0.3/24
hours in discussion as
inclusion criteria
different than stated in
inclusion criteria
Fairly small sample
size. No power
analysis
Brazilian population

Willebrand
factor, ABO
blood group
assessment
in
preeclampsia

groups, in women
with severe PE (sPE).

N= 50 non-pregnant
women.

group, as
compared to
normotensive
pregnant women
(P=0.01 and
P=0.05,
respectively)

Total N= 140

Level II-2

162

the frequency of
O and non O
blood groups in
sPE and
normotensive
pregnancies was
similar
31% and 69% in
sPE; 43% and
57% in
normotensive
pregnancies
P=0.25

Clark et al
(2007)
The GOAL
study: a
prospective
examination
of the impact
of

The impact of
FVL/ABO(H) on a
composite of all
major vascular
complications (PET,
IUGR, pregnancy loss
and VTE)

N=4157 consented to
participate.

Prospective
cohort study

No association
with ABO(H)
alone, or any
interaction
between ABO(H)
and
FVL was
observed.

4% AB blood type
Definition of
preeclampsia
>2 g proteinuria=not
ACOG definition
Severe vs mild no
longer used in
preeclampsia
nomenclature
Patients after 29 weeks
May have lost some
sPE patients who
delivered prior to 29
weeks

Scottish population

factor V
Leiden and
ABO(H)
blood groups
on
haemorrhagic
and
thrombotic
pregnancy
outcomes

163

Clark & Wu
(2008)
ABO(H)
blood groups
and preeclampsia. A
systematic
review and
meta-analysis

Examined the
literature to see if
there is a relationship
between ABO(H) and
pre-eclampsia, in
order to reveal
whether there is a true
association between
the two

17 eligible studies

A systematic
review and
meta-analysis

No consistent
link between
blood group AB
and preeclampsia,
with a pooled
odds ratio of
group AB versus
the remainder of
1.02 (95%CI
0.86 to 1.22)
Comparing a
combined group
of non-Os (i.e.
AA, AB and BB)
with group O
gave similar
results, with a

No specific features
(disease definition,
disease severity,
date of publication, or
ABO(H) distribution
in controls)
distinguished those
few studies giving any
form of positive
association
from the remainder.

164

Franchini,
Mengoli,
Lippi (2016)
Relationship
between ABO
blood group
and pregnancy
complications:
a systematic
literature
analysis

To elucidate the role
of ABO antigens in
pregnancy-related
complications, a
systematic review of
the literature
published in the past
50 years was
completed. A metaanalytical approach
was also applied to
the existing literature
on the association
between ABO
status and preeclampsia.

9 studies (7 case control/2
cohort)

Systematic
Review and
meta-analysis

pooled odds ratio
of
1.01 (95% CI
0.91 to 1.12), but
with some
evidence of
heterogeneity
(p=0.01) and
individual study
estimate
inconsistency (I2
49%)
Blood group O
was associated
with lower odds
of preeclampsia
Effect size .77
(95% C1 .67-.88)
(p=<.001).
For group A the
effect size was
1.78 (95% CI:
1.04-3.07),
higher prevalence
of this blood
group among the
patients with preeclampsia
(p=0.037). The
heterogeneity

Studies included were
done in varying ethnic
backgrounds, however
the ethnic backgrounds
were not described in
this meta-analysis.
Review dated back 50
years.

was substantial
(I2 =63.7%). For
group AB the
effect size was
1.94 (95% CI:
1.20-3.13), also
higher than one
(p=0.007) The
heterogeneity
was also
substantial
(I2 =64.2%).

165

Hentschke et
al. (2014)
Is there any
relationship
between
ABO/Rh
blood group
and patients
with preeclampsia
Hiltunen et al
(2009)
Blood group
AB and factor
V Leiden as
risk factors for
pre-eclampsia:

The purpose of this
study was to evaluate
the association
between preeclampsia
and blood groups in a
group of pregnant
women hospitalized
in a University
Hospital in Porto
Alegre, Brazi
ABO blood group,
seven thrombophilia
associated
polymorphisms, and
anti-beta2glycoprotein

N=414 women were
diagnosed as
preeclampsia/eclampsia
N=9611 women were
identified to the control
group.

Case Control

No difference in
blood group
distribution
P>0.05

Brazilian population

248 cases fulfilling strict
criteria for pre-eclampsia
and 679 controls

A population
based nested
case-control
study

Blood group AB
increased the risk
for pre-eclampsia
as a whole (OR
2.1, 95% CI 1.33.5), and in the
three subgroups

Population from
Finland
Done retrospectively
on medical records
Used strict diagnostic
criteria

166

A population
based
nested casecontrol study

I antibodies as risk
factors for preeclampsia

Lee et al
(2012)
ABO and
RhD blood
groups and
gestational
hypertensive
disorders: a
populationbased cohort
study

Examined the
association between
ABO and RhD
blood groups and
gestational
hypertensive
disorders in a large
population-based
cohort

López-Pulles
et al. (2010)

To identify the
immunogenetic
factors that trigger the
beginning of
preeclampsia
and eclampsia

Assessment of
Genetic
Contributions

All singleton deliveries in
Sweden born to first-time
mothers during the period
1987–2002 [total n = 641
926; any
gestational hypertensive
disorders, n = 39 011
(6.1%); preeclampsia
cases, n = 29 337 (4.6%);
severe pre-eclampsia cases,
n = 8477 (1.3%)].

Cohort study

142 pregnant women
in Obstetrics and
Gynecological Hospital
Isidro Ayora in Quito, who
are grouped into
two different groups,
diseased and healthy.

A
retrospective,
case-control
study

(OR 2.3, 3.8, 3.4;
95% CI 1.3-3.9,
2.0-7.1, 1.6-7.1).

Noted lower incidence
of preeclampsia in
their study sample than
in overall population

Compared with
blood group O,
all non-O blood
groups
had modest but
statistically
significantly
higher odds of
preeclampsia.
Blood group AB
had the highest
risk for preeclampsia
(OR = 1.10, 95%
CI 1.04–1.16)
and severe preeclampsia
(OR = 1.18, 95%
CI 1.07–1.30).
No statistical
difference when
comparing the
blood type and
Rh factor of the
two groups (p >
0.05).

Population from
Sweden
Utilized ICD 9 codes
to identify subjectsoutcome
Strict inclusion criteria
Included gestational
hypertension

Ecuadorian
Women
Small sample size
Several blood types
not represented.

to Risk of
Preeclampsia
in Ecuadorian
Women
Phaloprakarn
&
Tangjitgamol
(2013)
Maternal
ABO blood
group and
adverse
pregnancy
outcomes

167
Seyfizadeh et
al (2014)
Is there
association
between ABO
blood group
and the risk
factors of
unfavorable

To determine the
relationship between
maternal ABO blood
group and risk of
adverse pregnancy
outcomes.
preeclampsia,
gestational diabetes
mellitus (GDM),
preterm delivery,
low birth weight
(LBW)
small for gestational
age (1stSGA) infants

5320 singleton pregnant
women
350 (6.6%), preeclampsia,
333 (6.3%) GDM
543 (10.2%)

Examine the
relationship between
blood group and
pregnancy blood
levels of
Fasting blood sugar
Hgb
HCT
Urea

N= 792 Healthy pregnancy
women
Tabriz health centers (Iran)

Retrospective
cohort

Btw 6/08-7/10
1st PNC < 14vweeks
No known underlying
disease or condition
that could affect the
pregnancy outcome

Prospective
Cohort

Women with A
or AB blood
types, were found
at increased risk
of preeclampsia
compared with O
type individuals;
adjusted relative
risks were 1.7
(95%
confidence
interval (CI), 1.3
to 2.3; P¼0.001)
for A phenotype
and 1.7
(95% CI, 1.1 to
2.6; P¼0.01) for
AB phenotype
The serum
creatinine of AB
group was
significantly
higher than the
other 3 groups
p<0.005)

Thai population
Included GDM, LBW
& SGA and preterm
labor as outcomes
Retrospective,
potential risk factors
may not have been
identified
Did not include Rhpopulation

Confounders not
discussed
Statistical
Demographics of study
populations not shown
Completed in Iran

168

outcomes of
pregnancy?

Creatinine
RBC’s

Sezik et al.
(2002)

To determine if blood
group has an
association with some
of the risk factors of
unfavorable outcomes
in pregnancy
Evaluate the
relationship between
HELLP (hemolysis,
elevated liver
enzymes, low
platelets) syndrome
and the
maternal blood groups

Distribution
of ABO and
Rh blood
groups in
patients with
HELLP
syndrome.

Than et al
(2011)
PP13,
Maternal
ABO Blood
Groups and
the Risk
Assessment of

To test whether PP13binding to
erythrocytes, maternal
blood-group has an
effect on serum PP13
and its performance
as a predictor of

Serum urea
higher in AB
group than other
3 groups
(p<0.005)

N=547
severe preeclampsia divided
by blood groups

maternal serum PP13 in
Caucasian (n = 1078) and
Hispanic n = 242 women
were analyzed according to
blood groups

Retrospective
Cohort

Crosssectional

O negative risk
for HELLP-OR
3.1 CI (1.28–
7.43) ( p<0.01)
Did not detect
increased
incidence of
HELLP
syndrome
in patients with
the blood group 0
(independent of
the Rh type)
Women with
preeclampsia
associated with
IUGR had
the lowest PP13
MoMs in the first
trimester and the
highest MoMs

Turkish Women

Placenta sample from
women in Budapest
Hungary

Pregnancy
Complications

preeclampsia and
IUGR

in the second and
third trimesters
In Caucasian
women:
AB blood type
had lowest serum
levels of PP13 in
the first trimester.
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Blood group B
had the highest
median PP13
MoMs
throughout
pregnancy
In Hispanic
women:
Same as
Caucasian cohort

PP13 had
differential
binding to RBCs
according
to ABO blood
types. PP13binding was

similar in blood
groups A
and O, the
weakest in blood
group B, and the
strongest in
blood
group AB in
comparison to
other blood
groups

170
Witsenburg et
al.
(2005)

The aim of this study
was to determine
whether elevated
factor VIII levels are
associated with
uteroplacental
insufficiency, in

N= Controls 272 women
N=Plasma samples of 75
women with a history of
pregnancy complicated by
pre-eclampsia, HELLP
syndrome, pregnancy

Case Control

By adjusting to
ABO blood
group,
the prediction
accuracy of the
PP13 test is
improved for
preeclampsia,
IUGR and
preeclampsia
with IUGR
VIII:C levels
were similar at
123 IU/dl in both
the patient group
and the controls.
In a logistic
regression model,

Netherlands
Elevated factor VIII
levels were associated
with a

particular preeclampsia, HELLP
syndrome or
pregnancy-induced
hypertension and
intrauterine growth
retardation

induced hypertension or
intrauterine growth
restriction

after adjusting
for age and blood
group, no effect
of factor VIII:C
levels on the risk
of pregnancy
complications
was
observed, with
the exception of
IUGR with (OR
2.9, CI 1.0—8.7)
or without
hypertension (OR
2.0, CI 0.7—6.4).

two- to three-fold
increased risk of
IUGR.
No observed effect
from ABO-blood
group,
t this is acquired rather
than genetically
determined.
Limitations of study
not addressed
Very small sample size

171

Title of article
Author
Level of Evidence
Biswas, Ghoshal, Halder, Mandal
(2013)

Research Aim

The purpose of this
study was to establish
whether ABO blood g
Distribution
roup is related to
of ABO blood group andmajor card coronary
iovascular risk factors with
heart disease in an
coronary heart disease.
individual in Asian
Indian Bengali
Level II-2
population of eastern
part of India

Sample

N=250 CHD
patients and
250 age and
sex matched
healthy
subjects

172

Resear
Results
ch
Design
Case The distribution
control
of ABO blood groups in
patients versus
control group was A in
24.00 versus 21.60%, B in
30.80 versus 32.40%, O in
38.40 versus 21.60%, and
AB in 6.80 versus
24.40%. The analysis
showed significant
difference in frequency of
O (OR = 1.857, 95%CI =
1.112-3.100, P = 0.018)
and AB (OR = 0.447,
95%CI = 0.227-0.882, P =
0.020) blood group betwe
en healthy controls and
CHD individuals
AB blood group decreases
the risk of CHD in healthy
controls, and it might be
due to the higher
concentration of high
density lipoprotein
cholesterol (HDL-c),
while the

Strengths/
Limitations
Asian
Indian
Bengali
population

Chen et al. (2014)
Analysis of circulating cholesterol
levels as a mediator of an
association
between ABO blood group and
coronary heart disease.
Level II-2

To estimate the
mediation effect size
between
cardiovascular
disease and blood
type

6476
consecutive
patients

Case
Control

173

O blood group increases
the risk of CHD due to
lower HDL-c levels in
Bengali population of
eastern part of India.
Subjects of nonO type had higher levels
of total cholesterol, lowdensity lipoprotein
cholesterol, and non-highdensity lipoprotein
cholesterol (mean [SEM]
in mmol/L: 4.931[0.021],
3.041 [0.018], and 3.805
[0.020] in nonO type compared with
4.778 [0.026], 2.906
[0.021], and 3.669 [0.024]
in O type; P=3.8×10(-7),
P=1.5×10(-7), and
P=3.1×10(-7),
respectively).
10% of the effect of nonO type on coronary
artery disease
susceptibility was
mediated by increased
low-density lipoprotein
cholesterol level
(P=7.8×10(-4)) and 11%

Used
mediation
analysis
Which
revealed
LDL as a
mediator of
CHD risk
on patients
with Non O
blood type
Did not
discuss
limitations
of the study
Done in
Southern
China

Etemadi et al. (2015)
Mortality and cancer in relation to
ABO blood group phenotypes in
the Golestan Cohort Study
Level II-3

To study the
association
between ABO blood
groups and overall
and cause-specific
mortality in the
Golestan Cohort
Study

50,045 people
40- to 70-years
old

Populat
ion
based
cohort
design

174

of the effect of nonO type on myocardial
infarction risk was
mediated by raised lowdensity lipoprotein
cholesterol level
(P=2.0×10(-3)).
Non-O blood groups were
associated with
significantly increased
total mortality (hazard
ratio (HR) = 1.09; 95%
confidence interval (CI):
1.01 to 1.17) and
cardiovascular disease
mortality (HR = 1.15;
95% CI: 1.03 to 1.27)
plasma total cholesterol
and LDL in those with
blood group A

Did not
check for
differentiati
on between
Type A
subtypes.
Study
population
in
northeastern
Iran
No direct
analysis of
the
mediation
effect of
biochemical
changes in
the ABO
mortality
association.

Gasso et al. (2012)
A common variant of the ABO
gene protects against hypertension
in a Spanish population.
Level II-2

The objective of this
study was to establish
whether genetic
polymorphisms that
could be related to
angiotensinconverting enzyme
(ACE) levels are
associated with
hypertension.

269
hypertensive
patients and
254 healthy
controls.

Case
Control

175

Only one polymorphism
of the ABO gene
(rs495828) presented
nominal pointwise P<0.05
values (odds ratio = 0.33,
95% CI 0.19-0.58, P = 6 ×
10(-5)) and achieved
P<3.8 × 10(-3), the
nominal P-value
considered significant
after Bonferroni
correction. Analysis of the
genotype frequencies
showed that the model
that correctly explained
the observed association
was the recessive model
(odds ratio = 0.03, 95% CI
0.01-0.15, P = 1 × 10(-6)).
These results indicate that
genetic variants that could
be related to ACE activity
are good predictors of
hypertension, and identify
ABO as a good candidate

left
censoring
of the
mortality
data
Further
studies are
required to
confirm this
association.

Gong et al. (2014).
Relation of ABO blood groups to
the severity of coronary
atherosclerosis: an Gensini score
assessment.
Level II-2

Investigated the
relation of
the ABO blood group
s to the severity of
coronary
atherosclerosis
assessed by Gensini
score (GS)

2919
consecutive
patients
undergoing
coronary
angiography
were enrolled

Crosssectiona
l cohort
study

gene for genetic studies of
hypertension risk.
The frequency
of blood group A was
significantly higher in the
upper GS tertiles (24.4%
vs. 28.2% vs. 29.5%, p =
.032).
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Blood group A was
independently associated
with GS (β = 0.043, p =
.017). Group A remained
significantly associated
with mid-high GS (OR =
1.44, 95% CI 1.16-1.80, p
= .001),
Group O was showed as a
protective factor (OR =
0.77, 95% CI = 0.65-0.92,
p = .004).

Gong et al. (2014)
High-sensitivity C-reactive protein
mediates in part the impact
of ABO blood group on coronary
artery disease

CRP might play an
interesting role in the
association of ABO
group with CAD or
MI

3806
consecutive
patients who
underwent
selective

Crosssectiona
l study

There is a difference in
blood type distribution
between controls and
patients with CAD (p =

Single
center study

The
crosssection
al
nature of
the study
limits the
ability to
infer a
causal
relation
between
ABO blood
group and
cardiovascu
lar events
Large
Chinese
cohort
Used
mediation
analysis

coronary
angiography
for being
suspected or
known
coronary
atherosclerosis

Level II-3

0.005) and patients with
MI (p= 0.047)
Non-O blood group
remained significantly
association with CAD and
MI
(OR = 1.49, 95% CI 1.20–
1.84, p b 0.001; OR =
1.24, 95% CI =
1.04–1.47, p = 0.017),
respectively after
adjustment for common
cardiovascular
risk factors

177
He et al. (2012)
ABO blood group and risk of
coronary heart disease in two
prospective cohort studies.
Level I

investigate the
associations
between ABO blood
group and CHD risk
in prospective cohort
studies.

(the Nurses'
Health Study
[NHS]
including 62
073 women
and the Health
Professionals
Follow-up
Study [HPFS]
including 27
428 men)

Large
Chinese
cohort

Metaanalysis
of two
large
Prospec
tive
cohort
study

The effect of non-O blood
type on CAD and MI
susceptibility is mediated
partly by hs-CRP levels.
ABO blood group was
United
significantly associated
States
with the risk of
developing CHD in both
women and men (log-rank
test; P=0.0048 and 0.0002,
respectively).
In the combined analysis
adjusted
for cardiovascular risk
factors, compared with
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Jassim W.E. (2012)
Association of ABO blood group in
Iraqis with hypercholesterolaemia,
hypertension and diabetes mellitus.
Level II-2

Investigated the
possible association
of diabetes mellitus,
hypercholesterolaemi
a and hypertension
with ABO type.

920 patients
with diabetes
mellitus,
hypertension
and
hypercholester
olemia

Case
control

participants
with blood group O, those
with blood groups A, B, or
AB were more likely to
develop CHD (adjusted
hazard ratios [95% CI] for
incident CHD were 1.06
[0.99-1.15], 1.15 [1.041.26], and 1.23 [1.111.36], respectively).
Overall, 6.27% of the
CHD cases were
attributable to inheriting a
non-O blood group. Metaanalysis indicated that
non-O blood group had
higher risk of CHD
(relative risk =1.11; 95%
CI, 1.05-1.18; P=0.001)
compared with
O blood group.
Levels of total cholesterol, Iraqi
glucose and
population
systolic/diastolic blood
pressure were all
significantly higher in
male and female patients
in blood group O than
other groups, with a
decreasing trend

Karabuva, Carević, Radić &
Fabijanić (2013)
The association of ABO blood
groups with extent of coronary
atherosclerosis in Croatian patients
suffering from chronic coronary
artery disease.
Level II-2
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Lee et al. (2012)

Examined the
relationship
between ABO blood
groups and extent of
coronary
atherosclerosis in
patients with chronic
coronary
artery disease (CAD),
2)
compare ABO blood
groups distribution in
CAD patients and
general population, 3)
examine possible
differences in
traditional risk factors
frequency in CAD
patients with
different ABO blood
group
Aimed to investigate
the association
between

N= 646
chronic CAD
patients

Cohort

277
consecutive
subjects (men

Case
Control

from group A to B then
AB.
Similar trends
by blood group were seen
for the healthy controls
although the differences
were less marked
No association
between ABO blood grou
ps and the extent of
coronary atherosclerosis
in Croatian CAD patients
is observed. Observation
that
AB blood group might
possibly identify Croatian
males at risk to develop
the premature CAD has to
be tested in larger cohort
of patients.

Patients with CAD
showed a significantly
different blood group distr

Croatian
population

Taiwanese
population.

Association of blood group A with
coronary artery disease in young
adults in Taiwan.
Level II-2

the ABO blood group
s and the risk of
coronary
artery disease (CAD)
and myocardial
infarction (MI) in a
young Taiwanese
population

younger than
45 years and
women
younger than
55 years) who
underwent
coronary
angiography
(136 with
documented
CAD and 129
without CAD)
at our center,
between 2005
and 2008
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ibution (O, 30.1%; A,
39.7%; B, 26.5%; AB,
3.7%) than that shown by
the controls (O, 42.6%; A,
24.0%; B, 27.1%; AB,
6.2%; p=0.032). Patients
with blood group A had a
greater risk of CAD and
MI than those with nonA blood groups (OR=2.08,
95% CI=1.23-3.54;
OR=2.21, 95% CI=1.194.09, respectively). After
adjustment for
common cardiovascular ri
sk factors such as age,
gender, hypertension,
cigarette smoking,
diabetes mellitus, body
mass index, family history
of CAD, and lipid
profiles; blood group A
remained significantly
associated with an
increased risk of CAD and
MI (OR=2.61, 95% CI
1.11-6.14, p=0.028;
OR=3.53, 95% CI=1.2110.29, p=0.021,
respectively).

Angiograph
ically
determined
CAD
Focused on
younger
patients
Singlecenter
design
retrospectiv
e
Small
sample size,
incomplete
lipid profile
data, and
lack of
detailed
genotype
information
of the ABO
alleles

Reilly et al. (2011)
Identification of ADAMTS7 as a
novel locus for coronary
atherosclerosis and association of
ABO with myocardial infarction in
the presence of coronary
atherosclerosis: two genome-wide
association studies.
Level II-2

Tested whether
genetic factors
distinctly contribute
to either development
of coronary
atherosclerosis or,
specifically, to
myocardial infarction
in existing coronary
atherosclerosis.

N= patients
who had
angiographic
CAD and
myocardial
infarction
(n=5783)
N=those who
had
angiographic
CAD but no
myocardial
infarction
(n=3644).

Case
control
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In the comparison of
patients with angiographic
CAD who had myocardial
infarction versus those
with angiographic CAD
but no myocardial
infarction, there was a
novel association at the
ABO locus (p=7·62×10(9)). The ABO association
was attributable to the
glycotransferase-deficient
enzyme that encodes the
ABO blood group O
phenotype previously
proposed to protect
against myocardial
infarction.

CAD in
patients of
European
ancestry
genetic
predispositi
ons promote
the
developmen
t of
coronary
atherosclero
sis whereas
others lead
to
myocardial
infarction in
the presence
of coronary
atherosclero
sis. The
relation to
specific
CAD
phenotypes
might
modify how
novel loci
are applied
in

personalize
d risk
assessment
and used in
the
developmen
t of novel
therapies
for CAD.
CAD was
defined by
angiograph
y
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Multistudy
design
Misclassific
ation
possible as
patient with
CAD might
develop MI
Sode, et al. (2013)
Risk of venous thromboembolism
and myocardial infarction
associated with factor V Leiden
and prothrombin mutations
and blood type.

Examined
if ABO blood
type alone and in
combination with
mutations in factor V
Leiden R506Q and

Genotype of
66,001 white
participants
for ABO blood
type, factor V
Leiden R506Q

Prospec
tive
Cohort

Multivariable adjusted
HRs for myocardial
infarction by genotypes
did not differ from 1.0.

White and
Danish
population

Level II-2

Wauters E. et al. (2013).
Influence of 23 coronary
artery disease variants on recurrent
myocardial infarction or cardiac
death: the GRACE Genetics Study.
Level II-2
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prothrombin
G20210A is
associated with the
risk of venous
thromboembolism
and myocardial
infarction in the
general population.
Evaluated whether
these 23 loci also
predispose to
recurrent MI or
cardiac death
following an acute
coronary syndrome
(ACS).

and
prothrombin
G20210A.

Used ICD 9
codes to
define MI
Large
sample

2099 ACS
Prospec
patients
tive
enrolled in the Cohort
Global
Registry of
Acute
Coronary
Events
(GRACE) UKBelgian study

C-allele carriers of the
European
rs579459 variant, which is population
located upstream of
the ABO gene and
correlates
with blood group A, were
independently associated
with recurrent MI
[multivariable-adjusted
hazard ratio (HR) 2.25, CI
= 1.37-3.71; P = 0.001]
and with recurrent MI or
cardiac death
[multivariable-adjusted
(HR) 1.80, CI = 1.09-2.95;
P = 0.021] within 5 years
after an index ACS. The
association of rs579459
was replicated in 1250
Polish patients with 6
months follow-up after an
index ACS [multivariableadjusted (HR) 2.70, CI =
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Zakai et al. (2014)
ABO blood type and stroke risk:
The Reasons for Geographic And
Racial Differences in Stroke Stud
Level II-2

Assess the association
of blood type with
stroke and
whether blood
type contributes to
racial disparities in
stroke in the United
States.

30,239
participants

Casecohort

1.26-5.82; P = 0.011 for
recurrent MI]. Addition of
rs579459 to a prediction
model of 17 clinical risk
factors improved risk
classification for recurrent
MI or cardiac death at 6
months as calculated by
the integrated
discrimination
improvement method (P =
0.037), but not by Cstatistics (P = 0.096).
Blood type AB is
associated with an
increased risk of stroke
that is not attenuated by
conventional stroke risk
factors, and factor VIII
levels were associated
with 60% of the
association. While blood
type AB is rare in the US
population, it is a
significant stroke risk
factor and may play an
important role in stroke
risk in these individuals.

Blacks and
Whites
from the
United
States

Appendix D: ICD 9 Codes
Diagnosis

ICD 9 Codes

Preeclampsia

642.41/642.42/ 642.0/642.1/ 642.2/642.3/642.4/642.5/642.6
642.7/642.9
Premier queried using 4 digit ICD 9 codes, but asked system to include all cases with
5 digit codes which are inclusive of the 4 digit ICD 9 codes listed above.

Gestational
Hypertension
Severe Preeclampsia

642.31/642.32

Eclampsia

780.39

HELLP syndrome

642.51/642.52

Multiple Gestation

651.01/651.11/651.21/651.31/651.41/651.51/
651.61/651.71/651.81/651.91

Diabetes

250.00

Chronic
Hypertension

642.22/642.21/642.02/642.01/642.72/642.71

642.51/642.52
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Appendix E: Sample Size Calculation Using Hiltunen (2009)

Two-sided confidence level(1-alpha)
Power(% chance of detecting)
Ratio of Controls to Cases
Hypothetical proportion of controls with exposure
Hypothetical proportion of cases with exposure:
Least extreme Odds Ratio to be detected:

Sample Size - Cases
Sample Size - Controls
Total sample size:

Kelsey
126
251
377

Fleiss
123
245
368

References
Kelsey et al., M ethods in Observational Epidemiology 2nd Edition, Table 12-15
Fleiss, Statistical M ethods for Rates and Proportions, formulas 3.18 &3.19
CC = continuity correction
Results are rounded up to the nearest integer.
Results from OpenEpi, Version 3, open source calculator--SSCC
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95
80
2
56
70.96
1.92
Fleiss with CC
133
265
398

Appendix F: Database by Variable
Variable
ABO blood type
 A
 B
 AB
 O
Platelets
 < 20 weeks gestation
 >20 weeks -28 weeks
 Admission for delivery
Rh Factor
 Rh  Rh +
Early Pregnancy BMI

Infant Birthdate

Comorbid Disease
 DM
 CHTN
 GDM
Parity
 Nulliparous
 Multiparous
Age at delivery

Infant




Outcome
Live Birth
Fetal Death
Neonatal Death

Level of Measurement

Database

Categorical

Delivery Log

Continuous
< 20; > 20-28 weeks -Chart
Review
Categorical

Delivery Log

Continuous
Also assessed at the
categorical level
Collected as
Continuous
Recoded into
categorical levels by
season
Categorical

Chart Review

Delivery Log

Premier ® (ICD 9/10 Codes)
Confirmed during chart review

Categorical

Delivery Log

Continuous

Delivery Log

Categorical

Delivery Log
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Socioeconomic status
(insurance type proxy)
 Public Insurance
 Private Insurance
Race
 White
 Black
 Other

Categorical

Premier®

Categorical

Delivery Log

Smoking
 Non smoking
 Smoking
Gestational age at birth

Categorical

Premier or Delivery Log using
ICD 9-10 code and Chart Review

Continuous

Delivery Log

Infant


Infant

Categorical

Delivery Log

Continuous
Recoded to assess fetal
growth restriction.
Categorical (> 10%
<10%)
Categorical

Delivery Log and Chart Review

sex
Male
Female
birthweight-grams

Preeclampsia
 Early onset </= 33 6/7
weeks
 Late onset >/= 34
weeks
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Cases identified through Premier
® using (ICD 9/10 Codes)
Onset timing confirmed with
Chart Review
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